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TRIM24 orchestrates metabolic reprogramming and EMT 
in breast cancer 
 
Kaushik Thakkar, MS 
 
Advisory Professor: Michelle C. Barton, PhD 
 
 In this dissertation, I report the oncogenic functions of an epigenetic regulator 
Tripartite Motif Protein 24 (TRIM24) coupled with metabolic reprogramming and 
epithelial mesenchymal transition (EMT) in breast cancer. TRIM24 was first established 
by our laboratory as a previously unknown negative regulator of p53 via its RING 
domain, as a co-regulator of nuclear receptors and a PHD/Bromodomain reader of 
specific histone modifications. TRIM24 expression correlates with poor prognosis of 
breast cancer, but the mechanisms of TRIM24-mediated oncogenesis are unknown. In 
the first part of my thesis, I found that TRIM24 is aberrantly expressed in early stages 
of breast cancer progression. Ectopic expression of TRIM24 induces malignant 
transformation of immortalized human mammary epithelial cells (TRIM24-iHMECs) and 
efficient growth of intermediate to high-grade xenograft tumors. 
 TRIM24 induces gross metabolic changes in the iHMECs with increased 
glycolysis and TCA cycle along with glucose uptake. TRIM24 causes deregulation of c-
Myc and p53, the two key players that regulate cancer metabolism. TRIM24 is directly 
recruited to the promoters of several metabolic genes such as GLUT1, IDH1, IDH2 and 
c-Myc. Our hypothesis is that direct activation of various glucose metabolism genes by 
TRIM24 coupled with deregulation of key players of metabolism is critical for TRIM24-
mediated oncogenic transformation in breast cancer. 
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 TRIM24 is over-expressed in several cancers; however, a detailed analysis of 
how TRIM24 promotes tumorigenesis with progression to metastasis has not been 
elucidated. Prior to the metastatic progression of a tumor, cancer cells undergo a 
transition from an epithelial to a mesenchymal phenotype; termed as epithelial-
mesenchymal transition (EMT). In the second part of my thesis, I found that TRIM24 is 
a driver of EMT in breast epithelial cells.  
 Upon TRIM24 over-expression in MCF10A cells, a mesenchymal-like change in 
the cellular morphology was observed. TRIM24-MCF10A cells exhibited marked 
decrease of E-cadherin and acquisition of various mesenchymal markers such as N-
cadherin, fibronectin and vimentin. Similarly, upon TRIM24-knockdown in 
mesenchymal cells MDA-MB-231 and MDA-MB-468, there is reversal of EMT gene 
signature. Gene expression analysis of TRIM24-OE MCF10A cells further confirmed 
that EMT was among the top pathways that were enriched. Additionally, TRIM24 may 
be involved in direct transcriptional regulation of EMT genes as suggested by TRIM24-
ChIP analysis and the presence of Histone H3 – K23 acetylation (H3K23ac) signature, 
for which the TRIM24-Bromodomain acts as a histone reader, at several EMT genes in 
MDA-MB-468 cells. We propose that aberrant expression of TRIM24 impacts a network 
of transcription regulatory factors and pathways to induce EMT and cancer metastasis.  
 For effective reduction of cancer mortality, it is very critical to intervene in the 
critical transition of non-invasive ductal carcinoma to extremely lethal invasive breast 
cancer. Our preliminary analysis suggests that TRIM24 plays a critical role in 
mechanisms involving both primary and metastatic cancer. Future studies will be 
focused to develop a better understanding of molecular mechanisms of TRIM24’ 
oncogenic function and will pave the way for developing therapeutic opportunities by 
targeting TRIM24.	
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Chapter 1: Introduction 
1.1 Breast cancer: 
 Breast cancer is the most common malignant disease of Western women and it 
is the second leading cause of cancer-related deaths after lung cancer [1]. It is 
estimated that approximately 234,190 Americans will be diagnosed with invasive breast 
cancer and about 40,730 Americans will die of the disease in 2015-16. It is alarming to 
find out that the lifetime risk of breast cancer for American women has risen from 1 in 
11 in the 1970s to 1 in 8 in 2013, which is attributed to shifting breast cancer risk factor 
demographics and the increased use of screening mammography [1].  
 Breast tumors are highly heterogeneous and are composed of multiple subtypes 
with distinct morphologies and clinical implications [2]. Breast tumors are classified 
based on three different criteria: (i) histology into ductal or lobular carcinomas, (ii) 
differentiation state/gene expression profiles into luminal and basal-like subtypes, and 
(iii) the expression of receptors such as estrogen (ER), progesterone (PR) and HER2 
(human epidermal growth factor receptor 2) into ER+, HER2+, and ER– PR– HER2− 
(triple-negative breast cancer, TNBC) subtypes. Expression patterns of the ER+ and 
HER2+ tumors both have luminal features, however TNBCs show significant but not 
complete overlap with basal-like subtype [3]. One of the key reasons for a decrease in 
mortality rates of breast cancer patients is the widespread use of mammography that 
has led to increased diagnosis of early stage disease, including ductal carcinoma in situ 
(DCIS). Systematic characterization of breast cancer genomes has identified that 
somatic mutations in only three critical genes (TP53, PIK3CA and GATA3) occurred at 
more than 10% incidence across all breast cancers [3].  
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 Classification of breast tumors based on hormone receptor and HER2 status 
and the use of antihormonal and HER2-targeted therapy, respectively, are among the 
first examples for molecular-based classification and personalized cancer treatment 
that made a significant difference in clinical outcomes. Three main groups of 
medications used for adjuvant therapy of breast cancer include hormone-blocking 
agents, chemotherapy and monoclonal antibodies [4]. Blocking of estrogen action can 
be achieved by using selective estrogen receptor modulators (SERMs) such as 
tamoxifen, which compete with estradiol for binding to ERα, and which induce an 
alteration of ERα’s conformation that is not conducive for activation.  Selective ERα 
down-regulators (SERDs) such as fulvestrant induce destabilization and degradation of 
ERα. Finally, another way to block ERα action is to reduce the production of estrogen 
in peripheral tissues and within the tumor using inhibitors of aromatase, an enzyme 
which synthesizes estrogens from testosterone and androstenedione [5].  
 For almost three decades in both early and advanced breast cancer patients, 
tamoxifen has been the mainstay of endocrine therapy and remains to date the most 
successful targeted breast cancer therapy. However, it is unclear if aromatase 
inhibitors (AI) offer advantages over tamoxifen as adjuvant treatments for 
postmenopausal women [6]. The results of the Arimidex, Tamoxifen Alone or in 
Combination (ATAC) trial [7], and the International Breast Cancer Study Group's Breast 
International Group (BIG) 1-98 trial [8] showed small but significant improved efficacy of 
AIs, and in general fewer side effects.  
 Chemotherapy is primarily used for ER- breast tumors and for patients in 
advance stages of breast cancer. Combinatorial chemotherapy is the preferred option 
and it involves use of cyclophosphamide along with doxorubicin (‘AC’ regime) or 
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cyclophosphamide along with methotrexate and flurouracil (‘CAT’ regime) [9]. For 
HER2+ breast tumors, trastuzumab, a HER2-specific monoclonal antibody has 
improved the 5-year disease free survival to about 87% [10].  
 
1.2 Cancer metastasis and EMT: 	 Cancer progression involves the following steps: adenoma, carcinoma in situ 
and invasive carcinoma at the primary tumor site, (Fig. 1) [11]. A portion of cancer cells 
disseminate from the primary tumor, adapt and grow at a secondary site or organ other 
than the primary tumor sites, the phenomena is termed as ‘cancer metastasis’. The 
distribution of tumors and the sites of tumor growth are not a chance event, but it is 
determined by the amount of 'seeds' (the cancer cells) on the 'congenial soil' (the 
destination organ for metastasis) as postulated by the Dr. Stephen Paget in 1989 [12]. 
Approximately 90% of breast cancer-related deaths are caused by metastasis not by 
primary tumor [13]. Hence, for effective reduction of cancer mortality, it is very critical to 
intervene in the critical transition of non-invasive ductal carcinoma to extremely lethal 
invasive breast cancer. The pathogenesis of cancer metastasis consists of sequential 
steps such as migration, invasion, proliferation and angiogenesis [14].  
 Epithelial to mesenchymal transition (EMT) is a fundamental biological process 
and plays a critical role in morphogenic processes of the developing embryo, wound 
healing and organ fibrosis [15].  Tumor cells frequently use EMT to gain migratory and 
invasive properties in order to relocate and eventually form distant metastasis [16]. 
During EMT, the cancer cells undergo aggressive behavioral changes; acquiring a 
spindle-shape, loss of desmosomes and adherens junctions (such as E-cadherin, ZO-
1, occludins, and claudins), increased expression of mesenchymal markers (such as N-  
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Figure 1: Role of EMT in cancer progression.  
 
A primary tumor needs to undergo Epithelial to mesenchymal transition (EMT) in order 
to metastasize from a primary to a distant site. 
 
(Figure is taken with permission from Craene B.D. and Berx, G. Regulatory networks 
defining EMT during cancer initiation and progression. Nat. Rev Cancer. 2013; 13: 97-
110.)  License Number: 3777250370389 
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cadherin, fibronectin and vimentin) and secretion of proteolytic enzymes, such as 
matrix metalloproteases, in order to clear the extracellular matrix (ECM) and exhibit 
increased migratory properties (Fig. 2) [15].  Of note, cancer cells undergoing EMT 
exhibit increased chemotherapy resistance, decreased apoptosis and have traits 
similar to stem cells [17].  
 Both intrinsic and extrinsic stimuli are known to induce in EMT in cancer. 
Microenvironment, one of the key extrinsic stimuli, is composed of ECM, 
myofibroblasts, cancer-associated fibroblasts, immune cells and several secretory 
factors such as hepatocyte growth factor, epidermal growth factor, Wnt, transforming 
growth factor-β, Hedgehog and various cytokines such as interleukin-6 and tumor 
necrosis factor-β [18]. A cohort of transcription factors including those of the Snail, 
Twist and Zeb families are known to orchestrate the process of EMT [19]. These 
transcription factors have unique tissue-specific expression profiles and are known to 
control the expression of each other and cooperate functionally at target genes [20]. 
EMT transcription factors in concert not only repress epithelial genes but also activate 
mesenchymal genes, and often the same transcription factor is responsible for both 
activation and repression [11].  
 EMT transcription factors recognize E-box DNA sequences located near the 
transcription start site of CDH1 gene, and recruit various co-factors and histone 
deacetylases to transcriptionally repress CDH1. Notably, SNAI1 induces recruitment of 
HDAC1 and HDAC2 to induce repressive histone modifications at the CDH1 promoter 
and likewise, ZEB1 cooperates with deacetylase SIRT1 at the CDH1 promoter leading 
to deacetylation of histone H3 and reduced binding of RNA polymerase II [11].  In 
addition, various histone modifiers are linked to SNAI1 activity such as the   
	7	
		
Figure 2: An overview of regulators of EMT  
 
The EMT regulators transform the cancer cells from epithelial-cell like to mesenchymal-
cell like with suppression of epithelial markers and expression of mesenchymal 
markers. The final effects on cancer cells are cancer metastasis, drug resistance and 
with features of cancer stem cells. 	
(Figure is taken with permission from Shih JY, Yang PC. The EMT regulator slug and 
lung carcinogenesis. Carcinogenesis. 2011 Sep;32(9):1299-304.) License Number: 
3777750872518 
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methyltransferase EZH2, SUZ12 and G9a (EHMT2) [11]. Similarly, TWIST induces 
another repressive histone mark H4K20 monomethylation by recruiting the 
methyltransferase SET8 at E-cadherin promoters [21]. On the other hand, in head and 
neck carcinoma, expression of BMI1 is activated by TWIST1 and they both 
subsequently coordinate to repression of E-cadherin and p16 by recruiting the PRC2 
complex [22]. Interestingly under hypoxic conditions, the hypoxia inducible factor 
(HIF1a) induces EMT and tumor metastasis by enhancing TWIST expression [23]. The 
ZEB family of transcription factors recruits co-repressors such as C-terminal binding 
protein (CTBP) or chromatin remodeling protein, BRG1 [24]. Additionally, ZEB1 may 
also interact with p300/CBP-associated factor (PCAF) and p300 and form a 
transcriptional activation complex [25]. Therefore, similar to SNAI1 and TWIST, ZEBs 
function as transcriptional repressors or activators by binding to E-boxes and recruit 
corresponding complexes, ultimately repressing epithelial junction and polarity genes 
and activating mesenchymal genes that contribute to EMT.  
 
1.3 Cancer cells and deregulated metabolism: 
 In the second cancer hallmarks review published by Drs. Hanahan and 
Weinberg, ‘metabolic reprogramming’ is recognized as one of the key hallmarks of 
cancer [26]. Multiple research groups are trying to understand how a tumor evolves 
metabolically in order to adapt to the uptake of novel nutrients or microenvironment. 
However, because of the complex wiring of metabolic circuits and the constant 
evolution of metabolic switching, it has been difficult to completely characterize cancer 
metabolism. Current research is focused on understanding how to restrict nutrient 
consumption in these cancer cells or ways to deplete the nutrient uptake to starve 
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these cells, which would ultimately cause reduced proliferation and growth of the tumor. 
Additionally, identification of novel regulators of cancer metabolism and uncovering 
their mechanism of action are critical.  
 Normal cells convert glucose to pyruvate that is later converted to acetyl-CoA to 
fuel the tricarboxylic acid cycle (TCA cycle). NADH and FADH2 generated at the end of 
TCA cycle then provide electrons to the mitochondrial respiratory chain and ultimately 
each glucose molecule can produce up to 36 molecules of ATP. In normal cells, 
glycolysis is prioritized only when oxygen supply is limited. In contrast, cancer cells 
preferentially use glycolysis even in normoxic conditions; this phenomenon was 
discovered by Dr. Otto Warburg and is termed as ‘Warburg effect’ (Fig. 3) [27]. Hence, 
glycolysis in tumor cells is termed as ‘aerobic glycolysis’ to distinguish from the normal 
anaerobic glycolysis of healthy cells [28].  
 Glycolysis only generates 2 ATP per glucose molecule as compared to 36 ATP 
for each glucose molecule catabolized by mitochondrial respiration; hence, cancer cells 
have to compensate for the lower efficacy of energy production. They do this partly by 
up-regulating the expression of glucose transporters such has GLUT1 and GLUT4, to 
uptake more glucose and a majority of other glycolytic enzymes [29]. Oncogenes such 
as Ras, Myc, and HIF-1α are reported to be master inducers of cancer glycolysis [30]. 
Elevated transcriptional activity of c-Myc and HIF-1α along with p53 loss/mutation is 
responsible for enhancing expression of glycolytic enzymes. The majority of glycolytic 
gene promoters have consensus binding motifs of Myc and HIF-1α. In normoxia, c-myc 
promotes expression of glycolytic genes, whereas when cells are in hypoxic HIF-1α is 
activated that allows tumors to continuously drive glycolysis to not only support 
proliferation but also accelerated biosynthesis [31]. 
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Figure 3: Tumor metabolism and Warburg effect 
Normal differentiated tissues or cells, utilize glucose as an energy source through the 
glycolysis pathway and enter into Kreb’s cycle to produce more energy through 
oxidative phosphorylation. On the contrary, cancer cells, consume increased amounts 
of glucose and switch to produce lactate without entering oxidative phosphorylation. 
Cancer cells are dependent on this switch to aerobic glycolysis for proliferation 
 
(Figure is taken with permission from Vander Heiden, M.G., Cantley, L.C. and 
Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell 
proliferation. Science. 2009; 324(5930):1029-1033.) License Number: 3777851053796 
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In contrast, the tumor suppressor p53 inhibits glucose uptake by directly inhibiting the 
transcription of glucose transporter GLUT1 and GLUT4 [32]. Fructose 2,6-bisphosphate 
functions as an allosteric activator of PFK1, a major glycolytic enzyme. Fructose 2,6-
bisphosphate is produced by PFK2 from fructose 1-phosphate. p53 induces the 
expression of TIGAR and TIGAR significantly slows down tumor glycolysis by 
converting fructose 2,6-bisphosphate back to fructose 1-phosphate [33]. Hence, one of 
the key molecular interactions that define the status of cancer metabolism is that of 
p53, c-Myc and HIF-1α. 
 As per the Warburg hypothesis, it was erroneously believed that mitochondrial 
metabolism is inconsequential for the metabolic demands of actively proliferating 
cancer cells. Recent studies, provide ample genetic evidence that mitochondria are 
indeed essential for tumorigenesis [34]. Further, it is proposed that tumors are 
metabolically heterogeneous (Fig. 4). The bulk of tumor cells, exhibit aerobic glycolysis 
(Warburg effect) and there is a small population of slow-cycling tumorigenic cells that 
are dependent on OXPHOS activity. The slow-cycling cells are proposed to be the cells 
that are resistant to various cytotoxic treatments [35].  
 
1.4 TRIM family and TRIM24: 
 The TRIpartite Motif (TRIM) containing family of proteins consists of about 71 
proteins that have the signature tripartite, ‘RBCC’, motif of RING-finger domain, one or 
two zinc binding motifs named B-boxes, and an associated Coiled-Coil region. On the 
basis of differences in their C-terminal domain structure, the TRIM proteins can be 
classified into 11 different sub-families (Fig. 5). Most of the TRIM family proteins act as   
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Figure 4: Diverse metabolism in different population of cancer cells 
Different subpopulations of cancer cells coexist in tumors, contributing to functional 
heterogeneity. Rare tumorigenic cells exist in a quiescent/ slow-cycling state and are 
intrinsically resistant to cytotoxic treatments. Importantly, with respect to other cells 
inside the tumor, they seem to rely on a different metabolic program to maintain their 
energetics. In contrast to the bulk tumor, slow-cycling tumorigenic cells are more 
dependent on mitochondrial respiration (OXPHOS) and have impaired glycolytic 
capacity.  	
(Figure is taken with permission from Viale A, Corti D, Draetta GF. Tumors and 
mitochondrial respiration: a neglected connection. Cancer Res. 2015 Sep 
15;75(18):3685-6.) License Number: 3777860586185 
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Figure 5: The TRIM family of proteins.  
Based on protein structure the TRIM family of proteins is classified into nine eleven 
different sub-families. Almost all members have a RING-finger domain (R), one or two 
B-box domains (B) and a coiled-coiled domain (CC).  
 
(Figure is taken with permission from Hatakeyama S.	TRIM	 proteins	 and	 cancer.	Nat 
Rev Cancer. 2011 Oct 7;11(11):792-804.) License Number: 3777250370389 
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E3-ubiquitin ligases and they function in various cellular processes, including regulation 
of protein stability, transcription, cell proliferation and apoptosis [36]. 
 The Transcription Intermediary Factor (TIF1) sub-family is a unique sub-family of 
TRIM proteins that in addition to the N-terminal RBCC motif contains a tandem PHD-
Bromodomain at the C-terminus. TRIM24 (TIF1α) is the founding member of the TIF1 
sub-family, which includes TRIM28 (TIF1β), TRIM33 (TIF1γ) and TRIM66 (TIF1δ) [37].  
Generally, a PHD-domain interacts with methylated lysines of histones, whereas the 
Bromo-domains interact with acetylated lysines of histones [38, 39]. Various members 
of TIF1 sub-family play key roles in regulating epigenetic mechanisms of transcriptional 
regulation that involve histone modifiers, nuclear receptors and heterochromatin 
binding proteins [37].  
 Oncoprotein T18 was one of the very first reports of TRIM24, in which it was 
found to be a fusion partner along with B-Raf protein. T18 had the first 332 amino acids 
of TRIM24 in its N-terminus and B-Raf protein at the C-terminus [40]. Using yeast two-
hybrid screens, it was shown that mouse heterochromatin protein 1 alpha (mHP1a) 
interacts with TRIM24 via mHP1 chromo-shadow domain [41]. As the name suggests, 
HP1 proteins are associated with formation of heterochromatin and inhibition of gene 
expression. Using luciferase reporter assays, it was shown that interaction of TRIM24 
and mHP1a associated with gene repression. In contrast, another group showed that 
TRIM24 exhibits its transcription repression activity in the absence its HP1-binding 
region in a similar reporter system [42]. Bonus, a Drosophila homolog of TIF1 proteins, 
is essential for development and interacts with various nuclear receptors such as 
betaFTZ-F1 and DHR3 [43]. Of note, the N-terminal RBCC motif of Bonus is essential 
for its transcriptional repression activity, but not the HP1-binding region and the C-
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terminal PHD/Bromo domain. Hence, whether an HP1 interaction is essential for 
TRIM24-mediated gene regulation is not clear. 
 In contrast, TRIM24 localization studies reveal that TRIM24 associates with 
euchromatin of interphasic nuclei, and is not associated with condensed chromatin and 
metaphase chromosomes [44]. TRIM24 physically interacts with arginine 
methyltransferase 1 (CARM1) and glucocorticoid receptor-interacting protein 1 (GRIP1) 
to enhance transcriptional activation mediated by nuclear receptors [45]. TRIM24 
knockdown is reported to diminish transcriptional activation mediated by GRIP1 and 
AR. Additionally, TRIM24 also reportedly interacts with several chromatin remodeling 
proteins. In mouse development during the zygote stage, TRIM24 is localized to 
transcriptional active sites co-occupied by SNF2H and BRG-1 that are known 
chromatin-remodeling proteins [46]. Notably, TRIM24 depletion caused mislocalization 
of RNA Pol-II, BRG-1 and SNF-2 and down-regulation of their target genes in the 
zygote. Hence, these results suggest that TRIM24 may play an active role in 
transcriptional activation.  
 TRIM24 acts a transcriptional co-regulator by virtue of its LXXL motif by which it 
interacts with various nuclear receptors such as RARα, Vitamin D3, androgen and 
estrogen receptors (Fig. 6). TRIM24 modulates the transcriptional activity of various 
nuclear receptors either positively or negatively in a ligand dependent manner. In 
prostate cancer cells, TRIM24 directly interacts with a histone acetyltransferase, TIP60, 
a coactivator of androgen receptor (AR) [47]. Additionally, TRIM24 also binds to 
bromodomain-containing 7 (BRD7), a corepressor of AR and negative regulator of cell 
proliferation. Thus, TRIM24 regulates AR-mediated transcription through crosstalk 
between TIP60 and BRD7 in prostate cancer [47].  
	16	
 				
 
 
 
 
 
 
 
 
 
Figure 6: TRIM24 protein structure Diagram	of	TRIM24	protein	structure	and	domains,	along	with	its	known	functions.			
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In a mouse model targeting exon 4 of TRIM24 for germline deletion Trim24dlE4/dlE4, it 
was discovered that RAR-mediated signaling was reactivated, through re-expression of 
RARα and repressed genes in the liver, leading to eventual HCC [48]. Additionally, 
TRIM24 was shown to suppress HCC progression by inhibition of the IFN/STAT 
pathway via RAR dependent regulation of the Stat1 promoter [49]. Based on analysis 
of this mouse model, it was suggested that TRIM24 is a liver-specific, retinoid-
dependent tumor suppressor [48]. However, recent evidence suggests that 
Trim24dlE4/dlE4 mice retain normal levels of Trim24 RNA lacking exon 4 and are not null 
of TRIM24 in liver [50]. Our laboratory generated a new mouse model for complete 
TRIM24 knockdown by targeting exon 1 of TRIM24 (TRIM24dlE1/dlE1).  It was found that 
TRIM24dlE1/dlE1 mice have a significant depletion of visceral fat and spontaneously 
develop liver steatosis, fibrosis and ultimately hepatocellular carcinoma. In the murine 
liver, TRIM24 acts as a transcriptional co-repressor by repressing hepatic lipid 
accumulation, inflammation, and damage [51].  
 Based on multiple studies it can be concluded that TRIM24 plays a dual role of 
transcriptional co-activator and transcriptional co-repressor, and its role is dependent 
on the tissue type and associated complexes. Interestingly, it has been reported that 
TRIM24 may phosphorylate various transcription factors by acting as a protein kinase 
in vitro [52]. However, based on protein sequence analysis TRIM24 contains no 
conserved characteristics of protein kinase domains and there are no reported in vivo 
substrates.  
 Our laboratory identified TRIM24 as a p53-interacting protein, upon purification 
of an endogenous TAP-tagged version of p53 in embryonic stem cells (ES cells) [53]. 
Knockdown of TRIM24 ortholog, bonus, in Drosophila induces apoptosis. Further, 
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mosaic analysis in Drosophila depleted in the TRIM24 ortholog, bonus, shows that p53 
could rescue apoptosis of imaginal disc cells. Similarly, TRIM24 knockdown in breast 
cancer cell lines (MCF7) results in p53-depedent apoptosis [53]. Additional studies in 
MCF7 breast cancer cell lines, which harbor wild-type p53, showed that TRIM24 
responds to stress and damage by negatively regulating p53 through an autoregulatory 
feedback loop. It was found in response to DNA-damage the TRIM24-p53 interaction is 
disrupted due to ATM-mediated TRIM24 phosphorylation. In turn, the damage-
activated p53 binds to p53 response elements on TRIM24 gene and induces TRIM24 
gene expression. Finally, the newly synthesized TRIM24 terminates the DNA damage 
response by targeting phosphorylated-p53 for proteasomal-mediated degradation.  This 
feedback loop was found to be independent of MDM2 and dependent upon direct 
binding of p53 to p53 response elements (p53 REs) in the distal promoter region of 
TRIM24 [54]. 
 The aforementioned studies provide genetic evidence that TRIM24 acts as a 
tumor suppressor in murine liver, but there are multiple studies that provide evidence 
that TRIM24 acts as an oncogene in various cancers such as in prostate cancer [47], 
breast cancer [55, 56], non-small cell lung cancer [57], head and neck carcinoma [58], 
colorectal cancer [59], gastric cancer [60], glioblastoma [61], bladder cancer [62] and 
even human hepatocellular carcinoma [63] (Table 1). Expression of TRIM24 has been 
reported to correlate negatively with survival of breast cancer patients [55, 56]. 
Molecular and three-dimensional structural analysis showed that TRIM24 via its 
tandem PHD-Bromo domain acts as a dual histone code reader of H3K4me0 and 
H3K23ac. It was found that TRIM24 binds estrogen receptor and chromatin (at specific   
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Table 1: List of various studies of TRIM24 in different cancers 
  
Cancer Human/ Mouse 
Oncogene/Tumor 
Suppressor 
Clinical 
data Mechanism Ref. 
HCC Mouse Tumor Suppressor No 
RAR-a 
corepressor [48, 51] 
Breast Human Oncogene Yes ER-a coactivator [55] 
NSCLC Human Oncogene Yes NA [57] 
HNSCC Human Oncogene Yes NA [58] 
CRC Human Oncogene No NA [59] 
Gastric Human Oncogene Yes NA [60] 
GBM Human Oncogene Yes PIK3CA/Akt [61] 
Bladder Human Oncogene Yes NA [62] 
HCC Human Oncogene Yes NA [63] 
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histone modifications mentioned above) to activate estrogen-dependent genes 
associated with tumor development and cell proliferation [55]. Hence, by reading a non-
canonical histone signature the PHD-Bromo domain of TRIM24 provides a structural 
rationale for gene regulation, establishing a novel route by which histone readers may 
influence pathogenesis of cancer.  
 Similar to other correlations in human cancers, it was found that TRIM24 
expression positively correlates with glioma malignancy and it is a marker of poor 
prognosis for patients with newly diagnosed glioblastoma (GBM) [61]. TRIM24 
expression is critical for efficient cell proliferation, cell cycle progression, and in vivo 
tumor growth in GBM. These authors showed that TRIM24 directly activates PIK3CA 
gene expression in a PHD-Bromo domain dependent manner. Intriguingly, TRIM24-
mediated regulation of the PI3K/AKT/NF-κβ pathway induces the expression of DNA 
repair gene O6-methylguanine-DNA methyltransferase (MGMT) and induces 
chemoresistance to temozolomide in GBM cells [61].  
 Although, it has yet to be determined if TRIM24 can target mutant p53 for 
proteasomal-based degradation, in a very elegant study it was found that TRIM24 may 
be part of a protein complex responsible for conversion of mutant p53 conformation to 
its WT form [64]. The studies were done in mouse embryonic stem cells harboring 
mutant p53 (ES-cellsmutp53) that remained pluripotent and had a normal karyotype as 
compared to ES-cells knocked out of p53. In ES-cellsmutp53, the mutant p53 was 
transcriptionally active in response to DNA-damage and activated canonical p53-target 
genes such as p21 and btg2. Among the network of proteins identified by MS-based 
interactome analysis of p53, in addition to TRIM24, was CCT complex, USP7, Aurora 
kinase and Nedd4 [64].  
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 To summarize, there are several reports of TRIM24 association with poor 
prognosis and survival in various cancers [55, 56]. TRIM24 regulates gene expression 
by acting either as transcriptional activator or repressor. However, whether TRIM24 
plays a causal role in malignant transformation during tumor development and 
progression has yet to be studied. Further, the mechanisms involved in potential 
TRIM24-mediated tumor initiation and progression are unknown. 
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2.1 Cell culture 
Previously established HMEC cultures, 184D (normal pre-stasis [65]), 184B-7p 
(abnormal, post-stasis [65]), 184A1 (Immortal non-malignant[66]) and 184AA2 
(Immortal malignant [67]) were cultured in M87A medium with 0.1% AlbuMAX bovine 
serum albumin (Invitrogen) and 0.1 nmol/L oxytocin (Bachem) as described [65].  
MCF10A cells were cultured as described [68]. Human breast cancer cell lines (MCF-7, 
MDA-MB-231, MDA-MB-468, and SKBR3) from ATCC were cultured according to the 
supplier’s protocols. For transient knockdown experiments, TRIM24 (L-047483-00) and 
non-silencing control (D-00120-01-20) small interfering RNAs (siRNAs) (Dharmacon) 
were transfected at 100 nM for 48 hours using Lipofectamine RNAiMAX reagent 
(Invitrogen) as per manufactures instructions. 
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2.2 Cell proliferation, soft agar colony formation, and cell-cycle analysis 
For cell proliferation (7500 cells in 24 well plate, in triplicates) and XTT assays (500 
cells in 96 well plates, in quadruplets), respective cell numbers were seeded and 
counted every 2 days for upto 6 days (Beckman Coulter counter). For soft agar colony 
formation, 5000 cells were seeded in 1.5 ml of respective medium with 0.35% low-
melting-temperature agarose (BD Biosciences) overlying 1.5 mL of 0.7% low-melting 
agarose in 6-well plates and incubated at 37°C for 14 days. For cell-cycle analysis, 
cells were washed and fixed with 70% ethanol for 1 hour at 4°C and stained with 
propidium iodide at a concentration of 50 µg/mL, along with RNase A (100 U/mL), prior 
to analysis using Flow cytometry and ModFit software program (Verity Software 
House).  
 
2.3 Generation of stable cells 
TRIM24 full-length coding sequences were amplified from the vector pCMV-XL4-
hsTRIM24 (OriGene Technologies) using gene-specific primers (Appendix 1), digested 
with XbaI and PmlI and cloned into pEntry4-FLAG vector [69]. TRIM24 coding 
sequences and FLAG-only sequences were transferred to pLenti-PGK-Neo-DEST [69] 
using Gateway cloning (Invitrogen). Lentiviruses containing culture supernatants were 
prepared as described [55]. Briefly, 800 ng of clone/vector DNA were transfected into 
HEK293T cells with packaging vectors pPAX2 and pMD2 (800 ng each) using 
Effectene (Qiagen) according to manufacturer’s instructions. After 48 hours, target cell 
line was transduced using virus-containing culture supernatants with 8 µg /mL 
Polybrene (Sigma). After 48 hours, cells were selected using 700 µg/mL G418 
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(Stratagene) for 10 days. Stable cell lines, ectopically expressing TRIM24 or FLAG only 
were maintained in regular culture medium containing 200 µg/ml G418. 
 
2.4 Quantitative real-time PCR (qRT-PCR) 
Total RNA was isolated with TRIzol reagent (Invitrogen) and qRT-PCR analysis was 
performed as described [55].  Primers used are listed in Appendix 1.  
 
2.5 nCounter analysis 
A panel of 420 breast cancer associated genes was used for nCounter analysis 
(NanoString Technologies) [70]. Three biological replicates of RNA from TRIM24 and 
Control iHMECs (100ng each) were processed according to the manufacturer’s 
recommendations (http://www.nanostring.com). Data were analyzed using the nSolver 
digital analyzer software program (http://www.nanostring.com/products/nSolver). 
Differentially expressed genes were identified using the Student t-test: genes with 
expression significantly (p < 0.05) up- (fold change ≥ 1.2) or down-regulated (fold 
change ≤ 0.8) were identified.  Unsupervised hierarchical clustering of differentially 
expressed genes was performed using the GENE-E software program 
(http://www.broadinstitute.org/cancer/software/GENE-E/) and a Euclidean distance 
matrix. Gene Ontology (GO) category (http://www.geneontology.org/) enrichment 
analysis and KEGG pathway analysis were done using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/) [71]. 
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2.6 Immunoblotting and Immunohistochemistry 
Immunoblotting of proteins in TRIM24 and Control iHMECs was performed using 
standard techniques with antibodies listed in Appendix 2. Immunohistochemistry (IHC) 
of breast tumor arrays, BR2082 (US Biomax) and BR1503 (US Biomax), was 
performed, as described [55], using a VECTASTAIN Elite ABC Kit and a DAB Detection 
Kit (Vector Laboratories) with an anti-TRIM24 antibody (1:200 dilution; Proteintech). 
IHC staining data for ER, PR, and ErbB2 were available and TRIM24 staining was 
quantified using the Allred scoring method (for details of the Chi-square method and 
calculations please see Appendix 3) [72].  
 
2.7 Metabolic experiments and glucose uptake 
The extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of 
TRIM24 and Control iHMECs were measured using an XFe96 Extracellular Flux 
Analyzer (Seahorse Bioscience) as described [73]. Briefly, 50,000 cells were seeded 
into XFe96 tissue culture plates in quadruplicate and ECAR and OCR measured under 
basal conditions and after sequential treatment of the cells with Oligomycin (1 µM), 
FCCP (Carbonylcyanide p-trifluoromethoxyphenylhydrazone, 500 nM) and Rot + Ant 
[Rotenone (1 µM)  + Antimycin A (1 µM)]. Cells were trypsinized and counted using a 
Coulter counter (Beckman Coulter) and the cell count used for normalization purposes. 
For glucose uptake assays, a non-metabolic fluorescent-labeled glucose (2- NBDG) 
was used. iHMECs were seeded in the regular HMEC medium for 24h and just prior to 
performing the assay were washed with glucose-free medium. Cells were incubated 
with glucose-free medium, containing 120 µM 2-NBDG (Invitrogen) for 0.5h, 1.0h, 1.5h 
and 2h, followed by FACS analysis. 
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2.8 Xenograft experiments 
Female athymic Nu/Nu mice (age 6–8 weeks) were housed under pathogen-free 
conditions. 1 million TRIM24 iHMECs or Control iHMECs suspended in 50 µl of serum 
free DMEM were co-injected subcutaneously with 50 µl of high concentration Matrigel 
(BD Biosciences); 10-15 mice were injected for each cell line. Tumor sizes were 
measured weekly by caliper for up to 64 days and xenograft volume calculated as 
previously described [74]. All procedures were approved by the University of Texas M 
D Anderson Cancer Center Institutional Animal Care and Use Committee and 
performed with veterinary supervision. 
 
2.9 The Cancer Genome Atlas data and statistical methods 
The Cancer Genome Atlas – Breast invasive carcinoma (TCGA-BRCA) data on RNA 
expression (Level 3) of Breast invasive carcinoma patients (1008) and normal tissues 
(92) in terms of RSEM (RNA-seq by Expectation-Maximization) were downloaded from 
the Broad Institute TCGA Firehose Genome Data analysis center pipeline (standard 
data run 2013/11/14). 950 of 1008 BRCA samples had PAM50 subtype information 
available. Gene set enrichment analysis (GSEA) was run with default parameters with 
TRIM24 expression levels as phenotype and C2 (canonical pathways) gene 
sets.  GSEA with patient samples limited to Basal subtypes and TRIM24 expression as 
phenotype gave very similar results. 
 
2.10 Invasion and migration assays 
Cells were resuspended in 500 µl serum-free media and seeded in a 24-well Transwell 
or Matrigel plate (BD Biosciences, pore size 8 µm) at a concentration of (5 to 7.5) x 104 
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per well. 750 µl of DMEM/ RPMI supplemented with 10% FBS was added to the lower 
chamber and cells were allowed to migrate or invade for 16 h in 5% CO2 at 37°C. 
Migrating cells were stained with 0.1% crystal violet. Non-migrating cells were removed 
using a cotton swab. Migrated cells were quantified based on five microscopic fields at 
a 4X magnification and results were represented as mean ± standard deviation and 
student’s t-test was performed for statistical significance. Each assay was performed in 
triplicates. 
 
2.11 Acini formation assay 
The overlay method of acini formation assay for MCF10A cells was performed as 
described [68]. Briefly, 40ul of growth-factor reduced matrigel (BD Biosciences – No. 
354230) was added to each well of an eight-well glass chamber slide (Fisher – 
1256518)  and spread evenly in the well using the P-200 tip (the slides can be 
assembled on ice). MCF10A cells were trypsinized and resuspended in 2 ml of 
Resuspension medium and spun down for 3 min at 150g in a tissue culture centrifuge. 
The cells were then mixed in assay medium without EGF and mixed 10-25 times to 
obtain a single-cell suspension. 25,000 cells per ml cells were mixed 1:1 with assay 
medium containing 4% matrigel and 10 ng/ml of EGF (usually 1ml of each). 400 µl of 
this mixture was plated on the top of solidified matrigel in each well of the chamber 
slide. Final concentration of cells is 5000 cells per well in assay medium containing 2% 
matrigel and 5 ng/ml EGF. Cells are allowed to grow in 5% CO2 humidified incubator at 
37oC for 10-12 days and the cells are refed with fresh assay medium containing 2% 
matrigel and 5 ng/ml EGF every 4 days.  	
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2.12 Experimental lung metastasis studies 
To determine the experimental metastatic potential of cells, 5 x 105 MDA-MB-231 
control-shRNA (GIPZ) and TRIM24-shRNA (GIPZ) cells labeled with RFP-firefly 
luciferase were injected into NOD/SCID mice via the tail vein. SCID Mice were 
assessed weekly for presence of lung metastasis after the intraperitoneal injection of D-
Luciferin (Fisher – PI88293). In vivo bioluminescence was assessed using the IVIS 
imaging system 200 series (PerkinElmer), approximately 10 mins post-injection. Until 
about 6-7 weeks, mice were monitored for lung metastasis weekly and were 
euthanized after 7 weeks. Lungs were removed surgically and fixed using Bouin's fluid 
and the number of lung tumor nodules was counted and subjected to hematoxylin and 
eosin staining thereafter. Lungs were also stained for RFP and TRIM24 to ascertain the 
presence of MDA-MB-231 cells and TRIM24 expression, respectively. All procedures 
were approved by the University of Texas M D Anderson Cancer Center - IACUC and 
performed under proper supervision of veterinary personnel. 	
2.13 HTG EdgeSeq analysis 
mRNA expression profiling of 2,560 genes was done using the HTG EdgeSeq 
Oncology Biomarker Panel assay. The assay uses an NGS-based gene expression 
system powered by HTG EdgeSeq chemistry. Samples were processed according to 
the manufacturer’s recommendations (http://www.htgmolecular.com/science/sample-
prep). Differentially expressed genes were identified using the Student t-test: genes 
with expression significantly (p < 0.05) up- (fold change ≥ 1.2) or down-regulated (fold 
change ≤ 0.8) were identified. Gene Ontology (GO) category enrichment analysis and 
KEGG pathway analysis were done using the molecular signatures database (MSigDB) 
[75].  
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2.14 Chromatin immunoprecipitation (in breast cancer cells) 
Chromatin immunoprecipitation (ChIP) is routinely used in our laboratory [55]. Briefly 
for chromatin immunoprecipitation, cells are harvested and then cross-linked with 
formaldehyde for 10 min and neutralized with glycine. Cells are lyzed with 1 mL Cell 
Lysis Buffer (5mM PIPES pH 8.0, 85mM KCl, 0.5% NP-40, fresh protease inhibitors) for 
15 minutes. After sonication, the tubes are spun. Supernatant is transferred to a new 
tube to check for fragment size. Lysates are divided and diluted using ChIP Lysis 
Buffer. Immunoprecipitation is performed overnight with specific antibodies. The next 
day, Protein A Sepharose beads (GE Health) are incubated with antibody/protein 
bound complexes for 2 hr at 4°C. Then, Protein A beads are washed and re-suspended 
and incubated with RNase A for 30 min at 37°C and then Protease K for 2 hours at 
55°C. The crosslinks are reversed by incubating the samples at 65°C overnight. The 
next day, protein /antibody bound DNA fragments are extracted with 
Phenol/Chloroform. qPCR analyses are performed to analyze specific antibody- and 
protein-bound.  
	
2.15 Co-immunoprecipitation  
Cells were lysed in NTEP buffer (25mM Tris-HCl pH 7.5, 150mM NaCl, 5mM EDTA, 
0.5% NP-40) for 30 minutes at cold room. Using high-speed centrifugation, 14,000rpm 
for about 10 minutes, the cell lysate is spun down. Protein concentration was measured 
with BCA assay. 500 µg of cell lysate was pre-cleared by incubating with Protein A 
sepharose beads (GE health). 500 µg cell lysate was used to incubate per respective 
antibody overnight in the cold room. Then, protein A Sepharose beads (GE Health) 
were added for additional 2 hours incubation. After extensive washing, 35 µl SDS 
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loading dye was added into the beads, the beads was boiled for 5-10 minutes to elute 
the protein complex. Elute was then subject to western blot in various percentage of 
SDS-PAGE gels.  
 
2.15 Karyotyping 
a) Protocol for Chromosome preparation:   
Exponentially growing cells were exposed to Colcemid (0.04 µg/ml) for one hour at 
37°C and to hypotonic treatment (0.075 M KCl) for 20 minutes at room temperature. 
Cells were fixed in a methanol and acetic acid (3:1 by volume) mixture for 15 minutes, 
and washed three times in the fixative.  Slides were prepared by dropping 50-100 µl the 
cell suspension on wet slides and air-dried.   
b) Protocol for G-banding:   
Slides were baked at 90° C for 3 hours. They were then treated with trypsin (200µl 
of 40X trypsin +1X HBSS, pH 7) for 2.5 ~ 3.5 minutes. Stained in 8% Giemsa staining 
solution for 3 ~ 4 minutes. Images were captured using Nikon 80i microscope equipped 
with Spectral Karyotyping software from Applied Spectral Imaging (ASI, Vista, CA). 15-
20 metaphases were karyotyped from each cell line.     
 *Karyotyping was performed at MD Anderson Cytogenetics Core 
 
2.16 Immunofluorescence 
Cells were grown on a sterile glass cover slips or slides overnight in 37oC/5% 
CO2 incubator. Slides were then rinsed briefly with PBS and cells were fixed by 
incubation with 1% formalin in PBS for 10 minutes. Slides were then rinsed three times 
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with PBS. Incubate with primary antibody for 1 hour at room temperature or overnight 
at 4oC. Optimal antibody concentration is usually from 1-10ug/ml in PBS-BSA. Wash 
three times with PBS. Incubate with conjugated secondary antibody for 45 minutes. 
Again, optimal antibody concentration is usually from 1-10ug/ml in PBS-BSA. Wash 
three times with PBS. Mount aqueous coverslip 							
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3.1 Introduction and Rationale 
 
 Recent studies indicate that specific members of the tripartite motif (TRIM) protein 
family, characterized by conserved amino (N)-terminal zinc-finger domains of a RING-
type E3 ubiquitin ligase, B-boxes and coiled coil, are important regulators of 
carcinogenesis [36]. Among these, we identified TRIM24, as a previously unknown E3-
ubiquitin ligase of p53 in embryonic stem cells and breast cancer cell lines, and as a 
histone reader that activates estrogen-dependent genes associated with cellular 
proliferation and tumor development	 [53, 55, 76]. Of note, we and others reported that 
high expression of TRIM24 is associated with poor prognosis and survival in breast 
cancer patients [55, 56]. However, whether TRIM24 plays a causal role in malignant 
transformation of breast epithelial cells during breast tumor development and 
progression has yet to be studied. Further, the mechanisms involved in potential 
TRIM24-mediated breast tumor initiation and progression are unknown. 
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3.2 Aberrant expression of TRIM24 during breast cancer progression 
 
 To determine whether TRIM24 expression in breast tissues was deregulated during 
breast cancer progression, we performed IHC-staining to detect TRIM24 protein 
expression in a human tissue microarray (BR2082, US Biomax) consisting of samples 
of normal breast tissue, atypical ductal hyperplasia, intraductal breast carcinoma, and 
invasive breast carcinoma. We detected low TRIM24 protein expression in normal 
breast tissue but high expression in atypical ductal hyperplasia and carcinoma (Fig. 
7A), suggesting that TRIM24 expression is deregulated in breast cancer and likely early 
in progression. We then examined the expression of TRIM24 in 1008 breast cancer 
patients and 92 normal samples from The Cancer Genome Atlas – Breast invasive 
carcinoma (TCGA-BRCA) dataset.  We found the TRIM24 was significantly upregulated 
in breast invasive carcinoma patients (p-value: 1e-16, Fig. 7B) and its expression in 
paired samples was greater than 1.5 fold in 40 out of 106 (37.8%) patients (Fig. 8A).  
 Next, we assessed whether high levels of TRIM24 expression were associated with 
any specific breast cancer sub-type by using the TCGA-BRCA dataset and by 
performing TRIM24-IHC in an array of tissue samples from 72 breast cancer cases. In 
the TCGA-BRCA dataset, the PAM50 (Prediction analysis of Microarray – 50 genes 
expression signature[77]) breast-cancer subtypes showed different distribution in 
TRIM24 high expressing versus low expressing patients (p-value: 1.32e-07).  The basal 
subtype (Odds ratio: 1.98, p-value: 3.8e-04) was significantly over-represented in the 
TRIM24 high expressing patients, followed by HER2 (Odds ratio: 1.78, p-value: 0.03) 
and Luminal B subtype (Odds ratio: 1.4, p-value: 0.047); whereas, the Luminal A 
subtype (Odds ratio: 0.43, p-value: 1.46e-08) was significantly under-represented (Fig. 
7C).  For details of the intersection of PAM50 and TRIM24-expression analysis, please   
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Figure 7: Aberrant expression of TRIM24 during breast cancer progression.	
A, TRIM24-Immunohistochemical (IHC) staining was performed on a breast tissue 
array (BR2082, US Biomax) with tissues from different stages of breast cancer 
progression such as normal mammary gland, atypical ductal hyperplasia, Intraductal 
carcinoma and invasive ductal carcinoma, B, Distribution of TRIM24 expression (p-
value:1.32e-07) in TCGA breast invasive carcinoma patients (1008) and normal tissues 
(92) and C, in PAM50 breast cancer subtypes (950). D, TRIM24 expression in breast 
tissue array (BR1503, US Biomax) by Allred score (left), Correlation of TRIM24 
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expression with ER, PR, HER2, p53, and Ki67 (right and bottom left, as assessed by 
IHC). ***p < 0.001.  
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Figure 8: Aberrant expression of TRIM24 in paired samples of invasive 
carcinoma and classification based on breast cancer-subtypes 	
A, Distribution of TRIM24 expression in TCGA breast invasive carcinoma patients in 
106 paired samples; B, Distribution of TRIM24 expression in TCGA breast invasive 
carcinoma patients based on PAM50 breast cancer subtypes (950). TRIM24 high-
expression patients were defined as 30% of patients with high TRIM24 expression. The 
A B 
•  Fold change > 0 for 78 of 106 (73%) 
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p-values suggest enrichment of a particular subtype in TRIM24 high-expressing 
patients 
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see Fig. 8B. In the breast cancer tissue array (BR2082, US Biomax), TRIM24 
expression stratified into three classes: low (score, 0-2), undetectable to low expression 
in few foci (25%); intermediate (score, 3-5), abundant foci with expression in nuclear 
and cytoplasmic compartments (47%); and high (score, 6-8), abundant foci with high 
expression in nuclei (28%, Fig.6D). Of note, chi-square testing identified a statistically 
significant positive correlation of TRIM24 expression with ErbB2 (HER2) expression (p 
< 0.0001) and ER (p = 0.003) – Appendix 3. 
 To estimate a timeline for deregulation of TRIM24 expression in breast cancer cells 
during malignant transformation, we used an isogenic human mammary epithelial cells 
(iHMECs) model that facilitates assessment of molecular changes from the earliest 
stages of human breast carcinogenesis (Fig. 9A). In this model, the transformation of 
normal, finite lifespan iHMECs to malignant cells requires overcoming two distinct 
senescence-associated barriers to immortality [78, 79]. The first, a stress-associated 
barrier called stasis, is overcome or bypassed in cultured iHMECs by inactivation of the 
RB pathway, commonly through loss of p16ink4a expression [65, 66, 80, 81]. iHMECs 
that escape stasis undergo further proliferation before encountering the second, more 
stringent barrier to immortality due to critically shortened telomeres [81]. In rare 
instances, cells that gain telomerase expression escape this barrier and acquire 
immortal potential. Additional perturbations, such as insertional mutagenesis of p53 
[67] or transduction of specific oncogenes [82] can confer malignant properties to the 
immortally transformed cells. We found that endogenous TRIM24 expression increases 
at both RNA and protein levels early in the transformation process, after stasis is 
overcome (184B-7p [65, 78]), and continues to be highly expressed in the immortalized 
HMEC lines 184A1[66] and 184AA2[67] (Fig. 9B). Strikingly, TRIM24 expression was 
even more highly up-regulated in MCF-7 cells (p53 wild type and ER positive),   
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Figure 9: Aberrant expression of TRIM24 in an isogenic HMEC model 
A, Schematic of the isogenic HMEC model showing transition of the cells from finite-
lifespan cells to immortal and malignant cells. B, TRIM24 mRNA (left) and protein 
(right) expression in HMEC lines transitioning from “normal” finite-lifespan cells before 
stasis to immortal and malignant cells. Data are averages from three biological 
replicates ± standard deviation (SD). **p < 0.01.  
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MDAMB231 (p53- mutant and triple negative) and SKBR3 (p53-mutant and HER2 
positive) cultured lines of breast tumor-derived cells (Fig. 9B).  Thus, the progressive 
stages of breast cancer in human patient tumor samples and immortalization of 
isogenic HMEC lines support a correlation between TRIM24 expression and loss of 
normal, cellular homeostasis. 
 
3.3 TRIM24 drives iHMEC transformation and survival 
 
 To answer the critical question of whether TRIM24 causes malignant transformation 
of iHMECs, we induced ectopic expression of TRIM24 in the non-malignant, immortal 
184A1 HMEC (iHMEC) line. Analysis of stable control- (FLAG-only) and TRIM24-
expressing, lentiviral-transduced iHMEC pools from two independent experiments 
(TRIM24-1 and TRIM24-2) showed increased TRIM24 expression at both the RNA and 
protein level, compared to control pooled cells (Fig. 10A). Of note, we see a 
corresponding decrease in p53 protein expression in both TRIM24-1 and TRIM24-2 
iHMECs suggesting that the ectopically expressed TRIM24 is enzymatically active [53]. 
The growth rates of TRIM24-1 and TRIM24-2 iHMECs were significantly higher than 
control vector-transduced iHMECs, suggesting increased proliferation (by cell count 
see Fig. 10B; by XTT assay see Fig. 10C). Consistent with this, both TRIM24-1 and 
TRIM24-2 iHMECs exhibited significant enrichment of cells in the S and G2/M phases 
of the cell cycle, compared to control cells enriched in G1, indicating rapid cell-cycle 
progression as a result of TRIM24 expression (Fig. 10D, for flow data see Fig. 11). 
 To assess the oncogenic potential of TRIM24-iHMECs, we examined their ability to 
grow in an anchorage-independent manner in soft agar. Our control iHMEC line failed 
to form colonies in soft agar, whereas TRIM24-iHMECs formed colonies comparable in   
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Figure 10: TRIM24 drives iHMEC transformation and survival.  
A, qRT-PCR analysis of TRIM24 mRNA and Immunoblot of TRIM24 and p53 in 
Control, TRIM24-1, and TRIM24-2 iHMECs. B & C, Cell proliferation analysis of 
Control, TRIM24-1, and TRIM24-2 iHMECs by cell count and XTT-based analysis. C, 
Cell-cycle analysis of Control, TRIM24-1, and TRIM24-2 iHMECs. D, Anchorage-
independent proliferation of Control iHMECs, TRIM24-1 iHMECs, and MCF-7 cells as 
determined using a soft agar colony formation assay (left) and quantification of the 
colonies per field ± SD (right). The data are averages from two replicates ± SD. *p < 
0.05; **p < 0.01; ***p < 0.001.  
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Figure 11: Graphical representation of cell cycle changes in control vs TRIM24-
iHMECs  
Flow data for cell cycle analysis of Control, TRIM24-1 and TRIM24-2 iHMECs. 
  
Control 
TRIM24-1 
TRIM24-2 
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size and number to colonies of MCF-7 cells used as a positive control (Fig. 10E). Thus, 
ectopic expression of TRIM24 confers anchorage-independent growth to iHMECs, 
suggesting that TRIM24 over expression is sufficient to induce malignant 
transformation of immortal, nontumorigenic HMECs.  
 
3.4 TRIM24 regulates multiple cancer-associated pathways and promotes a 
glycolytic and TCA-cycle gene signature in HMECs 
 To understand the mechanisms of TRIM24-induced transformation of iHMECs, we 
analyzed the gene expression profiles of 420 cancer-associated genes in TRIM24-
iHMECs and control iHMECs using the nCounter analysis system. This analysis 
identified 233 genes (55% of the total) that were significantly changed suggesting that 
TRIM24 mediated deregulated expression of cancer-relevant genes. Expression of 127 
(30%) of these genes was upregulated, whereas 106 genes (25%) were downregulated 
(Appendix 4).  Unsupervised hierarchical clustering of the 233 differentially expressed 
genes clearly distinguished the control and TRIM24-iHMECs (Fig. 12A), supporting 
TRIM24-mediated transformation of iHMECs via effects on cancer-associated genes 
and pathways.  
 TRIM24 induced expression of genes frequently altered in cancers, including PTEN, 
NRAS, KRAS and others that enrich amongst multiple cancer pathways (see Appendix 
5 and 6). Additionally, TRIM24 up-regulated genes are significantly enriched (p≤0.05) in 
functional pathways that impact metabolism and growth, including the citrate cycle 
(TCA), ErbB, insulin, mitogen-activated protein kinase (MAPK) and mTOR signaling 
and cell cycle regulation (Fig. 12B). The highly significant pathways downregulated by   
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Figure 12: Regulation of multiple cancer-associated pathways in iHMECs by 
TRIM24. 
A, Heat map showing unsupervised hierarchical clustering of 233 differentially 
expressed genes in TRIM24-1 compared to the Control. B, Table showing the list of 
Upregulated pathways associated with Growth and Metabolism in TRIM24-iHMECs C, 
qRT-PCR analysis of Glycolytic genes in Control, TRIM24-1, and TRIM24-2 iHMECs 
showing upregulation of their expression. D, Immunoblot for various Glycolytic proteins 
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in Control, TRIM24-1, and TRIM24-2 iHMECs. E, qRT-PCR analysis of TCA-cycle 
genes in Control, TRIM24-1, and TRIM24-2 iHMECs. The data are averages from three 
biological replicates ± SD. F, GSEA profiles of different pathways positively correlated 
to TRIM24 expression in TCGA-BRCA dataset. NES: Normalized Enrichment Score. *p 
< 0.05; **p < 0.01; ***p < 0.001.  
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TRIM24 expression includes TP53, representing a breadth of cancer types and 
pathways, as well as members of the ErbB pathway (see Appendix 5 and 6).  
 Analysis of individual glycolytic regulatory genes uncovered a glycolytic signature, 
specific to TRIM24-iHMECs versus control, marked by increased Hexokinase 2 (HK2), 
Phospho-glutamase 1 (PGM1), Enolase 1 (ENO1), Glucose-6-phosphate isomerase 
(GPI), Pyruvate dehydrogenase kinase 1 (PDK1), and Lactate dehydrogenase C 
(LDHC) mRNA expression (Fig. 12C). Gene expression changes were reflected in 
elevated HK2, PGM1, ENO1, PDK1, and LDHC protein expression, along with elevated 
Aldolase A (Aldo) protein (Fig. 12D). HK2 is a key enzyme involved in tight regulation of 
glycolysis via catalysis of individual, irreversible steps of glucose to glucose-6-
phosphate and phosphoenolpyruvate to pyruvate [83].  
 Additionally, we found that expression of TCA-cycle genes was also higher in 
TRIM24-1 and TRIM24-2 iHMECs compared to control iHMECs. Succinate 
dehydrogenase complex, subunits A, B, and D (SDHA, SDHB and SDHD); 
dihydrolipoamide S-acetyltransferase (DLAT); isocitrate dehydrogenase 2 (IDH2); 
oxoglutarate dehydrogenase (OGDH); aconitase 1 (ACO1); malate dehydrogenase 2 
(MDH2) and fumarate hydratase (FH) were among the TCA-associated genes with up-
regulated expression (Fig. 12E). Collectively, these results suggest that TRIM24 
expression in iHMECs and subsequent transformation rely on increased glucose 
metabolism to meet the higher energy demands of increased growth and proliferation. 
This metabolic shift is marked by up-regulation of both glycolysis and expression of 
TCA-cycle genes. 
 To determine if these findings are relevant to human breast disease, we assessed 
whether TRIM24 expression correlated with altered expression of glucose metabolism 
genes in human breast tumors using TCGA-BRCA expression data and Geneset 
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enrichment analysis (GSEA) on invasive breast carcinoma samples. Consistent with 
our in vitro findings, we found that the glucose transport pathway (p-value: 0.001, 
Normalized Enrichment Score (NES[75]): 1.88) was among the top 10 pathways 
positively correlated with TRIM24 expression (Fig. 12F). For a complete list of enriched 
pathways please see Appendix 7. Thus, TRIM24 has a significant and/or strong 
tendency to be co-expressed with genes that regulate glucose metabolism in breast 
tumors, supporting clinical relevance of our findings. 
 
3.5 TRIM24 expression results in diverse metabolic states and increased glucose 
uptake in iHMECs 
To determine the functional impact that TRIM24 expression has on cellular metabolism, 
we examined the two main bio-energetic pathways: oxidative phosphorylation 
(OXPHOS) and glycolysis. The rate of oxygen consumption by cells (OCR) is an 
indicator of mitochondrial respiration [73]. Additionally, cells generate ATP via 
glycolysis (the conversion of glucose to lactate) independently of oxygen.  
Measurement of the lactic acid produced indirectly via protons released into the 
extracellular medium, which causes acidification of the medium surrounding the cells, 
provides the extracellular acidification rate or ECAR [73]. Previous studies suggest that 
maintenance of high reserve mitochondrial capacity is a major factor that defines the 
vitality and/or survival of cancer cells [84].   
 To examine the bio-energetic phenotype of TRIM24-iHMECs and control iHMECs, 
we measured respiration, glycolysis rate and ATP turnover in the cells in response to 
pharmacological modulators of glucose metabolism (Fig. 13A and B). TRIM24-1 and 
TRIM24-2 iHMECs exhibited higher basal ECARs and OCRs compared to control   
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Figure 13: TRIM24 leads to diverse metabolic states and increased glucose 
uptake.  
A and B, Extracellular Acidification rate (ECAR) and Oxygen Consumption Rate (OCR) 
in the presence of Oligomycin (1 µM), FCCP (Carbonylcyanide p-
trifluoromethoxyphenylhydrazone, 500 nM) and Rot + Ant [Rotenone (1 µM)  + 
Antimycin A (1 µM) measured using an XFe96 Extracellular Flux Analyzer (Sea-horse) 
for Control, TRIM24-1 and TRIM24 iHMECs. Both ECAR and OCR were normalized 
using cell number. C, 2-NBDG (Florescent Glucose) uptake assay for Control, TRIM24-
1, and TRIM24-2 iHMECs for 0 hours (untreated) and 2 hours. Florescent intensity 
curves of the 2-NBDG uptake are shown. D, qRT-PCR analysis of GLUT4 and GLUT1 
mRNA expression in Control, TRIM24-1, and TRIM24-2 iHMECs. The data are 
averages from three biological replicates ± SD. ***p < 0.001.  
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Figure 14: Glucose uptake time course for control vs TRIM24-iHMECs as 
measured by FACS 
A and B, 2-NBDG (glucose) uptake assay for Control, TRIM24-1, and TRIM24-2 
iHMECs for 0h (untreated), 0.5h, 1h and 2 h respectively. Bar graphs (A) and 
Florescent intensity curves (B) of the 2-NBDG uptake are shown.  
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iHMECs, suggesting increased basal glycolysis and mitochondrial respiration, 
respectively. We then metabolically perturbed the cells by treating the cells with 
compounds that shift the bio-energetic profiles of the cells. Oligomycin, an inhibitor of 
the mitochondrial ATP synthase, triggered a robust increase in lactic acid production 
(Fig. 13A), expressed as changes in ECAR levels in control and TRIM24-iHMECs. After 
uncoupling the proton gradient in the electron transport chain from oxidative 
phosphorylation by treating the cells with FCCP, TRIM24-1 and TRIM24-2 iHMECs had 
much higher reserve mitochondrial capacities than did control iHMECs (Fig. 13B). With 
these effects on metabolism, TRIM24-iHMECs are more responsive to stress under 
conditions of increased energy demand, compared to control iHMECs. Taken together, 
our findings suggest that ectopic expression of TRIM24 in iHMECs leads to increased 
basal glycolysis and basal mitochondrial respiration in parallel with an increased 
reserve of mitochondrial capacity.  
 Next, we studied whether the altered bio-energetic states of TRIM24-iHMECs result 
in increased glucose uptake by these cells. We compared control and TRIM24-iHMECs 
using the fluorescent 2-deoxyglucose analog (2-NBDG) staining. Our results indicated 
higher glucose uptake in both TRIM24-1 and TRIM24-2 iHMECs, compared to control 
iHMECs, further confirming the increased glycolytic state of TRIM24-transformed cells. 
(Fig. 13C and Fig. 14A-B). Consistent with this, we observed significantly increased 
glucose transporter protein GLUT4 gene expression and measurable GLUT1 activation 
in TRIM24-iHMECs (Fig. 13D). 
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3.6 TRIM24 causes deregulation of two key players of cancer metabolism 
 p53 and c-Myc are two important regulators that determine the fate of cellular 
metabolism. The tumor suppressor p53 regulates energy metabolism by lowering rates 
of glycolysis and inducing mitochondrial respiration. GLUT1 and GLUT4 are direct p53 
direct targets of transcriptional regulation [85]. p53 indirectly represses GLUT3 by 
repressing NF-κβ gene expression [86]. p53 induces the expression of TIGAR (TP53-
inducible glycolysis and apoptosis regulator) and TIGAR significantly slows down tumor 
glycolysis by converting fructose 2,6-bisphosphate back to fructose 1-phosphate [33]. 
Fructose 2,6-bisphosphate functions as an allosteric activator of PFK1, a major 
glycolytic enzyme. Fructose 2,6-bisphosphate is produced by PFK2 from fructose 1-
phosphate. Additionally, p53 indirectly represses activation of several glycolytic 
enzymes by activating miR-34a [87]. The net result of constitutive p53 activation is 
primarily to direct the glycolytic flux towards pyruvate that can then enter the TCA 
cycle.  
 In contrast, the oncogene c-Myc is known to upregulate glycolysis, 
glutaminolysis and mitochondrial biogenesis in cancer cells. c-Myc directly upregulates 
the expression of HK2, PFK1, TPII, LDHA and several others in the glycolytic pathway. 
The majority of glycolytic enzymes contain c-Myc binding motifs in their gene promoters 
[88]. Two major glutamine reporters, ASCT2 and SN2, are trans-activated by c-Myc in 
several tumors [89]. GLS1, one of the major enzymes responsible for glutaminolysis, is 
indirectly upregulated by c-Myc suppressing miR-23a/b [90]. c-Myc regulates 
expression of several nuclear-encoded genes critical for mitochondrial growth and 
biogenesis. Mitochondrial transcription factor A (TFAM), a critical regulator of 
mitochondrial DNA replication and transcription, is trans-activated by c-Myc [91].  
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	 Interestingly, in TRIM24-iHMECs there is a significant induction of c-Myc mRNA 
and protein expression with concomitant decrease in p53 protein levels (Fig. 15). 
Induction of c-Myc and degradation of p53 in TRIM24-iHMECs may explain the dual 
induction of glycolysis and TCA cycle in these cells. Whether or not TRIM24 directly 
regulates expression of genes associated with metabolism or does indirectly by 
regulating p53 and c-Myc needs to be determined. 
 
3.7 TRIM24 regulates expression of several genes associated with glucose 
metabolism in multiple breast cancer lines 
 We asked whether TRIM24-mediated regulation of glycolytic and TCA-associated 
genes is widespread amongst various cellular models of breast cancer by assessing 
multiple, established cell lines derived from breast tumors. Transient knock down of 
TRIM24 (siTRIM24) expression in MCF-7 (luminal), MDA-MB-231 (triple-negative), and 
SKBR3 (HER2-positive) indicated that depletion of TRIM24 down-regulated GLUT1, 
ACO1, IDH1, IDH2, PGM1, and OGDH expression in MCF-7 cells (Fig. 16A & Fig. 17). 
Moreover, expression of GLUT1, ACO1, IDH1, and IDH2 was likewise decreased in 
MDA-MB-231 and SKBR3 cells treated with TRIM24 siRNA, suggesting that regulation 
of specific metabolic genes by TRIM24 is conserved, albeit to varying levels. We then 
checked for expression of the aforementioned metabolic genes in the isogenic panel of 
HMECs. Interestingly, we found that the endogenous expression pattern of ACO1 and 
IDH2 parallels endogenous TRIM24 expression and follows an upward trend along the 
transformation process, and OGDH and HK2 gain highest expression in the 
immortalized malignant HMECs (Fig. 16B). Taken together, these results suggest that   
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Figure 15: TRIM24 induces deregulation of two key players of cancer metabolism  
A & B, qRT-PCR analysis of cMyc mRNA (A) and Immunoblot of TRIM24, c-Myc and 
p53 in Control, TRIM24-1, and TRIM24-2 iHMECs. The data are averages from three 
biological replicates ± SD. *p < 0.05 and **p < 0.01.  
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Figure 16: TRIM24 regulates expression of several genes associated with 
glucose metabolism in multiple breast cancer subtypes 
A, MCF-7, SKBR3 and MDA-MB-231 cells were transfected with siControl or siRNA 
against TRIM24 (siTRIM24) and harvested 48 hours later. Effect of TRIM24 knockdown 
on expression of a glucose metabolism gene panel (by qRT-PCR analysis) is shown. 
The data are averages from three replicates ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. 
B, mRNA expression for ACO1, IDH2, OGDH and HK2 in HMEC lines transitioning 
from normal finite-lifespan pre-stasis cells to abnormal finite post-stasis, non-malignant 
immortal and malignant cells. The data are averages from three biological replicates ± 
SD. *p < 0.05 and **p < 0.01.  
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Figure 17: siRNA based TRIM24 knockdown in multiple breast cancer cell lines 
TRIM24 RNA and protein levels in various breast cancer cell lines MCF-7, SKBR3 and 
MDA-MB-231 cells were transfected with siControl or siRNA against TRIM24 
(siTRIM24). TRIM24 RNA (by qPCR) and protein expression (by Western) are shown. 
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TRIM24-mediated deregulation of glucose metabolism is a relatively global 
phenomenon that occurs in multiple breast cancer subtypes. 
  
3.7 TRIM24-HMECs form intermediate to high-grade tumors in nude mice 
 We assessed the impact of TRIM24 expression in iHMECs by in vivo xenograft 
formation. To this end, we injected female nude mice subcutaneously with either 
Control or TRIM24-iHMECs in 50% high concentration matrigel. TRIM24-1 and 
TRIM24-2 xenografts displayed significantly higher xenograft volume as compared to 
their control counterparts (Fig. 18A and Fig. 19A-C). H&E staining showed that 
xenograft tumors from TRIM24-iHMECs contained intermixed neoplastic epithelial cells 
and fibrous tissue in various proportions (Fig. 18B, left panel), whereas no epithelial 
cells were detected in xenografts from Control-iHMECs (Fig. 18C and Fig. 19D-E). 
TRIM24-expressing, neoplastic epithelial cells formed tumors that reflect a spectrum of 
low, intermediate and high-grade malignancy (Fig. 18B, left panel). The expression 
levels of TRIM24 in these tumors correlated with the malignancy grade, as shown by 
TRIM24-IHC (Fig. 18B, right panel). The grade of malignancy was based on the degree 
of cellular atypia, anysokaryosis and degree of vascularization (Fig. 19F-H and 
Appendix 8). Of note, about 60-70% of the tumors formed with TRIM24-iHMECs were 
either intermediate or high grade (Fig. 18C) with the proportion of epithelial cells in the 
subcutaneous tumors at 30-40% (Fig. 18D and Fig. 19E), compared to xenografts of 
Control-iHMECs that consisted of fibrous tissue only (Fig. 19E and Appendix 8).  Taken 
together, these data indicate that over expression of TRIM24 can confer in vivo 
tumorigenic growth of iHMECs. 
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Figure 18: TRIM24-HMECs form intermediate to high-grade tumors in nude mice 
A, Tumor volume after 65 days post-injection of Control and TRIM24-iHMECs in nude 
mice. **p < 0.01 (all compared to Control). B, H&E Staining and TRIM24-IHC for 
various grades of tumors obtained from nude mice injected with TRIM24-iHMECs. C, 
Distribution of various grades of tumors from mice injected with either Control or 
TRIM24-iHMECs. D, Distribution of epithelial cells in tumors from mice injected with 
either Control or TRIM24-iHMECs.  
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Figure 19: Characterization of xenograft tumors formed by control and TRIM24-
HMECs  
A, Tumor volume post-injection of Control and TRIM24-iHMECs in nude mice after Day 
14, Day 27 and Day 41. *P < 0.05, **P < 0.01  (all compared to Control). B, Images 
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from mice injected with Control or TRIM24-iHMECs (showing tumors). C, Tumors 
obtained from mice injected with Control or TRIM24-iHMECs 
D, H&E Staining and TRIM24-IHC for a representative tumor obtained from mice 
injected with Control-iHMECs. E, Percentage of Epithelial cells v/s fibrous tissue in 
tumors obtained from mice injected with Control or TRIM24-iHMECs. F, G and H, 
Cellular atypia grade, Anysokaryosis grade and Vascularization grade of tumors 
obtained from mice injected with Control of TRIM24-iHMECs. 
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3.8 TRIM24 directly regulates expression of various metabolic genes 
 To elucidate critical targets of TRIM24-induced transformation, previously published 
TRIM24 ChIP-seq (in MCF7 cells) was intersected with the transcriptional signature 
obtained after TRIM24-overexpression in iHMECs. Interestingly, several metabolic 
genes were bound by TRIM24. Recruitment of TRIM24 at several of these metabolic 
genes was confirmed by TRIM24-ChIP followed by qPCR in MCF7 cells. As shown in 
Fig. 20, TRIM24 is recruited to the promoters of several metabolic genes such as 
GLUT1, IDH1 and IDH2. Hence, it is clear that GLUT1, IDH1 and IDH2 are direct 
TRIM24 targets.  
 Next, in order to determine which transcription factor(s) may help recruit TRIM24 at 
these metabolic genes, transcription factor affinity prediction (TRAP) analysis was 
performed. In TRAP analysis, it was found peroxisome proliferator activated receptor-γ 
(PPARγ) was among the top-three transcription factors to be significantly enriched at 
TRIM24-binding sties (Fig. 21). One of the key players that regulates adipogenesis and 
whole-body lipid metabolism is PPARγ [92]. In addition, it is also crucial for controlling 
gene networks involved in glucose homeostasis including increasing the expression of 
GLUT4 and c-Cbl associated protein (CAP)[92].  Intriguingly, in breast cancer cells 
ER-α physically associates with PPARγ and functionally interferes with PPARγ 
signaling [93]. Future studies will investigate the crosstalk between TRIM24, PPARγ 
and ER-α by co-immunoprecipitation and ChIP assays to confirm their recruitment and 
mechanism of action at various metabolic genes. 	
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Figure 20: TRIM24 ChIP in MCF7 cells 
TRIM24 ChIP confirms recruitment of TRIM24 at various metabolic genes such as 
GLUT1, IDH1 and IDH2, and c-Myc along with previous assessment of gene 
expression to show direct impact of TRIM24 binding. *P < 0.05, **P < 0.01 and ***P < 
0.001 (TRIM24 ChIPs done by Sabrina Stratton). 
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Figure 21: TRAP analysis of TRIM24-binding peaks in MCF7 cells 
A. Table showing Top 5 hits of Transcription factor affinity prediction of TRIM24 binding 
peaks in MCF7 cells. B. Binding motifs of Top 3 hits viz. ESR1, ESR2 and PPARG. 
(Bio-informatic analysis done by Whijae Roh). 
  
ESR1 
PPARG 
ESR2 
Rank	 Gene	 Matrix	ID	 Chi-Square	 P	value	 Adjusted	P	value	
1	 ESR1	 MA0112.2	 95.9	 1.99e-13	 2.35e-11	
2	 ESR2	 MA0258.1	 87.8	 6.25e-12	 3.69e-10	
3	 PPARG	 MA0066.1	 61.5	 2.87e-07	 1.13e-05	
4	 NFE2L2	 MA0150.1	 39	 0.0011	 0.0324	
5	 RORA1	 MA0071.1	 37.4	 0.00182	 0.043	
A 
B 
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3.8 Effect of TRIM24 over-expression on HMEC cell size and karyotype 
 Interestingly, H&E staining of TRIM24-iHMECs, showed that TRIM24-iHMECs 
were much bigger in size (Fig. 22A) and the overall nuclear to cytoplasmic ratio was 
very high in these cells. Also, when an equal number (4 million) of control and TRIM24-
iHMECs were spun down in a 15ml tube, the pellet formed by TRIM24-iHMECs 
occupied much more area (Fig. 22B).  
 Since, TRIM24-iHMECs are much bigger in size and exhibit all of the hallmarks 
of transformed cells, we determined if there was any change in the chromosome 
number upon TRIM24 overexpression. We performed a karyotype analysis in control 
and TRIM24-iHMECs and found that the majority of TRIM24-iHMECs were aneuploid 
with an average of 74-76 chromosomes per cell; the control-iHMECs had a normal 
karyotype with close to 46 chromosomes per cell (Fig. 23). In both TRIM24-iHMECs 
clones, increased chromosome copies (tri-, tetra- and penta- somy) and chromosomal 
rearrangements and translocations were observed with high frequency. A high 
frequency of mutated chromosomes (M) was also observed in TRIM24-iHMECs. 
 
3.9 Effect of dual TRIM24-BRPF1 Bromodomain inhibitor on glucose metabolism  
 As discussed previously, TRIM24 contains a tandem PHD and Bromo-domain in 
the C-terminus that reads a non-canonical histone signature (H3K4me0 and H3K23ac). 
Because of the druggability of bromodomain-containing proteins, the TRIM24-bromo-
domain offers a potential therapeutic for epigenetic regulation [94]. As part of the drug 
discovery program at the MD Anderson Cancer Center, a highly potent and selective 
dual TRIM24-BRPF1 bromodomain inhibitor (IACS-9571) was developed with an ITC 
Kd = 31 nM for TRIM24 and ITC Kd = 14 nM for BRPF1 [95].   
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Figure 22: TRIM24-iHMECs are bigger in size 
A. Bright light images of H&E staining of control and TRIM24-iHMECs. B. Bright light 
image of 15ml tube (bottom) after spinning down equal number (4 million) of control 
and TRIM24-iHMECs.   
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Figure 23: Over-expression of TRIM24 in HMEC stable cell lines causes 
aneuploidy.  
A. Individual chromosome numbers from metaphase spreads of immortalized stable 
HMEC line in control or stably over-expressing TRIM24 (TRIM24-1, TRIM24-2) were 
analyzed (n=100). B. Representative images of G-band karyotype in control HMEC, 
showing the 46 chromosomes with haploid 6 and trisomy 20 that is similar to the 
previous published data. (C, D) Over-expression of TRIM24 in immortalized HMEC is 
sufficient to induce chromosome instability (CIN): Representative images of G-band 
karyotypes in TRIM24-1 and -2.  
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 In order to determine if TRIM24-bromodomain function is critical for regulating 
glucose metabolism in breast cancer, MCF7 cells were treated with IACS-9571 for 48 h 
(1 µM and 5 µM).  The mRNA expression of several metabolic genes was evaluated by 
RT-qPCR. Interestingly we found that expression of several genes associated with 
glucose metabolism was downregulated upon treatment with IACS-9571 (Fig. 24). 
These results suggest that interaction of TRIM24 with chromatin via its bromodomain 
may be critical for regulating glucose metabolism in breast cancer. However, the effect 
of IACS-9571 on glucose metabolism needs to be tested in additional breast cancer 
cell lines. In the future, TRIM24-overexpressing stable cells with a bromodomain 
chromatin-binding mutant of TRIM24 will be generated and tested for various hallmarks 
of transformation and changes in glucose metabolism to clearly define the role of the 
TRIM24 bromo-domain in regulating cancer metabolism. 
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Figure 24: Effect of TRIM24-bromodomain inhibition on glucose metabolism in 
breast cancer  
RT-qPCR data of various glucose metabolism genes after treatment of MCF7 cells with 
respective concentration of IACS-9571. 	  
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Chapter 4: TRIM24 acts as a novel regulator of EMT in breast cancer  
4.1 Introduction and Rationale 
 
 TRIM24 is a multi-domain protein that i) negatively regulates p53 via its RING 
domain, ii) interacts with estrogen receptor (ER) via an LXXLL motif, and iii) recruits 
transcription factors to chromatin as a histone reader with PHD-Bromodomains that 
recognize H3K4me0/H3K23ac [96]. Recently, aberrant over-expression of TRIM24 in 
cancers of multiple origins, including prostate cancer [47], breast cancer [55, 56], non-
small cell lung cancer [57], head and neck carcinoma [58], colorectal cancer [59], 
gastric cancer [60], glioblastoma [61] and human hepatocellular carcinoma [63] has 
been reported. My previous work showed that TRIM24 expression caused major shifts 
in metabolism and promoted transformation of immortalized human mammary epithelial 
cells [97]. However, a detailed analysis of how TRIM24 promotes tumorigenesis with 
progression to metastasis has not been elucidated.  
 Metastasis is multi-step process consisting of migration of cancer cells from the 
primary tumor, followed by local invasion, intravasation, extravasation and finally 
colonization of cancer cells at distant organs. Each step of metastasis involves a series 
of specific cell-to-cell interactions and activation of different signaling pathways [16]. 
Prior to metastatic progression of a tumor, cancer cells undergo a transition from an 
epithelial to a mesenchymal phenotype; the process is called the epithelial-
mesenchymal transition (EMT). My preliminary analysis shows that TRIM24 is a driver 
of EMT. During the EMT process, epithelial cells lose cell polarity, disassemble their 
cell-cell adhesion machinery and acquire cell motility. The EMT process is marked by 
loss of E-cadherin and acquisition of various mesenchymal markers such as N-
cadherin and vimentin, as a result of activation of transcription factors such as Snail, 
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Slug, Twist and ZEB1/ZEB2 [16]. I hypothesize that aberrant expression of TRIM24 
impacts a network of transcription regulatory factors and signaling pathways to induce 
EMT and metastasis in breast cancer.  
 
4.2 TRIM24 induces a mesenchymal-phenotype in breast epithelial cells 
 MCF10A cells exhibit multiple characteristics of normal breast epithelium such 
as an absence of anchorage-independent growth, hormone-dependent and growth 
factors for survival and proliferation and absence of tumorigenicity in xenograft studies 
in mice [68]. To further understand the mechanism of TRIM24-mediated oncogenesis, 
TRIM24 (FLAG-tagged, wild-type) was stably overexpressed in MCF10A. 
Overexpression of TRIM24 was confirmed by RNA (RT-qPCR) and protein 
(immunoblotting) analyses (Fig. 25A). Interestingly, TRIM24-expression substantially 
altered the morphology of MCF10A cells, resulting in decreased clustering, loss of cell-
cell contacts and increased mesenchymal-like morphology (Fig. 25B). 
 In order to determine if TRIM24-overexpression induced EMT, RNA and protein 
expression analyses of known EMT markers were performed. Gene and protein 
expression analysis revealed an EMT signature, specific to TRIM24-overexpressing 
MCF10A cells versus vector only cells, marked by decreased E-cadherin (CDH1), and 
increased N-cadherin (CDH2), Fibronectin-1 (FN1, mRNA), Snail Family Zinc Finger 1 
(SNAI1, protein), Snail Family Zinc Finger 2 (SNAI2 aka Slug, mRNA) and Vimentin 
(VIM, protein) (Fig. 26C-D). Loss of E-cadherin (CDH1) in TRIM24-overexpressing 
MCF10A cells was further confirmed by immunofluorescence staining. As shown in Fig. 
24E, TRIM24-OE MCF10A cells have no detectable expression of CDH1 (red), 
whereas vector MCF10A cells show very high expression of CDH1. 
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Figure 25: TRIM24 induces EMT signature in breast epithelial cells 
A, qRT-PCR analysis of TRIM24 mRNA and Immunoblot of TRIM24 and actin in vector 
and TRIM24-OE MCF10A cells. B, Bright light images of vector and TRIM24-OE 
MCF10A cells. C & D, qRT-PCR and Immunoblot analysis of TRIM24, CDH1, CDH2, 
SNAI1, VIM and Actin in vector and TRIM24-OE MCF10A cells. E, 
Immunofluorescence analysis of TRIM24 (green) and CDH1 (red) in vector and 
TRIM24-OE MCF10A cells The data are averages from two replicates ± SD. *p < 0.05; 
**p < 0.01; ***p < 0.001.  	  
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Figure 26: TRIM24 regulates EMT-target gene expression in breast epithelial cells 
A, B & C, qRT-PCR analysis of TRIM24, CDH1, FN1, SNAI2, VIM1 and CDH2 mRNA 
in MDA-MB-468 (A) and MDA-MB-231 (B) –  shControl and shTRIM24, and MCF10A 
TRIM24-OE (C) – transfected with siControl or siTRIM24, respectively. The data are 
averages from two replicates ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.  
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 The effects of TRIM24-mediated regulation of EMT markers were also observed 
after stable depletion of TRIM24 (shTRIM24) in triple-negative breast cancer cells 
(MDA-MB-468 and MDA-MB-231) (Fig. 26A-B). Interestingly, in MDA-MB-231 there 
was significant upregulation of CDH1 upon TRIM24 knockdown, however no significant 
changes in other EMT markers were observed. Notably, siRNA mediated knock down 
of TRIM24 in MCF10A cells over-expressing TRIM24 reversed this effect, as shown by 
reduced expression of FN1, SNAI2 and slightly increased expression of CDH1 (Fig. 
26C). 
 In order to determine if TRIM24 expression functionally impacts epithelial cell 
migration, Boyden-chamber based migration assays were performed. As expected, 
TRIM24-OE MCF10A cells had significantly higher migration as compared to Control 
MCF10A cells and consistent with this there was significant reduction in migration of 
shTRIM24 MDA-MB-231 cells as compared to shControl MDA-MB-231 cells (Fig. 27A-
B).  
 
4.3 EMT-related pathways are significantly enriched upon TRIM24-
overexpression in MCF10A cells 
 To understand the mechanisms of TRIM24-induced transformation of MCF10A, we 
analyzed the gene expression profiles of 2560 cancer-associated genes using the HTG 
EdgeSeq Oncology biomarker assay and identified 501 genes (20%) whose expression 
was significantly altered, compared to vector only cells. TRIM24 overexpression 
resulted in activation of 223 (44%) and repression of 278 (56%) genes (Fig. 28A). For a 
complete list of deregulated genes, please see Appendix 9. Molecular signature 
hallmark analysis (GSEA) revealed that TRIM24-induced expression of genes altered  
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Figure 27: TRIM24 regulates migration of breast cancer cells 
A & B, Boyden chamber-based migration assay of MCF10A (vector and TRIM24-OE, 
A) and MDA-MB-231 (shControl and shTRIM24, B). The data are averages from two 
replicates ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. 
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Figure 28: EMT-related pathways are significantly enriched in TRIM24-OE 
MCF10A cells 
A, Pie-chart showing percentage of up-regulated and down-regulated genes upon 
TRIM24 over-expression as compared to Vector in MCF10A cells. B, Molecular 
Signature database-based pathway analysis of up-regulated and down-regulated 
genes upon TRIM24 over-expression as compared to Vector in MCF10A cells.   
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various hallmarks including apoptosis, epithelial mesenchymal transition (EMT) and 
TGF-beta signaling (Fig. 28B). Interestingly, TRIM24-activated genes include genes 
upregulated upon E-cadherin knockdown in HMLE (human mammary epithelial cells) 
cells, genes upregulated by BMP2 and genes upregulated in invasive ductal carcinoma 
(IDC) by using curative gene set search of molecular signature database. Similarly, 
TRIM24-repressed genes include genes downregulated upon E-cadherin knockdown in 
HMLE cells and genes downregulated in metastatic melanoma (Fig. 28B). For a 
complete list of enriched pathways, please see Appendix 10. 
 
4.4 TRIM24 directly binds to several EMT-target genes 	 To elucidate critical targets of TRIM24-induced transformation, previously published 
TRIM24 ChIP-seq data (from MCF7 cells) was intersected with the transcriptional 
signature obtained after TRIM24-overexpression in MCF10A. Interestingly, several 
differentially regulated EMT genes were bound by TRIM24. Recruitment of TRIM24 at 
several of these EMT genes was confirmed by TRIM24-ChIP followed by qPCR in 
MDA-MB-468 cells. As shown in Fig. 29A, TRIM24 is recruited at several EMT genes 
such as CDH1 and MMP2.  
 As previously mentioned TRIM24 via it’s C-terminal Bromo domain acts as a 
histone reader and binds with highest affinity to an H3K23ac signature but also has the 
capacity to bind H3K9me2 signature [55]. To confirm the presence of an H3K23ac 
histone signature at TRIM24 bound sites on EMT genes, ChIP analysis of H3K23ac 
was performed. As shown in Fig. 29B, an H3K23ac signature is enriched at several 
EMT genes such as CDH1 and MMP2 at TRIM24-bound sites. Hence, it is clear that   
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Figure 29: TRIM24 ChIP in MDA-MB-468 cells 
A & B, TRIM24 and H3K23Ac ChIP confirms recruitment of TRIM24 at various EMT 
genes such as CDH1 and MMP2 along with previous assessment of gene expression 
to show direct impact of TRIM24 binding. (TRIM24 ChIP done by Roxsan Manshouri). 
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CDH1 and MMP2 are direct TRIM24 targets and bromo-domain dependent histone 
reader function may be important for recruitment of TRIM24 at these EMT genes. 
4.5 TRIM24 over-expression inhibits acini formation  
 Primary mouse and human mammary epithelial cells, when grown on basement 
membrane gels, exhibit morphogenic changes to form polarized structures with a 
hollow lumen known as acini. Engelbreth-Holm-Swarm (EHS) tumor or matrigel (BD 
Biosciences) basement membrane is composed of matrix components such as laminin, 
collagen IV and entactin. MCF10A cells when cultured in matrigel-based 3D culture for 
about 10-12 days form acinar structures and retain several properties of glandular 
epithelial cells found in vivo. They exhibit extremely low levels of cell proliferation and 
are highly consistent with respect to size of acinar and cell number (8,9). Inhibition of 
cell proliferation and disruption of morphogenic events during acini formation is an 
important characteristic to investigate the effects of oncogenes and/or tumor 
suppressors on MCF10A morphogenesis.  
 Strikingly, when the TRIM24-OE MCF10A were subjected to 3D culture on 
growth-factor reduced matrigel they fail to form acini, whereas the vector cells formed 
distinct acini by Day 10 (Fig. 30A). By confocal microscopy analysis, it was further 
confirmed that TRIM24-OE MCF10A cells have very low expression of CDH1, whereas 
the vector cells have distinct CDH1 expression at cell-to-cell boundaries (Fig. 30B). As 
shown here, TRIM24-OE cells have very low expression of CDH1 and unlikely able to 
build proper cell-to-cell adhesion contacts, thus affecting MCF10A morphogenesis to 
form acinar structures. In future, CDH1 rescue studies will be performed to determine if 
CDH1 over-expression is sufficient ton rescue the loss of acinar phenotype in TRIM24-
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OE MCF10A cells or if a more complex network of TRIM24-dependent gene targets are 
involved. 	
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Figure 30: TRIM24 over-expression suppresses acini formation 
A, Bright field images of acini formed by Vector and TRIM24-OE MCF10A cells. 
B, Confocal images of Immunofluorescence for TRIM24 and CDH1 in acini formed by 
Vector and TRIM24-OE MCF10A cells (Confocal microscopy done by Erin Williams).  
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Chapter 5: Discussion and Future directions 
5.1 TRIM24 - a keystone to cancer metabolism 
 TRIM24 over-expression in immortalized human mammary epithelial cells 
induces oncogenic transformation coupled with an array of transcriptional and 
functional effects. In association with TRIM24-induced breast tumorigenesis, there is 
deregulation of multiple cancer related pathways including glucose metabolism. To the 
best of our knowledge, this is the first report of recognition of TRIM24 as one of the 
prime regulators of cancer metabolism. Over-expression of TRIM24 induces malignant 
transformation of iHMECs and when these cells are injecting sub-cutaneously into nude 
mice, a majority of tumors formed by TRIM24-iHMECs were either intermediate or high 
grade. Interestingly, tumors formed by TRIM24-iHMECs had about 40% epithelial cells 
with abnormally larger nuclei and this significantly correlated with TRIM24 expression.  
 In addition to glucose metabolism multiple growth-stimulating pathways such as 
the insulin [98], ErbB [99] and MAPK [100] that are linked with breast tumor 
development and progression were also significantly induced upon TRIM24-
overexpression in iHMECs. The induction of both glycolysis and TCA cycle in TRIM24-
iHMECs was confirmed by mRNA and protein analysis in addition to increased glucose 
uptake. Of note, Sea-horse analysis also showed that the Extracellular acidification rate 
(ECAR is rate of glycolysis) and Oxygen consumption rate (OCR is rate of TCA cycle) 
were higher in TRIM24-iHMECs. To determine whether a correlation between TRIM24 
expression and various metabolic pathways existed, a Gene set enrichment analysis 
(GSEA) using gene expression datasets of invasive breast tumors (n =1008) was 
performed. The glucose transport pathway was identified as one of the top ten 
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pathways that correlated positively with TRIM24 expression in invasive breast 
carcinoma patients from the TCGA database. 	 One of the key emerging hallmarks of cancer is metabolic reprograming [26].  
Otto Warburg reported that cancer cells intake high amounts of glucose and produce 
higher lactate even in the presence of oxygen, the phenomenon was termed as 
‘aerobic glycolysis’ or Warburg effect [27]. Although it is quite clear that epigenetic, 
oncogenic and tumor suppressor mechanisms play a crucial role in regulating 
metabolic reprogramming of cancer cells, the key molecules involved in regulation of 
cancer metabolism and their role in oncogenesis are not very well understood. As 
mentioned previously, TRIM24 overexpression in iHMECs caused induction of not only 
glycolysis but also the TCA cycle pathway. Although this is in disagreement with the 
conventional Warburg effect, similar to TRIM24 iHMECs there are several reports of 
certain cancer cells that preferentially use only OXPHOS or a mix of glycolysis and 
OXPHOS to produce energy [101]. Several recent reports provide ample genetic 
evidence that mitochondria are indeed essential for tumorigenesis [34]. It is 
hypothesized that tumors are metabolically heterogeneous. A majority of tumor cells, 
exhibit aerobic glycolysis (Warburg effect), however, a small population of slow-cycling 
tumorigenic cells are dependent on OXPHOS activity. These slow-cycling cells are 
proposed to be the cells that are resistant to various cytotoxic treatments [35].  
 The schematic in the Figure 31 depicts how we think TRIM24 might regulate 
metabolism in breast cancer. As shown previously, TRIM24 is over-expressed in breast 
cancer and TRIM24 targets p53 for proteasomal-mediated degradation. TRIM24 is 
recruited to promoters of several metabolic and cell proliferation related genes such as 
GLUT1, IDH1/2 and c-Myc and it induces their gene expression. Since p53 is degraded 
it can no longer suppress the expression of glucose transporters. Increased GLUT1   
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Figure 31: Schematic for role TRIM24 in regulating cancer metabolism in breast 
cancer 
(1) TRIM24 is over-expressed in breast cancer, (2) TRIM24 targets p53 for 
degradation,  (3) TRIM24 is recruited to promoters of metabolic and cell    proliferation 
related genes (GLUT1, IDH1 & c-Myc) and it induces their expression, (4) p53 can no 
longer block Glycolysis & Increased GLUT1 expression causes increased glucose 
uptake and Glycolysis, (5) Increased IDH1/IDH2 causes increase in TCA cycle,  (6) 
Increased c-Myc has multiple effects including increased glycolysis and TCA cycle and 
increased cell proliferation, ultimately leading to breast cancer. 
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expression causes increased glucose uptake and glycolysis. Increased IDH1/IDH2 
causes increase in TCA cycle. Higher c-Myc levels have multiple effects including 
increased glycolysis and TCA cycle and increased cell proliferation, ultimately leading 
to breast cancer. 	 It is plausible that abnormal TRIM24 expression in cancer might affect cellular 
homeostasis by virtue of its epigenetic functions. Research has shown that cross talk 
between cellular metabolism and epigenetics might be very crucial in cancer 
progression [102]. The metabolic status of a cell is directly affected by epigenetic 
alterations that regulate gene expression of enzymes associated with metabolism, thus 
contributing to metabolic reprogramming in cancer. On the other hand, almost every 
known epigenetic enzyme relies on metabolites as cofactors or substrates, such as 
acetyl CoA. Thus, metabolic reprogramming in cancer can affect epigenetic status and 
ultimately alter the gene expression of oncogenes as well as tumor suppressors [102]. 
 Of note, several metabolic enzymes are reportedly mutated in various cancers. 
One prominent example of cancer-associated mutation in metabolic enzymes is 
IDH1/IDH2 mutations found frequently in low-grade gliomas, that exhibit a gain of 
function by catalyzing the conversion of a-ketoglutarate (a-KG) to 2-hydroxy glutarate 
(2-HG), resulting in 100-fold higher intracellular concentration of 2-HG as compared to 
wild-type cells.  2-HG is a competitive inhibitor of a-KG dependent dioxygenases, 
including TET2 and the Jumonji C domain containing histone demethylases [103]. 
Further, various metabolic enzymes are mutated in several cancers for e.g. fumarate 
dehydrogenase (FH), succinate dehydrogenase (SDH) and phospho-glycerate 
dehydrogenase (PHGDH) [102].  
A key question in the cancer metabolism field is whether an alteration in 
metabolism is the cause or consequence of oncogenic transformation. In the current 
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study, we show that TRIM24 induces oncogenic transformation of iHMECs in concert 
with metabolic adaptations and it is plausible that TRIM24-mediated metabolic 
reprogramming is more likely a driver event in breast tumorigenesis. Given the 
enhanced expression profile of TRIM24 not only in breast cancer but also in various 
other cancers, it is expected that loss of TRIM24 would oppose cancer development in 
mouse models. Surprisingly, it was found that complete or liver specific loss of TRIM24 
in mouse models causes hepatocellular carcinoma. In the TRIM24 null mice, there was 
increased expression of lipase and inflammatory signaling genes, along with repression 
of de novo lipogenesis, steroid and lipid metabolism, and lipid transport. The TRIM24 
null phenotype of increased inflammation, fibrosis and lipid accumulation in the liver 
was very similar to human non-alcoholic fatty liver disease (NAFLD) and non-obese 
non-alcoholic steatosis (NASH).  
These contrasting phenotypes may be a result of differential interaction of TRIM24 
with tissue-specific transcriptional complexes and target genes and/or tissue-specific 
response to deregulated p53 levels. In future, these questions may be answered by 
generating conditional TRIM24-over expression mouse models (breast or liver specific) 
along with mechanistic studies to determine key functional domains of TRIM24 and 
transcriptional complexes critical in order to orchestrate metabolic reprogramming by 
TRIM24.  
 
5.2 Is the molecular interaction between TRIM24 and PPARγ  critical for metabolic 
reprogramming in breast cancer? 
As discussed previously, upon performing transcription factor affinity prediction 
(TRAP) analysis of TRIM24-ChIP binding sites it was found that Peroxisome 
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Proliferator Activated Receptor-γ (PPARγ) was among the top-three enriched 
transcription factors (Fig. 21). PPARγ is among the key players that regulate 
adipogenesis and whole-body lipid metabolism [92]. It regulates glucose homeostasis 
by inducing GLUT4 and c-Cbl associated protein (CAP) expression [92].  Its role in 
breast cancer is highly controversial. Based on studies in various breast cancer cell 
lines and mouse models, certain reports propose that PPARγ suppresses cell 
proliferation, induces differentiation and programmed cell death. In DMBA-induced 
breast cancer mouse models, PPARγ agonists have been reported to block breast 
cancer [104]. In contrast, when PPARγ transgenic mice (breast-specific) are crossed 
with MMTV-neu mouse model, they display severely accelerated rate of breast cancer 
propensity [105].  
Intriguingly, in breast cancer cells ER-α physically associates with PPARγ and 
functionally interferes with PPARγ signaling [93]. As discussed previously, TRIM24 
binds ER-α and chromatin (at specific histone modifications mentioned above) to 
activate estrogen-dependent genes associated with tumor development and cell 
proliferation [55]. Future studies will investigate the crosstalk between TRIM24, PPARγ 
and ER-α by co-immunoprecipitation studies in breast cancer cells. TRIM24 and 
PPARγ ChIP assays will be performed to confirm their co-recruitment and mechanism 
of action at various metabolic genes. Effects of PPARγ knockdown and over-
expression on TRIM24-induced metabolic reprogramming in breast cancer cells will be 
assessed. Ultimately, these experiments will address if PPARγ and TRIM24 association 
or dissociation is critical to induce metabolic reprogramming in breast cancer.  
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5.3 TRIM24 a novel regulator of EMT in breast cancer 
 Our preliminary analysis shows that TRIM24 is a driver of EMT in breast 
epithelial cells. Upon TRIM24 over-expression the MCF10A cells, exhibit 
mesenchymal-like morphology with decreased clustering and loss of cell-to-cell 
contacts. The TRIM24 over-expressing MCF10A cells exhibited various markers 
consistent with EMT program, i. e. loss of CDH1 and increased expression of CDH2, 
VIM1, FN1, SNAI1 and SNAI2. Similarly, upon TRIM24 knockdown in several triple-
negative breast epithelial cells a suppression of EMT program consistent with decrease 
in migration is observed.  
 Gene expression profiling of 2560 cancer-associated genes in TRIM24-OE 
MCF10A cells revealed that various hallmarks of cancer including apoptosis, epithelial 
mesenchymal transition and TGF-beta signaling were significantly altered. Molecular 
signature pathway analysis of TRIM24-activated genes revealed that these genes were 
upregulated in invasive ductal carcinoma; whereas TRIM24-repressed genes were 
among the genes that were downregulated in metastatic melanoma. In order to 
uncover the epigenetic mechanism of EMT regulation, we determined if TRIM24 was 
recruited to EMT genes. We found that TRIM24 is directly recruited to several EMT 
genes such as CDH1 and MMP2 and the TRIM24-bound sites have H3K23ac signature 
at these sites by ChIP analyses.   
 A major contributor of EMT is E-cadherin promoter methylation, resulting in 
suppression of E-cadherin expression, a key EMT signature. Amongst other 
mechanisms, methylation of histone H3 on lysine 9 (H3K9me2) by G9a is essential for 
DNA methylation of E-cadherin promoter in multiple breast cancer models [106]. 
Intriguingly, our laboratory has shown that the PHD and Bromo domains of TRIM24 can 
bind to H3K9me2 modification by performing in vitro GST-pull down assays [55]. 
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Additionally, based on TRIM24-pulldown and mass-spectrometry analysis in MCF7 
cells, TRIM24 interacts with G9a (EHMT2) (unpublished data).  In the future, I will 
determine whether G9a and H3K9me2 histone signature are present at sites of 
TRIM24 enrichment at the CDH1 promoter to uncover an epigenetic mechanism by 
which TRIM24 regulates E-cadherin expression. ChIP-PCR will be used to assess 
corecruitment of G9a (Transcription factor Y, Figure 32) and TRIM24 near CDH1 
promoter. In addition, effects of G9a knockdown of TRIM24 recruitment near CDH1 
promoter and vice-versa in MDA-MB-436 cells will be determined.  
 Future studies will examine the role of TRIM24 in invasion/metastasis by in vivo 
modeling. To determine the role of TRIM24 in regulation of metastasis, RFP/Luciferase 
labeled MDA-MB-231 cells will be generated with/without TRIM24 knockdown 
(shControl versus shTRIM24). Approximately, 0.5 x 106 cells will be injected via the tail 
vein of SCID mice and the presence of lung metastasis will be monitored every week 
using bioluminescent imaging. After an appropriate time, tumors will be harvested and 
tumor tissue and number of lung metastatic nodules will be determined. Metastatic 
tumors will be characterized by H&E staining and IHC for RFP and for expression of 
various metastatic markers. I expect that mice harboring TRIM24-depleted MDA-MB-
231 cells (shTRIM24) will show reduced tumor invasion/metastasis as compared to 
control cells (shControl).  
 
5.4 TRIM24-domain functional characterization for regulation of EMT: 
 Previous work from our laboratory has showed that histone reader TRIM24 not 
only negatively regulates p53 as an E3-ubiquitin ligase but also interacts with and 
recruits transcription factors, such as estrogen receptor, to chromatin via a tandem   
	92	
 
 
Figure 32: Proposed model for TRIM24 as a novel regulator of EMT in breast 
cancer 
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PHD-Bromo domains that binds unmethylated lysine 4 and acetylated lysine 23 of 
histone H3 (H3K4me0/H3K23ac). The question remains, which of the aforementioned 
functions is/are critical in regulation of TRIM24-mediated induction of EMT.  
 To test whether TRIM24-mediated EMT requires its histone reader, p53 
regulation, ER-interaction or any subset of these functions, MCF10A-stable cell lines 
that over express TRIM24 with site-specific mutations in PHD and/or Bromo, p53-
regulating RING domains, or LXXLL motifs will be generated. Stable cells will be 
characterized for various hallmarks of EMT such as change in morphology, gene 
expression changes and migration properties. Additionally, as part of a drug-discovery 
program we also have a TRIM24-bromodomain specific small molecule inhibitor 
(IACS9571). A titration of the IACS9571 inhibitor, guided by known IC50 level, will be 
used to assess how TRIM24-overexpressing cell lines respond at the level of EMT 
markers, proliferation and migration/invasion. Its effects will be compared to the 
phenotype of the TRIM24-Bromodomain point mutant rescue line. These studies may 
support use of combinations of epigenetic inhibitors that oppose EMT in breast 
cancers. 		
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Chapter 6: Conclusions 
 Since our laboratory’s initial report showing TRIM24 over expression correlates 
with poor survival of breast cancer patients [55], several studies reported roles of 
TRIM24 in multiple cancers such as in prostate cancer [47], breast cancer [55, 56], 
non-small cell lung cancer [57], head and neck carcinoma [58], colorectal cancer [59], 
gastric cancer [60], glioblastoma [61] and human hepatocellular carcinoma [63]. 
However, except for the glioblastoma study, none of the other studies uncovered the 
mechanism of TRIM24-mediated oncogenesis. It was found that TRIM24 is up 
regulated in early stages of breast cancer progression not only in clinical human breast 
cancer tissues but also in an isogenic human mammary epithelial cell (iHMEC) model 
system consisting of cells from various stages of breast cancer. Exogenous over-
expression of TRIM24 promoted oncogenic transformation of immortalized human 
mammary epithelial cells (TRIM24-iHMECs) and efficient growth of high-grade tumors 
in nude mice upon performing xenograft studies.  
 Gene expression analysis of TRIM24-iHMECs uncovered that aerobic glycolysis 
and tricarboxylic acid cycle was activated in addition increased glucose uptake was 
confirmed. In TRIM24-iHMECs, increased c-Myc expression and a decrease in p53 
protein levels were observed. c-Myc and p53 play key roles in regulating cellular 
metabolism, hence, we proposed that these could be the possible mediators of 
TRIM24-induced metabolic reprogramming. Additionally, TRIM24 is recruited to the 
promoters of several metabolic genes such as GLUT1, IDH1 and IDH2. Further, upon 
treatment of MCF7 breast cancer cells with a TRIM24-bromodomain inhibitor I found 
that several glucose metabolism genes were down regulated. Hence, it can be 
concluded that TRIM24 induces oncogenic transformation coupled with metabolic 
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reprogramming in breast cancer and TRIM24-bromodomain function may be critical for 
malignant transformation.  
 As mentioned before, TRIM24 is reported to be over-expressed in several 
cancers; however, a detailed analysis of how TRIM24 promotes tumorigenesis with 
progression to metastasis has not been elucidated. Our preliminary analysis shows that 
TRIM24 is a driver of epithelial to mesenchymal transition (EMT) in breast cancer. It 
was found that upon TRIM24 over-expression in MCF10A cells, there is mesenchymal-
like change in the cellular morphology. As observed in a classical EMT program, 
TRIM24-MCF10A cells exhibit marked loss of E-cadherin and acquisition of various 
mesenchymal markers such as N-cadherin, fibronectin and vimentin. Further, TRIM24-
knockdown in MDA-MB-231 and MDA-MB-468, there is reversal of EMT gene 
signature. HTG Oncology gene expression analysis of TRIM24-OE MCF10A cells 
further confirmed the EMT was among the top pathways that were enriched. TRIM24 
may be involved in transcriptional regulation of EMT genes as confirmed by TRIM24-
ChIP analysis and the presence of H3K23ac signature at several EMT genes in MDA-
MB-468 cells. Our hypothesis is that aberrant expression of TRIM24 impacts a network 
of transcription regulatory factors and signaling pathways to induce EMT and 
metastasis in breast cancer.  
 Approximately 90% of breast cancer-related deaths are caused by metastasis 
not by primary tumor [13]. Hence, for effective reduction of cancer mortality, it is very 
critical to intervene in the critical transition of non-invasive ductal carcinoma to 
extremely lethal invasive breast cancer. The proposed research holds great promise to 
identify a unique role of TRIM24 in metastasis and mechanisms involving EMT. These 
studies will provide a better understanding of molecular mechanisms that drive EMT 
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and will pave the way for developing therapeutic opportunities for metastatic tumors by 
targeting the epigenetic regulator TRIM24.  
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List of Appendices 	
Appendix 1: List of primers for cloning and qPCR 
Cloning Primers 
TRIM24-F1 ATTTTACACGTGATGGAGGTGGCGGTGGAGAA 
TRIM24-R1 CGGGGCTCTAGATTATTTAAGCAACTGGCGTT 
qRT-PCR primers 
Gene Species Forward primer Reverse primer 
TRIM24 Human GCGCCTACT TTTATTTCTTTACTG 
TTTGTCAAGAAAGGGTGTAA
CG 
β-ACTIN Human GGACTTCGAGCAAGAGA TGG AGCACTGTGTTGGCGTACAG 
TP53 Human  AAAGAAGAAACCACTGGATG  ATTCAGCTCTCGGAACAT  
GLUT1 Human CCA GCT GCC ATT GCC GTT GAC GTA GGG ACC ACA CAG TTGC 
GLUT4 Human GTCGGGCTTCCAACAGATAG ACCCCAATGTTGTACCCAAA 
HK2 Human ATG AGG GGC GGA TGT GTA TCA 
GGT TCA GTG AGC CCA TGT 
CAA 
ENO1 Human AAA GCT GGT GCC GTT GAG AAG 
AGC ATG AGA ACC GCC ATT 
GAT 
ALDO-A Human GGG TGT CAT CCT CTT CCA TGA 
GAC CAC GCC CTT GTC TAC 
CTT 
PGM1 Human ACC CAC TCC CTT CAT ACA ATC 
CTC CTC ACT GGT CAT GGC 
TTA 
PDK1 Human CCG CTC TCC ATG AAG CAG TT 
TTG CCG CAG AAA CAT AAA 
TGA G 
GPI Human GGT ACA CAG GCA AGA CCA TC 
GTT TTG GCA ATG TGA GTT 
CC 
PKM1 Human CGAGCCTCAAGTCACTCCAC GTGAGCAGACCTGCCAGACT 
PKM2 Human ATTATTTGAGGAACTCCGCCGCCT 
ATTCCGGGTCACAGCAATGA
TGG 
LDHC Human CCTCTTGGGCTATTGGACTG GCCTCCTCCTCAGAATTCAA 
ACO1 Human TTGGAGGATTCAAGATATGG ACTCATCACAATTCCGAAT 
DLAT Human GTTCCTACAGGTGTCTTC AAGGTAATAATGAGGTAT GGT 
IDH1 Human GAGATAACCTACACACCA AGT AACACCACCACCTTCTTC 
IDH2 Human GATGGATGGTGATGAGAT AAATACTTTAGCTGGATGTC 
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MDH2 Human TGTGATGTGGTAGTTATTCC ATTGGTGTTGAACAGGTC 
OGDH Human AATGTCATCAGGAAGGAG GGTGGTACTTCACATCTC 
PDHA1 Human ATGTATGCCAAGAACTTC ATTATACTTACAGGCTAGAG 
PDHB Human AGGAGTTGAATGTGAGGTGATAA ATGACACTGGCTTCTATGGT 
SDHA Human ATGCCATCCACTACATGA ATAAATCTTCCCATCTTCA GTT 
SDHB Human GACACCAACCTCAATAAG GATTCATCCTTCTTCTTCAA 
SDHD Human ACCGACCTATCCCAGAATG CAGCCTTGGAGCCAGAAT 
FH Human TTAAGATTGGAGGTGTGA CATAATCCTGGTTTACTTCA 
TWIST1 Human GCCGGAGACCTAGATGTCATT CCCACGCCCTGTTTCTTTGA 
TGFB Human CTTTGGATGCGGCCTATTGC TAAGCTCAGGACCCTGCTGT 
CDH1 Human TGCCCAGAAAATGAAAAAGG GTGTATGTGGCAATGCGTTC 
CDH2 Human ACAATCCTCCAGAGTTAC CTTATCGGTCAGAGTTAGA 
VIM Human AAGTGGAATGCCCTTAAAG ATAGTGTCTTGGTAGTTAGC 
SNAI2 Human TCCTGGTCAAAGAAGCATT ATCTCTGGTTGTGGTATGA 
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Appendix 2: List of antibodies used for Immunoblotting 
Antibody details 
(Catalog) Species Company Application 
TRIM24 (NB100-2597) Rabbit Novus Biologicals Western 
TRIM24 (14208-1-AP) Rabbit Protein tech IHC 
p53(DO1)-HRP (sc-126) Mouse Santa Cruz Western 
b-Actin- HRP (5125) Rabbit Cell Signaling Western 
Hexokinase II (2687) Rabbit Cell Signaling Western 
Aldolase (3188) Rabbit Cell Signaling Western 
Enolase -1 (3810) Rabbit Cell Signaling Western 
PDHK1 (3820) Rabbit Cell Signaling Western 
LDHA/ LDHC (3538) Rabbit Cell Signaling Western 
PGM1 (ab55616) Mouse Abcam Western 
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Appendix 3: All red score data for TRIM24 staining in Human breast tissue array 
Status Levels TRIM24 (Number of patients) Total Chi-square P-value 
  Low Medium High 
ER 
status 
Low 15 22 6 43   
High 3 12 14 29 11.87 0.0026 
Total 18 34 20 72   
  TRIM24 Total    Low Medium High 
PR 
status 
Low 14 24 10 48   
High 4 10 10 24 3.74 0.1541 
Total 18 34 20 72   
  TRIM24 Total    Low Medium High 
HER2 
status 
Low 14 8 0 22   
High 4 26 20 50 28.51 <.0001 
Total 18 34 20 72   
  TRIM24 Total    Low Medium High 
P53 
Low 12 16 12 40   
High 6 18 8 32 2.05 0.3588 
Total 18 34 20 72   
  TRIM24 Total    Low Medium High 
Ki67 
Low 8 7 7 22   
High 10 27 13 50 3.41 0.1818 
Total 18 34 20 72   
 
Key to All Red score 
TRIM24 ER/PR HER2 
Low (0-2) Low (0-3) Low (0-1) 
Medium (3-5) High (3-8) High (2-3) 
High (6-8)  
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Appendix 4: List of deregulated genes in TRIM24-iHMECs by nanostring analysis 
Upregulated genes 
 Control TRIM24  
Gene A B C A B C t-test Fold change 
TRIM39 0.00 167.49 132.51 605.68 572.34 591.15 0.00 5.9 
PDE4DIP 0.00 219.12 80.88 833.22 376.66 408.42 0.05 5.4 
GLS2 236.96 35.30 27.74 518.79 374.78 469.60 0.01 4.5 
PRKCI 91.91 92.75 115.34 397.29 440.82 450.99 0.00 4.3 
PRKCH 75.47 97.49 127.04 369.65 389.17 473.85 0.00 4.1 
CAMKK2 117.28 87.50 95.22 462.87 391.28 374.84 0.00 4.1 
SgK494 0.00 202.37 97.63 525.91 415.23 285.19 0.03 4.1 
TESK2 0.00 84.47 215.53 370.71 330.23 496.93 0.02 4.0 
MYC 84.91 106.26 108.84 336.89 370.51 392.51 0.00 3.7 
MAPKAPK5 70.14 94.23 135.63 331.82 317.40 397.15 0.00 3.5 
STRADA 21.47 168.55 109.99 285.93 384.41 290.46 0.01 3.2 
ME3 17.33 172.80 109.87 310.73 288.43 353.48 0.01 3.2 
FGFR2 100.45 114.59 84.96 273.19 277.81 358.25 0.00 3.0 
TTL 84.61 111.39 104.00 293.80 305.09 309.23 0.00 3.0 
DDX5 90.50 124.69 84.81 357.23 258.22 290.89 0.00 3.0 
TRIM26 44.07 142.46 113.47 260.31 272.90 327.49 0.01 2.9 
CEBPA 90.19 111.15 98.66 266.75 298.82 274.99 0.00 2.8 
TRIM37 85.26 113.30 101.44 292.72 278.46 264.67 0.00 2.8 
TRIM39 84.33 116.55 99.12 296.83 235.94 284.93 0.00 2.7 
MTOR 57.47 135.06 107.47 218.24 306.41 280.85 0.01 2.7 
PIK3CA 63.52 93.07 143.41 254.09 241.62 309.69 0.01 2.7 
BIRC3 98.26 102.09 99.65 288.82 256.61 243.06 0.00 2.6 
PTPN11 80.24 120.97 98.80 238.57 259.67 286.49 0.00 2.6 
PFKFB2 57.89 122.72 119.40 216.86 265.92 299.32 0.01 2.6 
EPHA1 86.47 88.62 124.92 274.97 203.83 302.21 0.01 2.6 
TTK 103.65 88.67 107.68 238.36 225.32 295.02 0.00 2.5 
YES1 80.08 109.47 110.45 240.24 247.23 272.17 0.00 2.5 
NEK6 99.98 87.87 112.15 256.38 207.41 255.11 0.00 2.4 
NADK 80.59 132.86 86.55 193.31 240.18 272.71 0.01 2.4 
STK38L 108.16 97.62 94.22 229.55 233.62 228.09 0.00 2.3 
CDKN2A 189.02 74.63 36.35 217.37 229.33 240.38 0.05 2.3 
ERN1 78.27 133.34 88.39 265.59 213.98 203.27 0.01 2.3 
SDHD 96.31 83.77 119.92 210.35 205.87 264.55 0.00 2.3 
TNK2 88.53 97.96 113.52 201.61 234.60 243.05 0.00 2.3 
LGR5 162.81 64.29 72.90 176.33 251.31 206.28 0.04 2.1 
COX6C 96.44 102.71 100.85 207.39 198.92 224.80 0.00 2.1 
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TSC1 80.94 107.44 111.62 220.08 174.18 231.16 0.01 2.1 
STK38 71.10 105.05 123.85 198.54 203.43 215.53 0.00 2.1 
TRIM59 73.62 115.41 110.97 207.78 203.48 203.30 0.00 2.1 
PIP4K2A 80.18 116.42 103.40 211.78 196.78 182.02 0.00 2.0 
BRCA1 61.92 123.09 115.00 190.10 195.23 195.77 0.01 1.9 
SIX4 117.49 84.35 98.17 166.19 214.52 202.52 0.01 1.9 
SIK3 97.85 116.82 85.33 189.45 199.08 193.78 0.00 1.9 
MASTL 63.29 121.37 115.34 197.64 184.52 198.17 0.01 1.9 
ADRBK1 98.21 95.03 106.76 176.92 204.95 197.93 0.00 1.9 
MAP3K5 101.84 103.09 95.07 208.56 139.72 227.76 0.03 1.9 
SUFU 112.01 99.86 88.12 168.24 211.29 196.43 0.00 1.9 
RPIA 104.92 102.65 92.43 152.23 192.15 221.93 0.01 1.9 
EZH2 78.28 98.23 123.49 211.74 164.89 187.48 0.01 1.9 
BRD3 66.22 104.59 129.19 194.66 160.63 189.77 0.02 1.8 
PFKFB3 100.47 114.40 85.13 186.71 186.88 170.40 0.00 1.8 
TRIM8 110.66 97.48 91.86 160.42 184.29 189.82 0.00 1.8 
GNAQ 114.66 96.08 89.26 192.33 166.22 174.53 0.00 1.8 
DLAT 88.02 116.26 95.71 157.99 208.15 163.98 0.01 1.8 
SUZ12 96.47 92.31 111.22 162.27 156.41 208.20 0.01 1.8 
RPS6KB1 109.51 99.07 91.42 167.09 187.02 165.46 0.00 1.7 
TUBB 97.55 95.46 106.99 175.70 162.12 179.90 0.00 1.7 
CSK 74.68 117.18 108.14 149.28 207.10 160.90 0.03 1.7 
AURKB 86.51 111.06 102.43 161.71 188.84 164.13 0.00 1.7 
HPRT1 103.22 87.37 109.41 171.22 164.29 179.41 0.00 1.7 
ACLY 88.10 95.11 116.79 171.95 156.01 185.87 0.00 1.7 
VEGFA 96.71 95.72 107.56 161.44 162.53 182.52 0.00 1.7 
SDHB 88.47 96.21 115.32 159.71 157.81 183.03 0.00 1.7 
SNX16 110.81 94.84 94.35 175.13 151.39 174.28 0.00 1.7 
PIK3R4 76.17 113.25 110.58 159.56 168.70 163.27 0.01 1.6 
EXOSC10 103.90 92.24 103.86 182.68 151.99 153.98 0.00 1.6 
DDR1 117.47 98.22 84.31 163.14 146.66 177.28 0.01 1.6 
TIAM1 139.77 86.31 73.93 163.60 150.38 173.17 0.04 1.6 
CSNK1D 75.44 119.51 105.05 149.96 171.24 160.75 0.01 1.6 
DNMT3A 119.72 82.23 98.05 151.03 154.57 177.99 0.01 1.6 
NRAS 83.60 121.47 94.93 163.56 167.72 152.35 0.01 1.6 
MELK 87.94 104.29 107.77 137.44 163.73 174.99 0.01 1.6 
GSG2 88.51 106.43 105.06 160.65 153.49 164.00 0.00 1.6 
KRAS 72.02 113.59 114.40 163.79 159.94 150.47 0.02 1.6 
PAK2 87.05 101.44 111.51 143.84 161.38 161.67 0.00 1.6 
PANK4 85.52 100.27 114.21 162.11 159.11 147.79 0.00 1.6 
GMPS 88.50 103.49 108.01 157.02 147.45 161.72 0.00 1.6 
CHEK1 95.68 101.35 102.97 166.56 147.35 150.39 0.00 1.6 
PDP1 104.21 84.35 111.44 147.34 148.89 165.52 0.01 1.5 
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SGK1 111.61 97.68 90.71 170.02 146.22 142.16 0.01 1.5 
MAPK8 106.53 101.84 91.63 144.52 149.29 163.98 0.00 1.5 
RIOK1 100.31 106.32 93.37 142.94 154.84 156.08 0.00 1.5 
BUB1B 103.13 90.63 106.24 167.40 138.12 140.39 0.01 1.5 
HIPK1 106.47 97.06 96.47 151.93 148.97 146.76 0.00 1.5 
DYRK1A 95.03 110.40 94.57 126.29 173.39 144.49 0.03 1.5 
SDHA 115.02 87.55 97.43 159.51 137.58 146.76 0.01 1.5 
HK1 69.60 108.27 122.13 139.79 145.81 156.05 0.05 1.5 
LGR4 92.55 101.35 106.10 174.12 134.23 128.84 0.04 1.5 
PRKAR2A 108.79 96.03 95.18 138.54 153.30 143.89 0.00 1.5 
SRPK1 77.14 124.73 98.13 134.12 147.25 151.52 0.04 1.4 
MARK2 112.57 85.94 101.49 128.35 137.62 167.43 0.03 1.4 
BRD8 95.25 113.48 91.27 129.06 142.60 159.09 0.02 1.4 
INPP4A 123.68 92.94 83.37 162.34 131.32 135.13 0.05 1.4 
GPR172A 110.01 92.75 97.24 150.82 140.09 134.87 0.00 1.4 
PAFAH1B2 97.27 92.88 109.85 131.99 140.01 151.57 0.01 1.4 
NLK 114.80 83.74 101.46 146.56 140.69 133.29 0.01 1.4 
MAP3K7 111.10 103.76 85.14 139.29 139.75 138.50 0.01 1.4 
CS 119.50 92.02 88.48 157.98 128.22 130.72 0.05 1.4 
P2RY2 90.52 92.84 116.64 137.82 134.08 145.78 0.01 1.4 
KIAA1524 106.11 94.53 99.36 146.37 145.96 124.19 0.01 1.4 
AK3 88.50 112.84 98.65 133.79 134.47 146.39 0.01 1.4 
BRD2 92.84 105.03 102.13 138.39 148.03 127.62 0.01 1.4 
ABL1 100.00 104.92 95.08 116.72 158.40 134.39 0.04 1.4 
SH3BP5 85.21 107.66 107.13 137.75 138.42 132.58 0.01 1.4 
BRD7 88.56 108.28 103.16 116.82 138.78 148.61 0.04 1.4 
C17orf75 102.12 94.30 103.58 120.93 145.56 131.93 0.01 1.3 
PI4K2B 81.40 114.94 103.65 137.73 127.26 131.01 0.04 1.3 
MDH2 106.64 99.58 93.78 132.61 136.44 125.99 0.00 1.3 
SMARCB1 89.38 105.81 104.81 115.12 141.11 135.71 0.03 1.3 
BRD9 109.05 100.42 90.53 144.25 128.72 120.62 0.02 1.3 
MAPK14 89.74 110.37 99.89 133.47 127.90 127.64 0.01 1.3 
VHL 111.08 98.47 90.45 136.91 135.91 112.84 0.04 1.3 
CSNK2B 87.32 101.10 111.58 120.88 135.08 131.34 0.02 1.3 
MAPK9 93.30 103.48 103.23 116.71 134.68 136.63 0.02 1.3 
FH 88.01 103.30 108.69 116.95 122.93 134.12 0.04 1.3 
RIPK2 107.86 93.78 98.36 128.03 118.96 127.05 0.01 1.3 
RB1 100.30 99.01 100.69 127.90 127.04 119.56 0.00 1.2 
MAPK6 89.31 101.11 109.58 112.56 134.50 123.49 0.05 1.2 
MAP2K4 106.21 87.45 106.34 113.59 124.80 128.78 0.04 1.2 
TGFBR1 106.30 96.83 96.87 123.82 125.83 116.76 0.01 1.2 
MET 100.36 97.04 102.60 117.81 120.36 123.81 0.00 1.2 
ACO1 91.31 106.02 102.67 116.76 121.04 122.48 0.01 1.2 
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GPI 98.78 108.12 93.10 125.55 118.94 111.49 0.04 1.2 
RAF1 100.61 102.72 96.68 114.38 109.57 131.47 0.05 1.2 
CDK4 101.71 103.23 95.06 113.55 113.40 125.26 0.02 1.2 
CDK1 94.53 104.79 100.68 113.34 112.18 125.61 0.03 1.2 
PTEN 104.69 102.38 92.93 118.46 113.63 114.01 0.02 1.2 
Down-Regulated Genes 
CANT1 102.26 102.13 95.61 74.26 77.76 72.82 0.00 0.7 
RPS6KA4 89.61 112.76 97.63 67.81 80.92 74.18 0.03 0.7 
ATIC 92.36 103.75 103.90 69.51 72.44 77.62 0.00 0.7 
RPS6KC1 97.65 110.53 91.82 63.45 84.16 71.48 0.03 0.7 
PRKAR1A 99.04 100.29 100.67 68.68 72.59 76.65 0.00 0.7 
RIPK1 100.25 95.01 104.74 63.70 69.64 83.27 0.01 0.7 
BRCA2 94.16 106.10 99.74 68.15 71.34 77.11 0.00 0.7 
PDXK 95.39 105.72 98.89 73.37 69.33 73.59 0.00 0.7 
LATS2 109.68 106.83 83.49 76.02 66.31 71.03 0.03 0.7 
AURKA 94.64 113.24 92.13 71.74 65.29 75.09 0.02 0.7 
SPTAN1 94.90 102.35 102.74 68.42 69.69 72.68 0.00 0.7 
CAMK2D 85.56 115.08 99.36 69.50 65.52 74.53 0.03 0.7 
BMPR1A 109.26 103.28 87.46 65.26 71.55 69.21 0.01 0.7 
TKT 94.42 106.27 99.31 65.99 67.99 70.86 0.00 0.7 
SGK196 86.59 112.34 101.08 72.34 66.83 65.30 0.01 0.7 
LIMK2 101.43 93.63 104.94 69.47 68.76 64.83 0.00 0.7 
FBXW7 106.32 104.96 88.72 72.23 65.27 65.31 0.01 0.7 
SRPK2 94.96 101.78 103.26 71.26 63.48 65.17 0.00 0.7 
SMAD4 106.16 95.81 98.03 58.31 63.28 74.85 0.00 0.7 
PIP5K1A 97.04 106.67 96.29 65.90 68.32 62.03 0.00 0.7 
CARS 109.98 104.43 85.59 63.52 60.63 65.80 0.01 0.6 
BRD1 120.83 90.76 88.41 65.75 63.12 60.99 0.03 0.6 
PDK1 103.94 109.44 86.61 73.79 60.17 53.65 0.01 0.6 
H6PD 124.34 78.77 96.89 54.75 70.57 60.73 0.05 0.6 
RUNX1 110.51 88.95 100.54 60.45 62.33 62.23 0.00 0.6 
PIKFYVE 105.65 89.69 104.66 65.22 53.00 66.37 0.00 0.6 
PRKD2 114.02 96.97 89.01 59.53 57.54 66.06 0.01 0.6 
NF2 104.52 97.14 98.34 60.72 64.47 57.76 0.00 0.6 
JUN 110.79 105.36 83.84 60.50 58.71 62.61 0.01 0.6 
BMPR2 102.34 97.17 100.49 61.37 54.70 63.72 0.00 0.6 
CCND1 107.49 97.78 94.73 58.79 58.02 61.48 0.00 0.6 
CDH1 93.28 106.31 100.41 58.32 61.00 58.15 0.00 0.6 
TRIB1 114.51 88.92 96.56 58.70 54.87 63.68 0.01 0.6 
ABL2 110.03 101.83 88.14 54.74 62.36 58.45 0.00 0.6 
NPM1 96.75 104.96 98.29 54.00 54.00 56.62 0.00 0.5 
ETNK2 95.16 87.67 117.17 44.66 52.02 66.98 0.01 0.5 
JAK1 70.16 104.17 125.66 55.93 54.15 51.56 0.05 0.5 
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PLXNB2 107.81 99.81 92.38 53.14 49.49 57.30 0.00 0.5 
NEK7 106.05 94.44 99.51 50.83 55.51 53.60 0.00 0.5 
HERC4 101.72 105.21 93.07 53.40 50.35 53.23 0.00 0.5 
RIOK3 114.66 102.70 82.64 52.09 41.01 62.60 0.01 0.5 
ATF2 93.99 107.22 98.78 38.01 56.30 58.19 0.00 0.5 
APC 93.07 133.46 73.47 54.11 50.09 48.61 0.05 0.5 
PIK3R1 71.49 110.08 118.43 55.74 41.38 52.83 0.03 0.5 
TNIK 92.42 118.61 88.97 48.05 40.12 59.52 0.01 0.5 
CXCR7 96.52 94.33 109.15 52.16 52.47 38.81 0.00 0.5 
GNAS 99.34 98.90 101.76 48.50 47.80 48.36 0.00 0.5 
PKN1 104.60 88.72 106.68 45.31 46.34 47.45 0.00 0.5 
LPAR1 93.72 116.63 89.65 36.29 49.87 48.58 0.00 0.4 
PIK3C2B 101.12 103.81 95.08 56.94 39.02 38.43 0.00 0.4 
IRAK2 85.32 108.56 106.12 42.10 56.71 35.03 0.00 0.4 
TGFBR2 87.37 113.03 99.60 37.35 40.70 43.57 0.00 0.4 
CALM3 88.83 102.81 108.35 36.49 43.15 36.87 0.00 0.4 
HRAS 69.46 116.39 114.15 38.16 35.63 41.85 0.02 0.4 
IDH1 106.85 109.69 83.46 37.03 29.78 47.63 0.00 0.4 
MAGI2 133.29 92.11 74.60 43.31 45.01 21.11 0.03 0.4 
FLT3 122.76 113.11 64.13 26.59 47.37 34.56 0.03 0.4 
PRKCQ 101.45 100.14 98.41 32.96 35.88 39.27 0.00 0.4 
ILK 96.77 106.34 96.88 29.07 34.35 42.80 0.00 0.4 
INPP4B 92.55 107.86 99.59 36.86 29.67 37.83 0.00 0.3 
PLK2 97.54 92.11 110.35 30.90 32.64 37.50 0.00 0.3 
AURKC 122.94 116.51 60.55 21.30 37.95 41.54 0.03 0.3 
FLNB 105.10 95.84 99.05 32.87 31.05 28.04 0.00 0.3 
EPHB6 121.89 96.25 81.86 26.40 39.20 25.74 0.01 0.3 
NTRK1 119.13 109.76 71.12 25.80 22.99 41.93 0.01 0.3 
TGFBR3 149.12 84.11 66.77 36.91 32.88 17.99 0.05 0.3 
TRIM5 119.21 101.99 78.80 22.75 26.84 35.36 0.00 0.3 
HKDC1 98.24 135.77 65.98 26.60 33.17 20.75 0.02 0.3 
TBX22 130.75 120.46 48.79 28.32 33.64 18.41 0.05 0.3 
HOXB7 118.67 96.82 84.51 24.45 31.31 19.46 0.00 0.3 
MST1R 104.36 103.37 92.27 22.22 24.91 26.15 0.00 0.2 
MYLK4 69.48 137.18 93.33 30.10 26.81 14.67 0.02 0.2 
MRGPRX3 118.30 93.42 88.28 25.62 22.83 16.65 0.00 0.2 
ALK 104.07 102.73 93.20 22.54 20.08 21.98 0.00 0.2 
INSR 99.84 92.06 108.09 13.64 17.95 29.07 0.00 0.2 
LRP1B 119.97 126.32 53.71 0.00 15.43 33.78 0.03 0.2 
EPHA4 128.80 106.80 64.40 20.46 14.91 12.69 0.01 0.2 
ERBB4 98.24 135.77 65.98 10.64 18.96 10.37 0.01 0.1 
ROBO1 103.32 95.99 100.69 14.48 12.90 11.55 0.00 0.1 
STK32A 84.10 121.76 94.14 10.12 16.23 7.89 0.00 0.1 
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MAP2K6 98.31 109.99 91.70 10.65 15.81 6.92 0.00 0.1 
RPS6KA6 143.73 83.17 73.10 14.01 10.05 7.98 0.02 0.1 
ANGPTL4 120.81 95.40 83.79 9.35 12.90 7.06 0.00 0.1 
FYN 82.16 118.31 99.54 8.37 8.39 9.18 0.00 0.1 
PRKD1 74.75 114.38 110.87 6.07 9.01 9.87 0.00 0.1 
SMO 120.56 92.82 86.62 0.00 15.95 0.00 0.00 0.1 
AKT3 88.61 105.97 105.42 3.84 4.88 5.35 0.00 0.0 
TP53 110.82 99.07 90.11 4.99 3.59 2.62 0.00 0.0 
CDK14 118.73 90.53 90.74 3.55 5.53 1.73 0.00 0.0 
ROS1 92.87 100.01 107.11 2.13 1.90 3.86 0.00 0.0 
HCK 100.78 126.35 72.87 0.00 0.00 0.00 0.00 0.0 
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Appendix 5: GO pathway analysis of deregulated genes in TRIM24-iHMECs  
Upregulated Genes 
Term Count % P-Value 
GO:0006468~protein amino acid phosphorylation 52 41.3 4.83E-37 
GO:0016310~phosphorylation 55 43.7 1.13E-36 
GO:0006793~phosphorus metabolic process 57 45.2 1.61E-34 
GO:0006796~phosphate metabolic process 57 45.2 1.61E-34 
GO:0007242~intracellular signaling cascade 38 30.2 2.28E-12 
GO:0043549~regulation of kinase activity 19 15.1 7.45E-10 
GO:0042325~regulation of phosphorylation 21 16.7 1.28E-09 
GO:0051338~regulation of transferase activity 19 15.1 1.44E-09 
GO:0019220~regulation of phosphate metabolic process 21 16.7 2.55E-09 
GO:0051174~regulation of phosphorus metabolic process 21 16.7 2.55E-09 
GO:0045859~regulation of protein kinase activity 18 14.3 3.28E-09 
GO:0006084~acetyl-CoA metabolic process 8 6.3 4.92E-09 
GO:0007243~protein kinase cascade 18 14.3 9.35E-09 
GO:0009060~aerobic respiration 8 6.3 1.23E-08 
GO:0046356~acetyl-CoA catabolic process 7 5.6 2.53E-08 
GO:0006099~tricarboxylic acid cycle 7 5.6 2.53E-08 
GO:0006732~coenzyme metabolic process 12 9.5 5.32E-08 
GO:0009109~coenzyme catabolic process 7 5.6 5.66E-08 
GO:0051187~cofactor catabolic process 7 5.6 1.75E-07 
GO:0042127~regulation of cell proliferation 23 18.3 4.02E-07 
GO:0046777~protein amino acid autophosphorylation 9 7.1 4.86E-07 
GO:0042981~regulation of apoptosis 23 18.3 5.78E-07 
GO:0051186~cofactor metabolic process 12 9.5 6.22E-07 
GO:0043067~regulation of programmed cell death 23 18.3 6.83E-07 
GO:0010941~regulation of cell death 23 18.3 7.27E-07 
GO:0000075~cell cycle checkpoint 9 7.1 8.24E-07 
GO:0044093~positive regulation of molecular function 19 15.1 1.41E-06 
GO:0043085~positive regulation of catalytic activity 17 13.5 5.66E-06 
GO:0043066~negative regulation of apoptosis 14 11.1 7.11E-06 
GO:0043648~dicarboxylic acid metabolic process 6 4.8 8.17E-06 
GO:0043069~negative regulation of programmed cell 
death 14 11.1 8.27E-06 
GO:0060548~negative regulation of cell death 14 11.1 8.52E-06 
GO:0006091~generation of precursor metabolites and 
energy 13 10.3 1.06E-05 
GO:0018107~peptidyl-threonine phosphorylation 5 4.0 1.25E-05 
GO:0006917~induction of apoptosis 13 10.3 1.33E-05 
GO:0012502~induction of programmed cell death 13 10.3 1.37E-05 
GO:0045333~cellular respiration 8 6.3 1.54E-05 
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GO:0051726~regulation of cell cycle 13 10.3 1.86E-05 
GO:0018210~peptidyl-threonine modification 5 4.0 2.39E-05 
GO:0010033~response to organic substance 19 15.1 2.46E-05 
GO:0019318~hexose metabolic process 10 7.9 3.02E-05 
GO:0006915~apoptosis 17 13.5 3.47E-05 
GO:0006006~glucose metabolic process 9 7.1 3.92E-05 
GO:0012501~programmed cell death 17 13.5 4.14E-05 
GO:0042770~DNA damage response, signal transduction 7 5.6 5.14E-05 
GO:0043065~positive regulation of apoptosis 14 11.1 5.49E-05 
GO:0043068~positive regulation of programmed cell death 14 11.1 5.90E-05 
GO:0010942~positive regulation of cell death 14 11.1 6.18E-05 
GO:0008219~cell death 18 14.3 8.34E-05 
GO:0016265~death 18 14.3 9.08E-05 
GO:0005996~monosaccharide metabolic process 10 7.9 9.33E-05 
GO:0006007~glucose catabolic process 6 4.8 1.15E-04 
GO:0007167~enzyme linked receptor protein signaling 
pathway 12 9.5 1.24E-04 
GO:0033674~positive regulation of kinase activity 10 7.9 1.26E-04 
GO:0000165~MAPKKK cascade 9 7.1 1.43E-04 
    
Down-regulated Genes 
Term Count % PValue 
GO:0016310~phosphorylation 50 54.9 5.39E-37 
GO:0006468~protein amino acid phosphorylation 47 51.6 1.07E-36 
GO:0006793~phosphorus metabolic process 50 54.9 5.99E-33 
GO:0006796~phosphate metabolic process 50 54.9 5.99E-33 
GO:0007242~intracellular signaling cascade 31 34.1 1.56E-10 
GO:0007167~enzyme linked receptor protein signaling 
pathway 17 18.7 6.50E-10 
GO:0042325~regulation of phosphorylation 19 20.9 1.07E-09 
GO:0051174~regulation of phosphorus metabolic process 19 20.9 2.01E-09 
GO:0019220~regulation of phosphate metabolic process 19 20.9 2.01E-09 
GO:0007243~protein kinase cascade 17 18.7 2.03E-09 
GO:0042127~regulation of cell proliferation 22 24.2 2.66E-08 
GO:0051094~positive regulation of developmental process 14 15.4 3.07E-08 
GO:0044093~positive regulation of molecular function 18 19.8 2.19E-07 
GO:0045597~positive regulation of cell differentiation 12 13.2 2.95E-07 
GO:0045859~regulation of protein kinase activity 14 15.4 3.77E-07 
GO:0043549~regulation of kinase activity 14 15.4 5.57E-07 
GO:0010033~response to organic substance 19 20.9 8.33E-07 
GO:0051338~regulation of transferase activity 14 15.4 8.86E-07 
GO:0001932~regulation of protein amino acid 
phosphorylation 10 11.0 1.96E-06 
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GO:0007169~transmembrane receptor protein tyrosine 
kinase signaling pathway 11 12.1 2.06E-06 
GO:0051130~positive regulation of cellular component 
organization 10 11.0 2.85E-06 
GO:0008284~positive regulation of cell proliferation 14 15.4 2.91E-06 
GO:0009725~response to hormone stimulus 13 14.3 4.81E-06 
GO:0051098~regulation of binding 9 9.9 7.25E-06 
GO:0007166~cell surface receptor linked signal 
transduction 29 31.9 1.27E-05 
GO:0009719~response to endogenous stimulus 13 14.3 1.30E-05 
GO:0051101~regulation of DNA binding 8 8.8 1.45E-05 
GO:0045860~positive regulation of protein kinase activity 10 11.0 1.55E-05 
GO:0033674~positive regulation of kinase activity 10 11.0 2.05E-05 
GO:0008285~negative regulation of cell proliferation 12 13.2 2.38E-05 
GO:0030097~hemopoiesis 10 11.0 2.43E-05 
GO:0051347~positive regulation of transferase activity 10 11.0 2.77E-05 
GO:0043085~positive regulation of catalytic activity 14 15.4 3.33E-05 
GO:0032388~positive regulation of intracellular transport 5 5.5 4.21E-05 
GO:0048534~hemopoietic or lymphoid organ development 10 11.0 5.18E-05 
GO:0006275~regulation of DNA replication 6 6.6 5.30E-05 
GO:0007569~cell aging 5 5.5 6.19E-05 
GO:0044092~negative regulation of molecular function 11 12.1 6.64E-05 
GO:0043408~regulation of MAPKKK cascade 7 7.7 8.05E-05 
GO:0002520~immune system development 10 11.0 8.21E-05 
GO:0007568~aging 7 7.7 8.47E-05 
GO:0042493~response to drug 9 9.9 8.64E-05 
GO:0007369~gastrulation 6 6.6 9.51E-05 
GO:0043388~positive regulation of DNA binding 6 6.6 9.51E-05 
GO:0032386~regulation of intracellular transport 6 6.6 1.02E-04 
GO:0051050~positive regulation of transport 9 9.9 1.08E-04 
GO:0030334~regulation of cell migration 8 8.8 1.22E-04 
GO:0031399~regulation of protein modification process 10 11.0 1.36E-04 
GO:0051259~protein oligomerization 8 8.8 1.47E-04 
GO:0051092~positive regulation of NF-kappaB 
transcription factor activity 5 5.5 1.47E-04 
GO:0051099~positive regulation of binding 6 6.6 1.59E-04 
GO:0042306~regulation of protein import into nucleus 5 5.5 1.94E-04 
GO:0010627~regulation of protein kinase cascade 9 9.9 2.30E-04 
GO:0018108~peptidyl-tyrosine phosphorylation 5 5.5 2.31E-04 
GO:0031346~positive regulation of cell projection 
organization 5 5.5 2.52E-04 
GO:0040012~regulation of locomotion 8 8.8 2.68E-04 
GO:0018212~peptidyl-tyrosine modification 5 5.5 2.73E-04 
GO:0051270~regulation of cell motion 8 8.8 2.77E-04 
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GO:0032880~regulation of protein localization 7 7.7 2.93E-04 		
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Appendix 6: KEGG pathway analysis of deregulated genes in TRIM24-iHMECs  
Up-regulated Genes 
Term Count % P-Value Benjamini 
Citrate cycle (TCA cycle) 9 7.1 2E-08 2E-06 
Pathways in cancer 22 17.5 3E-08 2E-06 
ErbB signaling pathway 12 9.5 1E-07 4E-06 
Chronic myeloid leukemia 11 8.7 3E-07 6E-06 
Renal cell carcinoma 10 7.9 2E-06 3E-05 
Pancreatic cancer 10 7.9 2E-06 3E-05 
Bladder cancer 8 6.3 4E-06 6E-05 
Neurotrophin signaling pathway 12 9.5 4E-06 5E-05 
Glioma 9 7.1 7E-06 7E-05 
Insulin signaling pathway 12 9.5 1E-05 9E-05 
Melanoma 9 7.1 2E-05 1E-04 
Acute myeloid leukemia 8 6.3 4E-05 3E-04 
MAPK signaling pathway 15 11.9 9E-05 6E-04 
Non-small cell lung cancer 7 5.6 2E-04 2E-03 
Fc epsilon RI signaling pathway 8 6.3 3E-04 2E-03 
T cell receptor signaling pathway 9 7.1 3E-04 2E-03 
Colorectal cancer 8 6.3 4E-04 2E-03 
Prostate cancer 8 6.3 6E-04 3E-03 
Epithelial cell signaling in 
Helicobacter pylori infection 7 5.6 8E-04 4E-03 
Cell cycle 9 7.1 9E-04 4E-03 
GnRH signaling pathway 8 6.3 1E-03 5E-03 
mTOR signaling pathway 6 4.8 2E-03 6E-03 
Endometrial cancer 6 4.8 2E-03 6E-03 
Progesterone-mediated oocyte 
maturation 7 5.6 3E-03 1E-02 
Gap junction 7 5.6 3E-03 1E-02 
NOD-like receptor signaling 
pathway 6 4.8 3E-03 1E-02 
Down-regulated Genes 
Term Count % P-Value Benjamini 
Neurotrophin signaling pathway 12 13.19 1.4E-07 1.2E-05 
Endometrial cancer 8 8.79 2.0E-06 8.4E-05 
Pathways in cancer 16 17.58 3.8E-06 1.1E-04 
Pancreatic cancer 8 8.79 1.8E-05 3.8E-04 
Chronic myeloid leukemia 8 8.79 2.4E-05 4.0E-04 
Colorectal cancer 8 8.79 5.0E-05 7.0E-04 
Glioma 7 7.69 8.4E-05 1.0E-03 
Thyroid cancer 5 5.49 3.3E-04 3.5E-03 
Apoptosis 7 7.69 5.0E-04 4.7E-03 
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ErbB signaling pathway 7 7.69 5.0E-04 4.7E-03 
Acute myeloid leukemia 6 6.59 5.5E-04 4.6E-03 
MAPK signaling pathway 11 12.09 9.8E-04 7.6E-03 
Melanoma 6 6.59 1.4E-03 9.8E-03 
T cell receptor signaling pathway 7 7.69 1.6E-03 1.0E-02 
Phosphatidylinositol signaling 
system 6 6.59 1.7E-03 1.2E-02 
Fc epsilon RI signaling pathway 6 6.59 2.1E-03 1.9E-02 
Non-small cell lung cancer 5 5.49 3.6E-03 1.9E-02 
Axon guidance 7 7.69 3.9E-03 2.3E-02 
Fc gamma R-mediated 
phagocytosis 6 6.59 5.0E-03 2.5E-02 
GnRH signaling pathway 6 6.59 5.7E-03 3.7E-02 
Focal adhesion 8 8.79 8.9E-03 5.0E-02 
Adherens junction 5 5.49 1.2E-02 4.9E-02 
Bladder cancer 4 4.40 1.3E-02 7.3E-02 
Prostate cancer 5 5.49 2.0E-02 7.2E-02 
Insulin signaling pathway 6 6.59 2.1E-02 8.3E-02 
Inositol phosphate metabolism 4 4.40 2.5E-02 9.7E-02 
Toll-like receptor signaling pathway 5 5.49 3.1E-02 9.7E-02 
Wnt signaling pathway 6 6.59 3.2E-02 1.3E-01 
Long-term potentiation 4 4.40 4.6E-02 1.4E-01 																		 	
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Appendix 7: GSEA report for pathways positively correlating with TRIM24 
expression in invasive carcinoma patients  
Pathways postively enriched with TRIM24 
NAME FDR q-val ES NES NOM p-val 
KEGG_OOCYTE_MEIOSIS 0.06408 0.52151 1.87444 0.00000 
REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY 0.06434 0.62592 1.87805 0.00382 
REACTOME_KINESINS 0.06713 0.83314 1.87817 0.00192 
PID_AURORA_B_PATHWAY 0.06795 0.71556 1.85762 0.00763 
REACTOME_TRANSPORT_OF_MATURE_MRNA_DERIVED_FROM
_AN_INTRONLESS_TRANSCRIPT 0.06845 0.71711 1.88203 0.00389 
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEA
SOME_DEGRADATION 0.07023 0.49987 1.85804 0.00186 
REACTOME_GLUCOSE_TRANSPORT 0.07066 0.63171 1.88390 0.00186 
REACTOME_TRANSCRIPTION 0.07192 0.55355 1.91430 0.00546 
REACTOME_MITOTIC_G2_G2_M_PHASES 0.07214 0.56097 1.84754 0.00546 
REACTOME_NEP_NS2_INTERACTS_WITH_THE_CELLULAR_EXP
ORT_MACHINERY 0.07263 0.75149 1.85856 0.00195 
REACTOME_ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GE
NES 0.07322 0.61327 1.88518 0.00000 
KEGG_RNA_DEGRADATION 0.07602 0.59834 1.91539 0.00000 
REACTOME_REGULATION_OF_GLUCOKINASE_BY_GLUCOKINA
SE_REGULATORY_PROTEIN 0.07690 0.71516 1.88557 0.00190 
REACTOME_TRANSPORT_OF_RIBONUCLEOPROTEINS_INTO_T
HE_HOST_NUCLEUS 0.07828 0.75012 1.88901 0.00000 
REACTOME_LATE_PHASE_OF_HIV_LIFE_CYCLE 0.07982 0.55328 1.83218 0.00570 
REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTO
PLASM 0.08048 0.68610 1.89741 0.00388 
REACTOME_MEIOSIS 0.08146 0.59509 1.91615 0.00000 
BIOCARTA_ATRBRCA_PATHWAY 0.08189 0.76268 1.89002 0.00000 
REACTOME_MEIOTIC_RECOMBINATION 0.08225 0.64034 1.82548 0.00188 
REACTOME_INTERACTIONS_OF_VPR_WITH_HOST_CELLULAR_
PROTEINS 0.08325 0.72806 1.92217 0.00195 
REACTOME_MRNA_3_END_PROCESSING 0.08413 0.69132 1.81575 0.00586 
REACTOME_RNA_POL_II_TRANSCRIPTION 0.08626 0.55333 1.80294 0.01095 
REACTOME_METABOLISM_OF_NON_CODING_RNA 0.08628 0.66598 1.81632 0.00576 
REACTOME_TELOMERE_MAINTENANCE 0.08643 0.68094 1.80537 0.01328 
REACTOME_HIV_LIFE_CYCLE 0.08865 0.54442 1.80587 0.00949 
REACTOME_MEIOTIC_SYNAPSIS 0.08981 0.62712 1.92364 0.00000 
PID_PLK1_PATHWAY 0.09299 0.70542 1.93973 0.00366 
PID_BARD1PATHWAY 0.09308 0.70553 1.79135 0.00593 
REACTOME_MITOTIC_M_M_G1_PHASES 0.09489 0.67837 1.92756 0.00372 
REACTOME_CLEAVAGE_OF_GROWING_TRANSCRIPT_IN_THE_T
ERMINATION_REGION_ 0.09509 0.67971 1.78624 0.00568 
PID_E2F_PATHWAY 0.09586 0.53455 1.78174 0.00727 
REACTOME_G2_M_CHECKPOINTS 0.09661 0.74742 1.77472 0.01326 
KEGG_CELL_CYCLE 0.09687 0.55862 1.77733 0.01296 
REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 0.09713 0.54059 1.76872 0.00749 
REACTOME_CELL_CYCLE_MITOTIC 0.09823 0.63418 2.01532 0.00366 
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PID_ATM_PATHWAY 0.09938 0.62878 1.76889 0.00559 
REACTOME_G0_AND_EARLY_G1 0.09998 0.74488 1.76329 0.00765 
REACTOME_MRNA_PROCESSING 0.10062 0.55231 1.75046 0.01527 
PID_P53REGULATIONPATHWAY 0.10128 0.51186 1.75457 0.00384 
REACTOME_CELL_CYCLE_CHECKPOINTS 0.10152 0.63477 1.75934 0.01498 
REACTOME_DEADENYLATION_OF_MRNA 0.10189 0.67875 1.75146 0.00411 
REACTOME_DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCL
EOSOMES_AT_THE_CENTROMERE 0.10204 0.71104 1.73884 0.01333 
REACTOME_MITOTIC_G1_G1_S_PHASES 0.10254 0.59616 1.74061 0.01679 
REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICA
TION_STRESS 0.10291 0.76476 1.75521 0.01331 
REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVE
LOPMENT_AND_PLATELET_PRODUCTION 0.10315 0.44949 1.74232 0.00514 
REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX 0.10343 0.49065 1.74428 0.00179 
PID_ATR_PATHWAY 0.10404 0.73865 1.94007 0.00185 
REACTOME_G1_S_TRANSITION 0.10676 0.61844 1.73105 0.02052 
REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_REPLICATI
ON 0.10906 0.67603 1.72596 0.02068 
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE 0.11120 0.63876 1.72137 0.02385 
PID_FANCONI_PATHWAY 0.11789 0.73211 1.94110 0.00188 
REACTOME_PACKAGING_OF_TELOMERE_ENDS 0.11850 0.68107 1.69037 0.02457 
REACTOME_TRANSCRIPTIONAL_ACTIVITY_OF_SMAD2_SMAD3_
SMAD4_HETEROTRIMER 0.11936 0.51551 1.69138 0.00549 
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_
PRE_MRNA 0.11967 0.55976 1.71013 0.02682 
REACTOME_DNA_STRAND_ELONGATION 0.12033 0.76700 1.68599 0.01905 
KEGG_VIBRIO_CHOLERAE_INFECTION 0.12037 0.51593 1.69642 0.01289 
REACTOME_DNA_REPAIR 0.12056 0.51428 1.69222 0.02617 
REACTOME_DOUBLE_STRAND_BREAK_REPAIR 0.12056 0.65993 1.69440 0.02574 
REACTOME_RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_T
RANSCRIPTION 0.12074 0.50434 1.68373 0.01842 
REACTOME_SYNTHESIS_OF_DNA 0.12095 0.64069 1.69964 0.02578 
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROT
EINS_AND_COMPLEXES 0.12103 0.50539 1.70437 0.00914 
REACTOME_S_PHASE 0.12119 0.61692 1.69748 0.03142 
REACTOME_CHROMOSOME_MAINTENANCE 0.12125 0.67446 2.02219 0.00000 
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING
_PRESENTATION 0.12180 0.44952 1.70082 0.00550 
REACTOME_DOWNREGULATION_OF_SMAD2_3_SMAD4_TRANS
CRIPTIONAL_ACTIVITY 0.12293 0.60638 1.70455 0.00787 
REACTOME_HIV_INFECTION 0.12411 0.50023 1.67602 0.02421 
REACTOME_MITOTIC_PROMETAPHASE 0.12438 0.70370 1.95132 0.00189 
PID_FOXOPATHWAY 0.12481 0.48528 1.67349 0.00890 
REACTOME_PROCESSING_OF_CAPPED_INTRONLESS_PRE_MR
NA 0.12514 0.69404 1.67675 0.01934 
REACTOME_DNA_REPLICATION 0.13022 0.68481 1.96305 0.00368 
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLE
X 0.13127 0.77417 1.66250 0.01934 
KEGG_DNA_REPLICATION 0.13129 0.71138 1.66065 0.03781 
PID_MYC_ACTIVPATHWAY 0.13238 0.51319 1.66345 0.03825 
REACTOME_RNA_POL_I_TRANSCRIPTION 0.13568 0.54073 1.65408 0.03097 
BIOCARTA_MPR_PATHWAY 0.13574 0.53412 1.65234 0.01835 
PID_NFAT_3PATHWAY 0.13881 0.45721 1.64747 0.01622 
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REACTOME_APC_CDC20_MEDIATED_DEGRADATION_OF_NEK2
A 0.14737 0.65242 1.63723 0.02985 
REACTOME_EXTENSION_OF_TELOMERES 0.14908 0.71081 1.63372 0.03738 
KEGG_BASAL_TRANSCRIPTION_FACTORS 0.15401 0.54087 1.62712 0.02124 
KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION 0.16323 0.44447 1.61206 0.01068 
BIOCARTA_G2_PATHWAY 0.16461 0.60109 1.61253 0.03137 
REACTOME_CELL_CYCLE 0.16472 0.61694 2.03270 0.00361 
REACTOME_RNA_POL_II_PRE_TRANSCRIPTION_EVENTS 0.16534 0.49104 1.60485 0.03683 
KEGG_MISMATCH_REPAIR 0.16577 0.64843 1.61320 0.03512 
KEGG_NUCLEOTIDE_EXCISION_REPAIR 0.16581 0.51854 1.60270 0.03795 
REACTOME_M_G1_TRANSITION 0.16619 0.63197 1.60577 0.05639 
PID_CDC42_PATHWAY 0.16620 0.44910 1.61468 0.01299 
PID_FOXM1PATHWAY 0.16721 0.55348 1.60655 0.05128 
REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS 0.16792 0.51664 1.59923 0.04135 
REACTOME_HOMOLOGOUS_RECOMBINATION_REPAIR_OF_RE
PLICATION_INDEPENDENT_DOUBLE_STRAND_BREAKS 0.16930 0.65792 1.59629 0.03512 
REACTOME_LAGGING_STRAND_SYNTHESIS 0.17241 0.71544 1.59174 0.04461 
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MIT
OTIC_PROTEINS 0.18120 0.60192 1.58256 0.07063 
REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC
20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE
_MITOSIS_EARLY_G1 
0.19813 0.59770 1.56708 0.07421 
KEGG_SPLICEOSOME 0.20514 0.51304 1.55945 0.06434 
KEGG_HOMOLOGOUS_RECOMBINATION 0.20534 0.60543 1.55755 0.06180 
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_
TRANSITION_ 0.21934 0.56082 1.54500 0.08736 
REACTOME_RNA_POL_I_PROMOTER_OPENING 0.22835 0.64999 1.53680 0.06857 
PID_PI3KCIAKTPATHWAY 0.23155 0.45818 1.53275 0.03018 
REACTOME_ORC1_REMOVAL_FROM_CHROMATIN 0.23915 0.58463 1.52366 0.09888 
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS
_THAT_BIND_AU_RICH_ELEMENTS 0.24074 0.51165 1.52429 0.07934 
BIOCARTA_PROTEASOME_PATHWAY 0.24789 0.65029 1.51581 0.09478 
PID_TELOMERASEPATHWAY 0.26377 0.41596 1.50312 0.02974 
PID_INSULIN_GLUCOSE_PATHWAY 0.26954 0.48411 1.49755 0.06579 
REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21 0.27322 0.57794 1.48846 0.11359 
REACTOME_SIGNALING_BY_WNT 0.27351 0.51564 1.49312 0.08679 
BIOCARTA_ACTINY_PATHWAY 0.27415 0.59575 1.48946 0.06903 
REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX 0.27479 0.59730 1.49072 0.10841 
REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION 0.29102 0.41678 1.47185 0.07196 
SA_G1_AND_S_PHASES 0.29140 0.59326 1.47326 0.08812 
PID_ECADHERIN_NASCENTAJ_PATHWAY 0.29210 0.47020 1.47468 0.05321 
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 0.29307 0.54255 2.04425 0.00188 
KEGG_PYRIMIDINE_METABOLISM 0.29385 0.45504 1.46808 0.07547 
REACTOME_GENERIC_TRANSCRIPTION_PATHWAY 0.29591 0.40078 1.46340 0.09464 
REACTOME_TRANSCRIPTION_COUPLED_NER_TC_NER 0.29715 0.50489 1.46426 0.08969 
REACTOME_RNA_POL_I_TRANSCRIPTION_INITIATION 0.30228 0.52275 1.45781 0.08364 
REACTOME_AUTODEGRADATION_OF_CDH1_BY_CDH1_APC_C 0.30504 0.55141 1.45445 0.13197 
REACTOME_INSULIN_RECEPTOR_RECYCLING 0.31323 0.55970 1.44766 0.11132 
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PID_AURORA_A_PATHWAY 0.31582 0.48821 1.44424 0.08672 
REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS 0.32016 0.51224 1.43992 0.12037 
REACTOME_P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE 0.32274 0.54136 1.43336 0.13458 
REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_
EMI1 0.32282 0.57213 1.43491 0.13645 
REACTOME_NUCLEOTIDE_EXCISION_REPAIR 0.32432 0.46860 1.43563 0.09830 
REACTOME_MRNA_SPLICING 0.33122 0.48743 1.42301 0.11686 
REACTOME_RNA_POL_II_TRANSCRIPTION_PRE_INITIATION_AN
D_PROMOTER_OPENING 0.33273 0.47377 1.42540 0.09641 
KEGG_PROTEASOME 0.33354 0.59200 1.42326 0.15789 
KEGG_PROTEIN_EXPORT 0.33894 0.58179 1.41684 0.12398 
BIOCARTA_G1_PATHWAY 0.34162 0.46818 1.41175 0.09009 
PID_AJDISS_2PATHWAY 0.34311 0.40989 1.41251 0.06944 
PID_MYC_PATHWAY 0.34561 0.45365 1.40774 0.08663 
REACTOME_DOWNREGULATION_OF_TGF_BETA_RECEPTOR_SI
GNALING 0.34578 0.49901 1.40418 0.10638 
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Appendix 8: Histopathological report of tumors obtained after injection of 
Control or TRIM24-HMECs 
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Appendix 9: List of deregulated genes in TRIM24-OE MCF10A cells by HTG 
Edgeseq analysis 
Upregulated genes 
  Vector Normalized FC WT Normalized FC 1 FYN 18 0.001 1 101 0.005 6.19 
2 MMP2 197 0.010 1 978 0.053 5.47 
3 IGFBP2 90 0.004 1 423 0.023 5.18 
4 CITED2 1211 0.060 1 4958 0.270 4.51 
5 ITGAM 3 0.000 1 12 0.001 4.41 
6 CCL17 11 0.001 1 43 0.002 4.31 
7 F2R 117 0.006 1 448 0.024 4.22 
8 NOV 5 0.000 1 19 0.001 4.19 
9 TIMP1 5089 0.251 1 18943 1.031 4.10 
10 STC1 19 0.001 1 62 0.003 3.60 
11 NEIL1 12 0.001 1 38 0.002 3.49 
12 BMP4 82 0.004 1 259 0.014 3.48 
13 DKK1 2435 0.120 1 7608 0.414 3.44 
14 HSF4 15 0.001 1 46 0.003 3.38 
15 ADRA2A 4 0.000 1 12 0.001 3.31 
16 FCGR1A 7 0.000 1 21 0.001 3.31 
17 LFNG 13 0.001 1 39 0.002 3.31 
18 APBB1 12 0.001 1 34 0.002 3.12 
19 ANGPT1 202 0.010 1 572 0.031 3.12 
20 TXNRD1 1960 0.097 1 5528 0.301 3.11 
21 EFNA2 4 0.000 1 11 0.001 3.03 
22 FAT4 88 0.004 1 241 0.013 3.02 
23 PDCD1LG2 7 0.000 1 19 0.001 2.99 
24 IGFBP4 314 0.016 1 843 0.046 2.96 
25 IL27 3 0.000 1 8 0.000 2.94 
26 FBN1 309 0.015 1 797 0.043 2.84 
27 FOXO1 195 0.010 1 484 0.026 2.74 
28 GSTM1 27 0.001 1 66 0.004 2.69 
29 PRMT8 10 0.000 1 24 0.001 2.65 
30 HSP90AA1 15 0.001 1 36 0.002 2.65 
31 PBX1 80 0.004 1 192 0.010 2.65 
32 CARD11 33 0.002 1 77 0.004 2.57 
33 CLDN3 6 0.000 1 14 0.001 2.57 
34 TNFRSF8 12 0.001 1 28 0.002 2.57 
35 SLC7A11 110 0.005 1 256 0.014 2.57 
36 CD68 269 0.013 1 619 0.034 2.54 
37 RELN 12 0.001 1 27 0.001 2.48 
38 SULT2A1 13 0.001 1 29 0.002 2.46 
39 HPSE 123 0.006 1 272 0.015 2.44 
40 IRS1 134 0.007 1 295 0.016 2.43 
41 TAT 12 0.001 1 26 0.001 2.39 
42 S100A4 497 0.025 1 1061 0.058 2.35 
43 DAPK1 65 0.003 1 137 0.007 2.32 
44 PPAP2B 71 0.004 1 146 0.008 2.27 
45 WNT5A 218 0.011 1 448 0.024 2.27 
46 ID4 5 0.000 1 10 0.001 2.20 
47 GNLY 21 0.001 1 42 0.002 2.20 
48 BTC 26 0.001 1 52 0.003 2.20 
49 TCL1A 30 0.001 1 60 0.003 2.20 
50 PROK1 35 0.002 1 70 0.004 2.20 
51 MAF 3 0.000 1 6 0.000 2.20 
52 PDPN 49 0.002 1 98 0.005 2.20 
53 SIX1 41 0.002 1 81 0.004 2.18 
54 GADD45B 407 0.020 1 800 0.044 2.17 
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55 MAGEA4 26 0.001 1 51 0.003 2.16 
56 TSC1 51 0.003 1 99 0.005 2.14 
57 MYBL1 46 0.002 1 89 0.005 2.13 
58 MAP1LC3A 85 0.004 1 164 0.009 2.13 
59 AXL 348 0.017 1 669 0.036 2.12 
60 LTF 25 0.001 1 48 0.003 2.12 
61 COL18A1 64 0.003 1 122 0.007 2.10 
62 GPER1 19 0.001 1 36 0.002 2.09 
63 IFNW1 18 0.001 1 34 0.002 2.08 
64 GAS6 637 0.031 1 1197 0.065 2.07 
65 HOXB13 16 0.001 1 30 0.002 2.07 
66 SYP 30 0.001 1 56 0.003 2.06 
67 SCUBE1 7 0.000 1 13 0.001 2.05 
68 IL11 33 0.002 1 60 0.003 2.00 
69 TOP3B 21 0.001 1 38 0.002 1.99 
70 GSN 107 0.005 1 193 0.011 1.99 
71 CDKN2C 67 0.003 1 120 0.007 1.97 
72 ABCC3 2222 0.110 1 3979 0.217 1.97 
73 CST6 57 0.003 1 102 0.006 1.97 
74 NQO1 6428 0.317 1 11484 0.625 1.97 
75 FLRT1 14 0.001 1 25 0.001 1.97 
76 CYR61 743 0.037 1 1316 0.072 1.95 
77 CDKN2D 39 0.002 1 69 0.004 1.95 
78 FGF13 17 0.001 1 30 0.002 1.95 
79 IKBKG 17 0.001 1 30 0.002 1.95 
80 KLF17 17 0.001 1 30 0.002 1.95 
81 EPS8 515 0.025 1 908 0.049 1.94 
82 BMF 83 0.004 1 146 0.008 1.94 
83 SOX3 28 0.001 1 49 0.003 1.93 
84 FZD2 183 0.009 1 320 0.017 1.93 
85 DUSP10 132 0.007 1 230 0.013 1.92 
86 ZEB1 160 0.008 1 278 0.015 1.92 
87 S1PR1 34 0.002 1 59 0.003 1.91 
88 PFKFB1 44 0.002 1 76 0.004 1.90 
89 BNIP3L 310 0.015 1 535 0.029 1.90 
90 MAOB 46 0.002 1 79 0.004 1.89 
91 IGFBP6 653 0.032 1 1120 0.061 1.89 
92 GFAP 28 0.001 1 48 0.003 1.89 
93 PRDM14 28 0.001 1 48 0.003 1.89 
94 CAMKK1 31 0.002 1 53 0.003 1.88 
95 STAT2 344 0.017 1 586 0.032 1.88 
96 DCK 10 0.000 1 17 0.001 1.87 
97 DNAJC4 76 0.004 1 129 0.007 1.87 
98 PDCD1 29 0.001 1 49 0.003 1.86 
99 ACADS 57 0.003 1 96 0.005 1.86 
100 CLIC3 119 0.006 1 199 0.011 1.84 
101 ARNT2 9 0.000 1 15 0.001 1.84 
102 FGF22 18 0.001 1 30 0.002 1.84 
103 PDZK1 53 0.003 1 88 0.005 1.83 
104 ZBTB16 449 0.022 1 745 0.041 1.83 
105 IDH2 315 0.016 1 522 0.028 1.83 
106 RPS6KB1 20 0.001 1 33 0.002 1.82 
107 SMAD7 134 0.007 1 221 0.012 1.82 
108 IL2RB 37 0.002 1 61 0.003 1.82 
109 NUDT13 17 0.001 1 28 0.002 1.82 
110 SLCO2B1 17 0.001 1 28 0.002 1.82 
111 MAP3K1 198 0.010 1 326 0.018 1.82 
112 CALML5 39 0.002 1 64 0.003 1.81 
113 NRP1 204 0.010 1 334 0.018 1.80 
114 HSPA6 11 0.001 1 18 0.001 1.80 
115 DNAJB2 63 0.003 1 103 0.006 1.80 
116 TGFB1 49 0.002 1 80 0.004 1.80 
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117 GZMH 27 0.001 1 44 0.002 1.80 
118 RUNX3 27 0.001 1 44 0.002 1.80 
119 DMC1 8 0.000 1 13 0.001 1.79 
120 TIMP2 842 0.042 1 1368 0.074 1.79 
121 EYA1 34 0.002 1 55 0.003 1.78 
122 CTSD 3612 0.178 1 5810 0.316 1.77 
123 CIDEA 33 0.002 1 53 0.003 1.77 
124 BCL2L1 930 0.046 1 1489 0.081 1.76 
125 CREB5 25 0.001 1 40 0.002 1.76 
126 RAMP1 157 0.008 1 250 0.014 1.76 
127 NKX2_1 22 0.001 1 35 0.002 1.75 
128 AKR1C3 1864 0.092 1 2949 0.160 1.74 
129 ATP6V1G2 45 0.002 1 71 0.004 1.74 
130 TRADD 158 0.008 1 249 0.014 1.74 
131 TMEFF1 14 0.001 1 22 0.001 1.73 
132 UTF1 14 0.001 1 22 0.001 1.73 
133 PPP2R1B 44 0.002 1 69 0.004 1.73 
134 THBS1 12509 0.618 1 19505 1.061 1.72 
135 CYP2U1 104 0.005 1 162 0.009 1.72 
136 CNPY4 38 0.002 1 59 0.003 1.71 
137 MLPH 154 0.008 1 239 0.013 1.71 
138 EFNA5 956 0.047 1 1483 0.081 1.71 
139 DNAJC22 60 0.003 1 93 0.005 1.71 
140 ID1 2794 0.138 1 4329 0.236 1.71 
141 PLAT 473 0.023 1 732 0.040 1.71 
142 AHNAK2 145 0.007 1 224 0.012 1.70 
143 SPINK1 13 0.001 1 20 0.001 1.70 
144 FGFR1 160 0.008 1 246 0.013 1.69 
145 NOL3 54 0.003 1 83 0.005 1.69 
146 SQSTM1 3038 0.150 1 4652 0.253 1.69 
147 CLCF1 121 0.006 1 185 0.010 1.69 
148 COL1A2 19 0.001 1 29 0.002 1.68 
149 NCOA1 78 0.004 1 119 0.006 1.68 
150 CCL24 21 0.001 1 32 0.002 1.68 
151 HNF1B 23 0.001 1 35 0.002 1.68 
152 MAGED1 493 0.024 1 745 0.041 1.67 
153 DAAM1 96 0.005 1 145 0.008 1.67 
154 NGFRAP1 49 0.002 1 74 0.004 1.66 
155 ZEB2 106 0.005 1 160 0.009 1.66 
156 APH1B 95 0.005 1 143 0.008 1.66 
157 ID3 320 0.016 1 481 0.026 1.66 
158 LOX 348 0.017 1 523 0.028 1.66 
159 CKMT2 40 0.002 1 60 0.003 1.65 
160 KLF12 70 0.003 1 105 0.006 1.65 
161 CCDC103 48 0.002 1 72 0.004 1.65 
162 FTH1 180468 8.909 1 270144 14.702 1.65 
163 ITGB2 168 0.008 1 251 0.014 1.65 
164 FAS 61 0.003 1 91 0.005 1.64 
165 GLI2 31 0.002 1 46 0.003 1.64 
166 HECTD4 54 0.003 1 80 0.004 1.63 
167 DHH 23 0.001 1 34 0.002 1.63 
168 FRS3 38 0.002 1 56 0.003 1.62 
169 IFNB1 17 0.001 1 25 0.001 1.62 
170 ADORA2A 15 0.001 1 22 0.001 1.62 
171 PLG 54 0.003 1 79 0.004 1.61 
172 COL11A1 26 0.001 1 38 0.002 1.61 
173 CD5 22 0.001 1 32 0.002 1.60 
174 FLJ10474 275 0.014 1 400 0.022 1.60 
175 PDGFC 416 0.021 1 605 0.033 1.60 
176 CYP1B1 436 0.022 1 634 0.035 1.60 
177 TMEM45B 20 0.001 1 29 0.002 1.60 
178 NUMBL 55 0.003 1 79 0.004 1.58 
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179 PIK3R1 786 0.039 1 1128 0.061 1.58 
180 CYCS 23 0.001 1 33 0.002 1.58 
181 SLC10A1 26 0.001 1 37 0.002 1.57 
182 HSPB8 19 0.001 1 27 0.001 1.57 
183 PPP3R2 19 0.001 1 27 0.001 1.57 
184 TNFRSF1B 38 0.002 1 54 0.003 1.57 
185 FGFRL1 278 0.014 1 395 0.021 1.57 
186 TMEM74B 50 0.002 1 71 0.004 1.57 
187 HAVCR2 43 0.002 1 61 0.003 1.56 
188 TLR4 86 0.004 1 122 0.007 1.56 
189 CACNB4 12 0.001 1 17 0.001 1.56 
190 PRKCA 169 0.008 1 239 0.013 1.56 
191 LIN28B 29 0.001 1 41 0.002 1.56 
192 SPP1 29 0.001 1 41 0.002 1.56 
193 IL2RG 49 0.002 1 69 0.004 1.55 
194 PCOLCE 27 0.001 1 38 0.002 1.55 
195 MEF2C 32 0.002 1 45 0.002 1.55 
196 EGR3 62 0.003 1 87 0.005 1.55 
197 CD3D 40 0.002 1 56 0.003 1.54 
198 CCS 183 0.009 1 255 0.014 1.54 
199 CCL18 41 0.002 1 57 0.003 1.53 
200 GAMT 124 0.006 1 171 0.009 1.52 
201 PLK2 1449 0.072 1 1997 0.109 1.52 
202 LYN 43 0.002 1 59 0.003 1.51 
203 MEIS1 43 0.002 1 59 0.003 1.51 
204 RPTOR 43 0.002 1 59 0.003 1.51 
205 AQP4 35 0.002 1 48 0.003 1.51 
206 S100B 35 0.002 1 48 0.003 1.51 
207 NR5A2 27 0.001 1 37 0.002 1.51 
208 LATS2 73 0.004 1 100 0.005 1.51 
209 RHOU 141 0.007 1 193 0.011 1.51 
210 INSR 57 0.003 1 78 0.004 1.51 
211 GSR 949 0.047 1 1297 0.071 1.51 
212 PDK2 123 0.006 1 168 0.009 1.51 
213 CDH13 733 0.036 1 1000 0.054 1.50 
214 NOTCH4 11 0.001 1 15 0.001 1.50 
215 MKNK1 22 0.001 1 30 0.002 1.50 
216 CCL26 44 0.002 1 60 0.003 1.50 
217 BMP8B 39 0.002 1 53 0.003 1.50 
218 ITM2A 39 0.002 1 53 0.003 1.50 
219 ID2 67 0.003 1 91 0.005 1.50 
220 WISP2 109 0.005 1 148 0.008 1.50 
221 SLC38A2 4109 0.203 1 5577 0.304 1.50 
222 SLC7A7 28 0.001 1 38 0.002 1.50 
223 SIRT2 198 0.010 1 268 0.015 1.49 
224 SULT1A1 34 0.002 1 46 0.003 1.49 
225 ACSL5 20 0.001 1 27 0.001 1.49 
226 HSPB2 23 0.001 1 31 0.002 1.49 
227 NRG1 116 0.006 1 156 0.008 1.48 
228 CTGF 644 0.032 1 866 0.047 1.48 
229 CFTR 38 0.002 1 51 0.003 1.48 
230 GRN 503 0.025 1 675 0.037 1.48 
231 NFATC3 117 0.006 1 157 0.009 1.48 
232 SHC3 44 0.002 1 59 0.003 1.48 
233 FMO5 53 0.003 1 71 0.004 1.48 
234 SERPINE1 3651 0.180 1 4874 0.265 1.47 
235 IGF1 18 0.001 1 24 0.001 1.47 
236 ABCB5 36 0.002 1 48 0.003 1.47 
237 NR1H3 45 0.002 1 60 0.003 1.47 
238 CMTM1 12 0.001 1 16 0.001 1.47 
239 RAD52 21 0.001 1 28 0.002 1.47 
240 SLCO1A2 27 0.001 1 36 0.002 1.47 
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241 ABCC11 43 0.002 1 57 0.003 1.46 
242 ZNF189 86 0.004 1 114 0.006 1.46 
243 VEGFA 160 0.008 1 212 0.012 1.46 
244 CCL13 37 0.002 1 49 0.003 1.46 
245 SERPINC1 37 0.002 1 49 0.003 1.46 
246 NCOA2 145 0.007 1 192 0.010 1.46 
247 ACVR2A 59 0.003 1 78 0.004 1.46 
248 GATA2 56 0.003 1 74 0.004 1.46 
249 KRT8 4165 0.206 1 5501 0.299 1.46 
250 CEBPE 22 0.001 1 29 0.002 1.45 
251 HDAC2 44 0.002 1 58 0.003 1.45 
252 SF3A1 104 0.005 1 137 0.007 1.45 
253 CREBBP 120 0.006 1 158 0.009 1.45 
254 SALL4 98 0.005 1 129 0.007 1.45 
255 CDH2 541 0.027 1 712 0.039 1.45 
256 PMS2 362 0.018 1 476 0.026 1.45 
257 DACH1 35 0.002 1 46 0.003 1.45 
258 F8 83 0.004 1 109 0.006 1.45 
259 MESP1 32 0.002 1 42 0.002 1.45 
260 IGFBP7 224 0.011 1 294 0.016 1.45 
261 OR10J3 71 0.004 1 93 0.005 1.44 
262 CTSH 343 0.017 1 449 0.024 1.44 
263 NRP2 230 0.011 1 301 0.016 1.44 
264 BDNF 244 0.012 1 319 0.017 1.44 
265 GATA4 36 0.002 1 47 0.003 1.44 
266 CCT6B 56 0.003 1 73 0.004 1.44 
267 FGF2 478 0.024 1 620 0.034 1.43 
268 IRAK3 27 0.001 1 35 0.002 1.43 
269 FEN1 115 0.006 1 149 0.008 1.43 
270 HIF1A 2835 0.140 1 3673 0.200 1.43 
271 C1orf86 85 0.004 1 110 0.006 1.43 
272 BTG1 177 0.009 1 229 0.012 1.43 
273 PRICKLE1 86 0.004 1 111 0.006 1.42 
274 NPM1 52 0.003 1 67 0.004 1.42 
275 MGST1 6186 0.305 1 7968 0.434 1.42 
276 ANPEP 3038 0.150 1 3911 0.213 1.42 
277 LAT 7 0.000 1 9 0.000 1.42 
278 DDB2 70 0.003 1 90 0.005 1.42 
279 LRRK2 116 0.006 1 149 0.008 1.42 
280 TIPARP 991 0.049 1 1272 0.069 1.41 
281 SUFU 46 0.002 1 59 0.003 1.41 
282 TFDP2 235 0.012 1 301 0.016 1.41 
283 MCM7 25 0.001 1 32 0.002 1.41 
284 DMD 43 0.002 1 55 0.003 1.41 
285 MT1A 18 0.001 1 23 0.001 1.41 
286 NRG3 18 0.001 1 23 0.001 1.41 
287 RUNX2 310 0.015 1 396 0.022 1.41 
288 MLF1 44 0.002 1 56 0.003 1.40 
289 SLC22A9 44 0.002 1 56 0.003 1.40 
290 SNAI2 228 0.011 1 290 0.016 1.40 
291 STK32A 37 0.002 1 47 0.003 1.40 
292 GATA3 248 0.012 1 315 0.017 1.40 
293 HMOX1 89 0.004 1 113 0.006 1.40 
294 LETMD1 293 0.014 1 372 0.020 1.40 
295 FLNC 79 0.004 1 100 0.005 1.40 
296 CHI3L1 121 0.006 1 153 0.008 1.39 
297 PRF1 38 0.002 1 48 0.003 1.39 
298 LRP2 42 0.002 1 53 0.003 1.39 
299 SLC10A2 65 0.003 1 82 0.004 1.39 
300 PF4 50 0.002 1 63 0.003 1.39 
301 HOXA11 27 0.001 1 34 0.002 1.39 
302 NTRK1 27 0.001 1 34 0.002 1.39 
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303 LIN28A 35 0.002 1 44 0.002 1.39 
304 ITGB8 494 0.024 1 620 0.034 1.38 
305 CD40LG 59 0.003 1 74 0.004 1.38 
306 ENDOD1 244 0.012 1 306 0.017 1.38 
307 DLC1 185 0.009 1 232 0.013 1.38 
308 NOS2 4 0.000 1 5 0.000 1.38 
309 COL9A3 16 0.001 1 20 0.001 1.38 
310 TOLLIP 20 0.001 1 25 0.001 1.38 
311 KLK2 36 0.002 1 45 0.002 1.38 
312 DES 12 0.001 1 15 0.001 1.38 
313 NPPB 28 0.001 1 35 0.002 1.38 
314 PRKACG 28 0.001 1 35 0.002 1.38 
315 DNAJC12 57 0.003 1 71 0.004 1.37 
316 CDK5 322 0.016 1 401 0.022 1.37 
317 XCL2 49 0.002 1 61 0.003 1.37 
318 DNAJB12 239 0.012 1 297 0.016 1.37 
319 ACKR3 33 0.002 1 41 0.002 1.37 
320 PECAM1 58 0.003 1 72 0.004 1.37 
321 CAPNS1 1055 0.052 1 1309 0.071 1.37 
322 CCL7 25 0.001 1 31 0.002 1.37 
323 CDH3 50 0.002 1 62 0.003 1.37 
324 GHR 63 0.003 1 78 0.004 1.36 
325 PARP3 21 0.001 1 26 0.001 1.36 
326 LY96 38 0.002 1 47 0.003 1.36 
327 NR0B1 17 0.001 1 21 0.001 1.36 
328 CYBA 51 0.003 1 63 0.003 1.36 
329 SLC22A2 47 0.002 1 58 0.003 1.36 
330 PTGR1 270 0.013 1 333 0.018 1.36 
331 PPP2R2B 52 0.003 1 64 0.003 1.36 
332 NEIL3 139 0.007 1 171 0.009 1.36 
333 ITGB4 2049 0.101 1 2518 0.137 1.35 
334 OSM 44 0.002 1 54 0.003 1.35 
335 ATF1 194 0.010 1 238 0.013 1.35 
336 ETV1 75 0.004 1 92 0.005 1.35 
337 CPT1C 40 0.002 1 49 0.003 1.35 
338 TRAF3 80 0.004 1 98 0.005 1.35 
339 ORM2 49 0.002 1 60 0.003 1.35 
340 PIK3R2 640 0.032 1 783 0.043 1.35 
341 DNAJB5 36 0.002 1 44 0.002 1.35 
342 RPA3 36 0.002 1 44 0.002 1.35 
343 CTSB 494 0.024 1 603 0.033 1.35 
344 MCM4 23 0.001 1 28 0.002 1.34 
345 IRF2 92 0.005 1 112 0.006 1.34 
346 MAP2K6 37 0.002 1 45 0.002 1.34 
347 SIRT4 42 0.002 1 51 0.003 1.34 
348 UBE2Z 257 0.013 1 312 0.017 1.34 
349 TWIST1 234 0.012 1 284 0.015 1.34 
350 IFIT2 61 0.003 1 74 0.004 1.34 
351 CYLD 90 0.004 1 109 0.006 1.34 
352 LGALS3 488 0.024 1 591 0.032 1.34 
353 EPOR 38 0.002 1 46 0.003 1.33 
354 PRMT6 48 0.002 1 58 0.003 1.33 
355 MAP3K8 87 0.004 1 105 0.006 1.33 
356 IL18 1042 0.051 1 1257 0.068 1.33 
357 PAG1 39 0.002 1 47 0.003 1.33 
358 TEP1 39 0.002 1 47 0.003 1.33 
359 CES2 205 0.010 1 247 0.013 1.33 
360 PAF1 183 0.009 1 220 0.012 1.33 
361 NFAT5 213 0.011 1 256 0.014 1.32 
362 EXT1 763 0.038 1 917 0.050 1.32 
363 GLUD1 774 0.038 1 930 0.051 1.32 
364 FRMD6 973 0.048 1 1168 0.064 1.32 
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365 F2 5 0.000 1 6 0.000 1.32 
366 TEK 5 0.000 1 6 0.000 1.32 
367 UGT2B7 20 0.001 1 24 0.001 1.32 
368 CAPN3 70 0.003 1 84 0.005 1.32 
369 CD63 6672 0.329 1 7991 0.435 1.32 
370 HHAT 51 0.003 1 61 0.003 1.32 
371 WNT10A 46 0.002 1 55 0.003 1.32 
372 DNAJB14 115 0.006 1 137 0.007 1.31 
373 TTF1 63 0.003 1 75 0.004 1.31 
374 CAPN5 116 0.006 1 138 0.008 1.31 
375 ERG 27 0.001 1 32 0.002 1.31 
376 ERCC6 254 0.013 1 301 0.016 1.31 
377 FGF9 38 0.002 1 45 0.002 1.31 
378 SOCS5 478 0.024 1 566 0.031 1.31 
379 OTX2 49 0.002 1 58 0.003 1.30 
380 COL4A5 60 0.003 1 71 0.004 1.30 
381 MAP3K5 224 0.011 1 265 0.014 1.30 
382 CKB 44 0.002 1 52 0.003 1.30 
383 C1QA 50 0.002 1 59 0.003 1.30 
384 TERF2IP 179 0.009 1 211 0.011 1.30 
385 MAP1B 247 0.012 1 291 0.016 1.30 
386 SH2B1 225 0.011 1 265 0.014 1.30 
387 SELM 467 0.023 1 550 0.030 1.30 
388 NOG 17 0.001 1 20 0.001 1.30 
389 FN1 31349 1.548 1 36875 2.007 1.30 
        
Down-regulated genes 
  Vector Normalized FC WT Normalized FC 1 OLIG2 37 0.002 1 27 0.001 0.80 
2 SLC15A1 37 0.002 1 27 0.001 0.80 
3 SLC25A4 85 0.004 1 62 0.003 0.80 
4 NR1I2 48 0.002 1 35 0.002 0.80 
5 PRKG1 48 0.002 1 35 0.002 0.80 
6 RAD23B 3379 0.167 1 2462 0.134 0.80 
7 RBX1 1001 0.049 1 729 0.040 0.80 
8 POLD3 187 0.009 1 136 0.007 0.80 
9 MIA 11 0.001 1 8 0.000 0.80 
10 ERBB4 22 0.001 1 16 0.001 0.80 
11 GDF3 33 0.002 1 24 0.001 0.80 
12 PFKFB4 77 0.004 1 56 0.003 0.80 
13 DNAJC10 1052 0.052 1 765 0.042 0.80 
14 AIFM1 359 0.018 1 261 0.014 0.80 
15 RAD51B 183 0.009 1 133 0.007 0.80 
16 RAB25 84 0.004 1 61 0.003 0.80 
17 IL12B 51 0.003 1 37 0.002 0.80 
18 EMP1 3160 0.156 1 2291 0.125 0.80 
19 CASP4 457 0.023 1 331 0.018 0.80 
20 CX3CL1 29 0.001 1 21 0.001 0.80 
21 XRCC3 174 0.009 1 126 0.007 0.80 
22 WHSC1 756 0.037 1 547 0.030 0.80 
23 AICDA 47 0.002 1 34 0.002 0.80 
24 FOXA2 47 0.002 1 34 0.002 0.80 
25 MPO 36 0.002 1 26 0.001 0.80 
26 NCOA3 928 0.046 1 670 0.036 0.80 
27 BAMBI 212 0.010 1 153 0.008 0.80 
28 LTA4H 825 0.041 1 595 0.032 0.80 
29 COX5A 1697 0.084 1 1223 0.067 0.79 
30 POU5F1 243 0.012 1 175 0.010 0.79 
31 IL20RB 443 0.022 1 319 0.017 0.79 
32 FZD1 100 0.005 1 72 0.004 0.79 
33 CSNK1A1 2277 0.112 1 1639 0.089 0.79 
34 RAD17 339 0.017 1 244 0.013 0.79 
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35 CDKL5 57 0.003 1 41 0.002 0.79 
36 SFRP2 57 0.003 1 41 0.002 0.79 
37 KNG1 32 0.002 1 23 0.001 0.79 
38 AIMP2 312 0.015 1 224 0.012 0.79 
39 HSPA8 19076 0.942 1 13686 0.745 0.79 
40 CRTC2 473 0.023 1 339 0.018 0.79 
41 BCR 522 0.026 1 374 0.020 0.79 
42 SLC22A7 74 0.004 1 53 0.003 0.79 
43 EXOC3 155 0.008 1 111 0.006 0.79 
44 SMAD5 859 0.042 1 614 0.033 0.79 
45 TGFBR2 1537 0.076 1 1098 0.060 0.79 
46 IL12A 35 0.002 1 25 0.001 0.79 
47 IL22RA1 42 0.002 1 30 0.002 0.79 
48 PIK3CG 49 0.002 1 35 0.002 0.79 
49 POLD1 63 0.003 1 45 0.002 0.79 
50 ERCC8 289 0.014 1 206 0.011 0.79 
51 CDK2 452 0.022 1 322 0.018 0.79 
52 RBPMS2 66 0.003 1 47 0.003 0.79 
53 ABCB4 59 0.003 1 42 0.002 0.78 
54 DAPL1 45 0.002 1 32 0.002 0.78 
55 WNT1 45 0.002 1 32 0.002 0.78 
56 FLOT2 1306 0.064 1 928 0.051 0.78 
57 AFF1 228 0.011 1 162 0.009 0.78 
58 TP53 677 0.033 1 481 0.026 0.78 
59 ITGA5 556 0.027 1 395 0.021 0.78 
60 MIF 4457 0.220 1 3165 0.172 0.78 
61 CARM1 959 0.047 1 681 0.037 0.78 
62 ACSL3 438 0.022 1 311 0.017 0.78 
63 FZD9 31 0.002 1 22 0.001 0.78 
64 SIN3B 234 0.012 1 166 0.009 0.78 
65 NTF3 55 0.003 1 39 0.002 0.78 
66 HSPA12A 48 0.002 1 34 0.002 0.78 
67 RASGRF1 48 0.002 1 34 0.002 0.78 
68 BNIP2 1265 0.062 1 896 0.049 0.78 
69 CXCL10 65 0.003 1 46 0.003 0.78 
70 RTN1 65 0.003 1 46 0.003 0.78 
71 TFPI2 65 0.003 1 46 0.003 0.78 
72 SMC4 328 0.016 1 232 0.013 0.78 
73 WNT6 58 0.003 1 41 0.002 0.78 
74 LIFR 133 0.007 1 94 0.005 0.78 
75 MECOM 92 0.005 1 65 0.004 0.78 
76 RHOA 3524 0.174 1 2488 0.135 0.78 
77 HAND1 85 0.004 1 60 0.003 0.78 
78 CD74 102 0.005 1 72 0.004 0.78 
79 PML 469 0.023 1 331 0.018 0.78 
80 KEAP1 122 0.006 1 86 0.005 0.78 
81 HMGB1 850 0.042 1 599 0.033 0.78 
82 NRIP1 816 0.040 1 575 0.031 0.78 
83 ACTR2 5221 0.258 1 3679 0.200 0.78 
84 IL33 71 0.004 1 50 0.003 0.78 
85 NRG2 27 0.001 1 19 0.001 0.78 
86 AP2B1 1088 0.054 1 765 0.042 0.78 
87 FZD3 138 0.007 1 97 0.005 0.77 
88 CES1 84 0.004 1 59 0.003 0.77 
89 DNAJC7 225 0.011 1 158 0.009 0.77 
90 DLK1 47 0.002 1 33 0.002 0.77 
91 ZIC1 47 0.002 1 33 0.002 0.77 
92 ZNF420 104 0.005 1 73 0.004 0.77 
93 PPARD 181 0.009 1 127 0.007 0.77 
94 SPRY1 67 0.003 1 47 0.003 0.77 
95 IRF3 757 0.037 1 531 0.029 0.77 
96 MOB1B 442 0.022 1 310 0.017 0.77 
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97 ATG7 147 0.007 1 103 0.006 0.77 
98 BRIP1 197 0.010 1 138 0.008 0.77 
99 FUS 1865 0.092 1 1306 0.071 0.77 
100 CTLA4 30 0.001 1 21 0.001 0.77 
101 LRP1B 40 0.002 1 28 0.002 0.77 
102 RB1CC1 50 0.002 1 35 0.002 0.77 
103 PHB2 3448 0.170 1 2412 0.131 0.77 
104 RAD23A 998 0.049 1 698 0.038 0.77 
105 BIRC5 156 0.008 1 109 0.006 0.77 
106 USMG5 3786 0.187 1 2643 0.144 0.77 
107 CCNF 139 0.007 1 97 0.005 0.77 
108 CNTFR 33 0.002 1 23 0.001 0.77 
109 CYP2C19 56 0.003 1 39 0.002 0.77 
110 PIAS3 658 0.032 1 458 0.025 0.77 
111 COL4A2 1036 0.051 1 721 0.039 0.77 
112 FES 23 0.001 1 16 0.001 0.77 
113 SLC11A1 46 0.002 1 32 0.002 0.77 
114 PDGFRB 59 0.003 1 41 0.002 0.77 
115 CMKLR1 36 0.002 1 25 0.001 0.77 
116 PHF6 436 0.022 1 302 0.016 0.76 
117 PRL 52 0.003 1 36 0.002 0.76 
118 SCN3A 52 0.003 1 36 0.002 0.76 
119 SEC61G 1832 0.090 1 1268 0.069 0.76 
120 CAD 341 0.017 1 236 0.013 0.76 
121 BAG4 201 0.010 1 139 0.008 0.76 
122 UBE2I 1147 0.057 1 793 0.043 0.76 
123 BCAT1 68 0.003 1 47 0.003 0.76 
124 NUP62 680 0.034 1 470 0.026 0.76 
125 PIM2 97 0.005 1 67 0.004 0.76 
126 FASLG 42 0.002 1 29 0.002 0.76 
127 CEBPB 3662 0.181 1 2528 0.138 0.76 
128 CDK7 358 0.018 1 247 0.013 0.76 
129 NDC80 216 0.011 1 149 0.008 0.76 
130 AQP7 303 0.015 1 209 0.011 0.76 
131 C5AR1 58 0.003 1 40 0.002 0.76 
132 SRSF1 1184 0.058 1 815 0.044 0.76 
133 ADRA2B 93 0.005 1 64 0.003 0.76 
134 DISP2 64 0.003 1 44 0.002 0.76 
135 PRKAR1B 80 0.004 1 55 0.003 0.76 
136 NR1H4 48 0.002 1 33 0.002 0.76 
137 PIK3CA 466 0.023 1 320 0.017 0.76 
138 GPI 3807 0.188 1 2611 0.142 0.76 
139 SLCO2A1 108 0.005 1 74 0.004 0.76 
140 ATP5A1 6316 0.312 1 4327 0.235 0.76 
141 FOXRED1 200 0.010 1 137 0.007 0.76 
142 FBP1 19 0.001 1 13 0.001 0.75 
143 CACYBP 133 0.007 1 91 0.005 0.75 
144 XAB2 550 0.027 1 376 0.020 0.75 
145 CCNT1 395 0.020 1 270 0.015 0.75 
146 IRAK1 771 0.038 1 527 0.029 0.75 
147 CD80 60 0.003 1 41 0.002 0.75 
148 DENND4A 230 0.011 1 157 0.009 0.75 
149 EIF4E 107 0.005 1 73 0.004 0.75 
150 ITPKB 343 0.017 1 234 0.013 0.75 
151 PER1 686 0.034 1 468 0.025 0.75 
152 EN2 22 0.001 1 15 0.001 0.75 
153 CXCR6 66 0.003 1 45 0.002 0.75 
154 THEM4 198 0.010 1 135 0.007 0.75 
155 PSMD7 1049 0.052 1 715 0.039 0.75 
156 CASP8AP2 226 0.011 1 154 0.008 0.75 
157 PORCN 47 0.002 1 32 0.002 0.75 
158 PPP2CB 772 0.038 1 524 0.029 0.75 
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159 DNAJA4 28 0.001 1 19 0.001 0.75 
160 TLR5 56 0.003 1 38 0.002 0.75 
161 DNAJB1 578 0.029 1 392 0.021 0.75 
162 VAPA 2858 0.141 1 1938 0.105 0.75 
163 SOCS2 31 0.002 1 21 0.001 0.75 
164 POLD2 638 0.031 1 432 0.024 0.75 
165 MAOA 65 0.003 1 44 0.002 0.75 
166 EI24 1742 0.086 1 1179 0.064 0.75 
167 ZNF552 68 0.003 1 46 0.003 0.75 
168 PRC1 241 0.012 1 163 0.009 0.75 
169 GYS2 37 0.002 1 25 0.001 0.74 
170 ALDOC 151 0.007 1 102 0.006 0.74 
171 NFE2L2 40 0.002 1 27 0.001 0.74 
172 PAK1IP1 163 0.008 1 110 0.006 0.74 
173 MAGEB3 43 0.002 1 29 0.002 0.74 
174 STK3 162 0.008 1 109 0.006 0.74 
175 CNOT3 605 0.030 1 407 0.022 0.74 
176 RPS6KA6 55 0.003 1 37 0.002 0.74 
177 NPC1 116 0.006 1 78 0.004 0.74 
178 MAPK14 265 0.013 1 178 0.010 0.74 
179 FUBP1 2343 0.116 1 1573 0.086 0.74 
180 PAICS 3065 0.151 1 2057 0.112 0.74 
181 LPCAT1 76 0.004 1 51 0.003 0.74 
182 HSP90B1 8492 0.419 1 5693 0.310 0.74 
183 APP 5840 0.288 1 3912 0.213 0.74 
184 KIF14 118 0.006 1 79 0.004 0.74 
185 JUNB 1520 0.075 1 1017 0.055 0.74 
186 MYCN 18 0.001 1 12 0.001 0.73 
187 CX3CR1 33 0.002 1 22 0.001 0.73 
188 LRMP 39 0.002 1 26 0.001 0.73 
189 PLA2G5 45 0.002 1 30 0.002 0.73 
190 MRE11A 51 0.003 1 34 0.002 0.73 
191 DNAJB9 69 0.003 1 46 0.003 0.73 
192 IRF9 81 0.004 1 54 0.003 0.73 
193 FLRT3 144 0.007 1 96 0.005 0.73 
194 NCK2 156 0.008 1 104 0.006 0.73 
195 CD276 306 0.015 1 204 0.011 0.73 
196 PDIA4 462 0.023 1 308 0.017 0.73 
197 PAK7 3 0.000 1 2 0.000 0.73 
198 WWOX 24 0.001 1 16 0.001 0.73 
199 KL 27 0.001 1 18 0.001 0.73 
200 IL23A 75 0.004 1 50 0.003 0.73 
201 SLIT2 174 0.009 1 116 0.006 0.73 
202 SNCA 249 0.012 1 166 0.009 0.73 
203 HSPA9 1807 0.089 1 1204 0.066 0.73 
204 KRT18 8025 0.396 1 5344 0.291 0.73 
205 STAG2 670 0.033 1 446 0.024 0.73 
206 CHD1 603 0.030 1 401 0.022 0.73 
207 DNAJC11 337 0.017 1 224 0.012 0.73 
208 GPAM 146 0.007 1 97 0.005 0.73 
209 SRSF2 2771 0.137 1 1839 0.100 0.73 
210 PHB 1672 0.083 1 1109 0.060 0.73 
211 ATR 487 0.024 1 323 0.018 0.73 
212 CCT7 2444 0.121 1 1620 0.088 0.73 
213 HJURP 240 0.012 1 159 0.009 0.73 
214 SERPINF1 74 0.004 1 49 0.003 0.73 
215 PSMD2 876 0.043 1 580 0.032 0.73 
216 POLE2 133 0.007 1 88 0.005 0.73 
217 FAF1 443 0.022 1 293 0.016 0.73 
218 STAT5A 56 0.003 1 37 0.002 0.73 
219 GPC4 53 0.003 1 35 0.002 0.73 
220 CALM1 471 0.023 1 311 0.017 0.73 
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221 SERTAD1 250 0.012 1 165 0.009 0.73 
222 EAF2 91 0.004 1 60 0.003 0.73 
223 WWC1 91 0.004 1 60 0.003 0.73 
224 CLIC1 4551 0.225 1 3000 0.163 0.73 
225 MAPK10 88 0.004 1 58 0.003 0.73 
226 CRYAA 82 0.004 1 54 0.003 0.73 
227 TAP1 158 0.008 1 104 0.006 0.73 
228 MAGEA1 38 0.002 1 25 0.001 0.73 
229 OPCML 38 0.002 1 25 0.001 0.73 
230 TNKS2 225 0.011 1 148 0.008 0.73 
231 LTN1 594 0.029 1 390 0.021 0.72 
232 LPL 32 0.002 1 21 0.001 0.72 
233 DNAJA3 850 0.042 1 557 0.030 0.72 
234 GRP 58 0.003 1 38 0.002 0.72 
235 TNFSF8 84 0.004 1 55 0.003 0.72 
236 CCL23 55 0.003 1 36 0.002 0.72 
237 CXCL12 52 0.003 1 34 0.002 0.72 
238 SHC2 46 0.002 1 30 0.002 0.72 
239 CALML3 69 0.003 1 45 0.002 0.72 
240 GPSM2 634 0.031 1 413 0.022 0.72 
241 PTCH1 109 0.005 1 71 0.004 0.72 
242 BCL2L2 478 0.024 1 311 0.017 0.72 
243 MAFF 552 0.027 1 359 0.020 0.72 
244 CCNH 40 0.002 1 26 0.001 0.72 
245 EGF 60 0.003 1 39 0.002 0.72 
246 MSI1 120 0.006 1 78 0.004 0.72 
247 CXCL16 180 0.009 1 117 0.006 0.72 
248 MYCL 37 0.002 1 24 0.001 0.72 
249 TNXB 74 0.004 1 48 0.003 0.72 
250 CIDEB 54 0.003 1 35 0.002 0.71 
251 SORT1 695 0.034 1 450 0.024 0.71 
252 RPS4X 3881 0.192 1 2511 0.137 0.71 
253 ADM 1281 0.063 1 828 0.045 0.71 
254 E2F1 82 0.004 1 53 0.003 0.71 
255 ATP6V0C 814 0.040 1 526 0.029 0.71 
256 HMGB2 1119 0.055 1 723 0.039 0.71 
257 SYNCRIP 1355 0.067 1 875 0.048 0.71 
258 CRYAB 79 0.004 1 51 0.003 0.71 
259 ATG3 976 0.048 1 630 0.034 0.71 
260 AXIN1 138 0.007 1 89 0.005 0.71 
261 ADIPOR1 2580 0.127 1 1663 0.091 0.71 
262 TP53BP2 244 0.012 1 157 0.009 0.71 
263 SEC22C 157 0.008 1 101 0.005 0.71 
264 PDGFRA 56 0.003 1 36 0.002 0.71 
265 NOD2 42 0.002 1 27 0.001 0.71 
266 SRM 1150 0.057 1 739 0.040 0.71 
267 MAP3K4 494 0.024 1 317 0.017 0.71 
268 KRAS 533 0.026 1 342 0.019 0.71 
269 PYCARD 92 0.005 1 59 0.003 0.71 
270 ASPM 1201 0.059 1 769 0.042 0.71 
271 CSF2 25 0.001 1 16 0.001 0.71 
272 GJA1 75 0.004 1 48 0.003 0.71 
273 SMC3 789 0.039 1 504 0.027 0.70 
274 CCL21 83 0.004 1 53 0.003 0.70 
275 CBX5 1687 0.083 1 1077 0.059 0.70 
276 FGF3 47 0.002 1 30 0.002 0.70 
277 GTF2H3 290 0.014 1 185 0.010 0.70 
278 HSPA4 2941 0.145 1 1875 0.102 0.70 
279 GSK3B 1354 0.067 1 863 0.047 0.70 
280 SACS 583 0.029 1 371 0.020 0.70 
281 RIPK1 225 0.011 1 143 0.008 0.70 
282 XRCC1 85 0.004 1 54 0.003 0.70 
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283 RASD1 52 0.003 1 33 0.002 0.70 
284 FBXW11 1088 0.054 1 689 0.037 0.70 
285 CXCL6 79 0.004 1 50 0.003 0.70 
286 FANCE 117 0.006 1 74 0.004 0.70 
287 TNFRSF10A 185 0.009 1 117 0.006 0.70 
288 ZHX2 141 0.007 1 89 0.005 0.70 
289 FZD5 65 0.003 1 41 0.002 0.70 
290 PARP2 241 0.012 1 152 0.008 0.70 
291 ETV5 268 0.013 1 169 0.009 0.70 
292 NOLC1 522 0.026 1 329 0.018 0.69 
293 DKC1 868 0.043 1 547 0.030 0.69 
294 MTMR2 762 0.038 1 480 0.026 0.69 
295 CUL2 578 0.029 1 364 0.020 0.69 
296 NOD1 54 0.003 1 34 0.002 0.69 
297 IRAK2 97 0.005 1 61 0.003 0.69 
298 EIF5B 288 0.014 1 181 0.010 0.69 
299 FOXP1 304 0.015 1 191 0.010 0.69 
300 FLRT2 191 0.009 1 120 0.007 0.69 
301 DUSP5 320 0.016 1 201 0.011 0.69 
302 PPP2R4 486 0.024 1 305 0.017 0.69 
303 ATP7B 51 0.003 1 32 0.002 0.69 
304 FGF14 51 0.003 1 32 0.002 0.69 
305 CAV2 2812 0.139 1 1764 0.096 0.69 
306 TOP3A 142 0.007 1 89 0.005 0.69 
307 S100A2 163 0.008 1 102 0.006 0.69 
308 CD55 1228 0.061 1 768 0.042 0.69 
309 MAG 8 0.000 1 5 0.000 0.69 
310 CAMKK2 72 0.004 1 45 0.002 0.69 
311 RELB 56 0.003 1 35 0.002 0.69 
312 JUN 671 0.033 1 419 0.023 0.69 
313 SERPINH1 1864 0.092 1 1163 0.063 0.69 
314 CHEK2 170 0.008 1 106 0.006 0.69 
315 TNFRSF10B 1561 0.077 1 973 0.053 0.69 
316 RPL13 138 0.007 1 86 0.005 0.69 
317 PRKAG3 53 0.003 1 33 0.002 0.69 
318 CD209 151 0.007 1 94 0.005 0.69 
319 CRLF2 45 0.002 1 28 0.002 0.69 
320 CCL19 37 0.002 1 23 0.001 0.69 
321 NUF2 459 0.023 1 285 0.016 0.68 
322 PLA2G4C 58 0.003 1 36 0.002 0.68 
323 PIM3 303 0.015 1 188 0.010 0.68 
324 ECT2 740 0.037 1 459 0.025 0.68 
325 GYS1 158 0.008 1 98 0.005 0.68 
326 DNAJB11 752 0.037 1 466 0.025 0.68 
327 NUPR1 744 0.037 1 461 0.025 0.68 
328 HSPD1 6857 0.339 1 4248 0.231 0.68 
329 KRT13 76 0.004 1 47 0.003 0.68 
330 AK3 186 0.009 1 115 0.006 0.68 
331 CENPF 1733 0.086 1 1071 0.058 0.68 
332 ADIPOR2 709 0.035 1 438 0.024 0.68 
333 FGF1 34 0.002 1 21 0.001 0.68 
334 SLC16A1 1543 0.076 1 953 0.052 0.68 
335 FZD10 47 0.002 1 29 0.002 0.68 
336 PRKAA1 394 0.019 1 243 0.013 0.68 
337 BAK1 621 0.031 1 383 0.021 0.68 
338 NME1 1803 0.089 1 1111 0.060 0.68 
339 HRAS 614 0.030 1 378 0.021 0.68 
340 BMP1 554 0.027 1 341 0.019 0.68 
341 RASSF1 26 0.001 1 16 0.001 0.68 
342 HSPB3 39 0.002 1 24 0.001 0.68 
343 PALM2_AKAP2 65 0.003 1 40 0.002 0.68 
344 GNG4 122 0.006 1 75 0.004 0.68 
	133	
345 CRY1 96 0.005 1 59 0.003 0.68 
346 RUNDC1 272 0.013 1 167 0.009 0.68 
347 ACKR4 44 0.002 1 27 0.001 0.68 
348 DNAJC5G 44 0.002 1 27 0.001 0.68 
349 YWHAZ 15370 0.759 1 9414 0.512 0.68 
350 EVL 420 0.021 1 257 0.014 0.67 
351 XIAP 170 0.008 1 104 0.006 0.67 
352 BTG3 703 0.035 1 430 0.023 0.67 
353 MAPKAPK5 36 0.002 1 22 0.001 0.67 
354 FGF7 77 0.004 1 47 0.003 0.67 
355 SPC25 136 0.007 1 83 0.005 0.67 
356 TXNL4B 141 0.007 1 86 0.005 0.67 
357 BCL2L10 123 0.006 1 75 0.004 0.67 
358 NCOR1 361 0.018 1 220 0.012 0.67 
359 ACKR2 64 0.003 1 39 0.002 0.67 
360 NFKB1 471 0.023 1 287 0.016 0.67 
361 GUCY1A3 69 0.003 1 42 0.002 0.67 
362 C17orf53 194 0.010 1 118 0.006 0.67 
363 SHC4 74 0.004 1 45 0.002 0.67 
364 RIF1 630 0.031 1 383 0.021 0.67 
365 TMEM123 51 0.003 1 31 0.002 0.67 
366 ZFP42 51 0.003 1 31 0.002 0.67 
367 NEIL2 79 0.004 1 48 0.003 0.67 
368 MKI67 981 0.048 1 596 0.032 0.67 
369 GADD45A 1908 0.094 1 1159 0.063 0.67 
370 FAM117B 191 0.009 1 116 0.006 0.67 
371 BOD1 84 0.004 1 51 0.003 0.67 
372 DUSP8 117 0.006 1 71 0.004 0.67 
373 CBX3 4206 0.208 1 2551 0.139 0.67 
374 CPT1B 269 0.013 1 163 0.009 0.67 
375 IDH1 2504 0.124 1 1516 0.083 0.67 
376 GSTP1 10353 0.511 1 6267 0.341 0.67 
377 CDC14A 119 0.006 1 72 0.004 0.67 
378 KPNA2 2244 0.111 1 1357 0.074 0.67 
379 MAGEE1 43 0.002 1 26 0.001 0.67 
380 SMC1A 1084 0.054 1 655 0.036 0.67 
381 JAG2 106 0.005 1 64 0.003 0.67 
382 HHEX 121 0.006 1 73 0.004 0.67 
383 RRM2 1951 0.096 1 1177 0.064 0.67 
384 SNRPB 2786 0.138 1 1680 0.091 0.66 
385 PRKAR2B 73 0.004 1 44 0.002 0.66 
386 DNAJC17 479 0.024 1 288 0.016 0.66 
387 MBL2 15 0.001 1 9 0.000 0.66 
388 TERT 35 0.002 1 21 0.001 0.66 
389 TNFSF15 40 0.002 1 24 0.001 0.66 
390 HSPH1 45 0.002 1 27 0.001 0.66 
391 ALDH4A1 50 0.002 1 30 0.002 0.66 
392 TNFSF13B 60 0.003 1 36 0.002 0.66 
393 CCT2 1535 0.076 1 920 0.050 0.66 
394 USF2 112 0.006 1 67 0.004 0.66 
395 BID 393 0.019 1 235 0.013 0.66 
396 SLC25A13 393 0.019 1 235 0.013 0.66 
397 CTPS1 455 0.022 1 272 0.015 0.66 
398 MCM6 595 0.029 1 355 0.019 0.66 
399 GNAQ 585 0.029 1 349 0.019 0.66 
400 CTSS 99 0.005 1 59 0.003 0.66 
401 TNKS 47 0.002 1 28 0.002 0.66 
402 TAZ 185 0.009 1 110 0.006 0.66 
403 PROK2 37 0.002 1 22 0.001 0.66 
404 ATP5G1 1383 0.068 1 822 0.045 0.66 
405 IHH 32 0.002 1 19 0.001 0.65 
406 KDM5B 987 0.049 1 586 0.032 0.65 
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407 HK2 155 0.008 1 92 0.005 0.65 
408 GNL3 1813 0.090 1 1076 0.059 0.65 
409 PDGFA 258 0.013 1 153 0.008 0.65 
410 RRM1 1153 0.057 1 683 0.037 0.65 
411 AKAP1 884 0.044 1 523 0.028 0.65 
412 AR 44 0.002 1 26 0.001 0.65 
413 TLR7 44 0.002 1 26 0.001 0.65 
414 XRCC5 83 0.004 1 49 0.003 0.65 
415 RUNX1 432 0.021 1 255 0.014 0.65 
416 CASP9 39 0.002 1 23 0.001 0.65 
417 PCNA 2358 0.116 1 1390 0.076 0.65 
418 FGF12 56 0.003 1 33 0.002 0.65 
419 RASA1 503 0.025 1 296 0.016 0.65 
420 HUS1 204 0.010 1 120 0.007 0.65 
421 CCR8 34 0.002 1 20 0.001 0.65 
422 VIPR1 34 0.002 1 20 0.001 0.65 
423 SLC7A9 68 0.003 1 40 0.002 0.65 
424 ARMC1 631 0.031 1 371 0.020 0.65 
425 MDC1 150 0.007 1 88 0.005 0.65 
426 TYMS 1982 0.098 1 1162 0.063 0.65 
427 MYBL2 449 0.022 1 263 0.014 0.65 
428 FGF5 41 0.002 1 24 0.001 0.65 
429 COL5A1 82 0.004 1 48 0.003 0.65 
430 FEM1B 598 0.030 1 350 0.019 0.65 
431 IL15 118 0.006 1 69 0.004 0.64 
432 CASP10 77 0.004 1 45 0.002 0.64 
433 MAP7D1 125 0.006 1 73 0.004 0.64 
434 DNAJC16 72 0.004 1 42 0.002 0.64 
435 BMP2 12 0.001 1 7 0.000 0.64 
436 LTB 24 0.001 1 14 0.001 0.64 
437 MT1X 1247 0.062 1 727 0.040 0.64 
438 AGER 115 0.006 1 67 0.004 0.64 
439 TUBB3 184 0.009 1 107 0.006 0.64 
440 SLC19A3 43 0.002 1 25 0.001 0.64 
441 DHCR24 2919 0.144 1 1697 0.092 0.64 
442 ALPL 93 0.005 1 54 0.003 0.64 
443 CELSR2 100 0.005 1 58 0.003 0.64 
444 PPP3CB 383 0.019 1 222 0.012 0.64 
445 TPD52 1077 0.053 1 624 0.034 0.64 
446 SPHK1 95 0.005 1 55 0.003 0.64 
447 TMSB10 59206 2.923 1 34272 1.865 0.64 
448 GREM1 64 0.003 1 37 0.002 0.64 
449 SUV39H2 362 0.018 1 209 0.011 0.64 
450 NUMB 291 0.014 1 168 0.009 0.64 
451 PLA2G4A 279 0.014 1 161 0.009 0.64 
452 EOMES 59 0.003 1 34 0.002 0.64 
453 HMGXB3 177 0.009 1 102 0.006 0.64 
454 TRIP13 750 0.037 1 432 0.024 0.63 
455 FRZB 33 0.002 1 19 0.001 0.63 
456 BAG1 233 0.012 1 134 0.007 0.63 
457 ZNF589 127 0.006 1 73 0.004 0.63 
458 ITGAV 674 0.033 1 387 0.021 0.63 
459 OLR1 54 0.003 1 31 0.002 0.63 
460 RIPK2 218 0.011 1 125 0.007 0.63 
461 SLC38A5 82 0.004 1 47 0.003 0.63 
462 KCNIP1 89 0.004 1 51 0.003 0.63 
463 PLEK2 124 0.006 1 71 0.004 0.63 
464 CCR10 49 0.002 1 28 0.002 0.63 
465 CDH5 56 0.003 1 32 0.002 0.63 
466 IL4 63 0.003 1 36 0.002 0.63 
467 CCNE1 189 0.009 1 108 0.006 0.63 
468 ALDH2 21 0.001 1 12 0.001 0.63 
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469 MMP7 42 0.002 1 24 0.001 0.63 
470 TNNI3 42 0.002 1 24 0.001 0.63 
471 MOS 84 0.004 1 48 0.003 0.63 
472 HSF2 175 0.009 1 100 0.005 0.63 
473 MELK 562 0.028 1 321 0.017 0.63 
474 SORD 810 0.040 1 462 0.025 0.63 
475 ANXA1 6621 0.327 1 3771 0.205 0.63 
476 PLCG2 58 0.003 1 33 0.002 0.63 
477 MAP3K3 109 0.005 1 62 0.003 0.63 
478 PTPN11 814 0.040 1 463 0.025 0.63 
479 DNAJC9 405 0.020 1 230 0.013 0.63 
480 TINF2 127 0.006 1 72 0.004 0.62 
481 SMS 2142 0.106 1 1213 0.066 0.62 
482 E2F5 152 0.008 1 86 0.005 0.62 
483 VDAC1 8163 0.403 1 4618 0.251 0.62 
484 BUB1 1117 0.055 1 631 0.034 0.62 
485 TRAF6 232 0.011 1 131 0.007 0.62 
486 SUSD3 62 0.003 1 35 0.002 0.62 
487 CXCL5 39 0.002 1 22 0.001 0.62 
488 DUSP2 39 0.002 1 22 0.001 0.62 
489 SLC31A1 314 0.016 1 177 0.010 0.62 
490 TPX2 641 0.032 1 361 0.020 0.62 
491 CDCA7 112 0.006 1 63 0.003 0.62 
492 RAD51 217 0.011 1 122 0.007 0.62 
493 CKS2 2946 0.145 1 1655 0.090 0.62 
494 PLK1 1053 0.052 1 591 0.032 0.62 
495 GMPS 1290 0.064 1 724 0.039 0.62 
496 CXCL14 98 0.005 1 55 0.003 0.62 
497 RUVBL1 1645 0.081 1 923 0.050 0.62 
498 PLK4 423 0.021 1 237 0.013 0.62 
499 YBX3 981 0.048 1 549 0.030 0.62 
500 MYC 1496 0.074 1 837 0.046 0.62 
501 ERO1L 717 0.035 1 401 0.022 0.62 
502 DBI 6117 0.302 1 3421 0.186 0.62 
503 MAPK8 93 0.005 1 52 0.003 0.62 
504 CKS1B 1720 0.085 1 960 0.052 0.62 
505 TLR8 52 0.003 1 29 0.002 0.61 
506 PDK1 296 0.015 1 165 0.009 0.61 
507 CD22 79 0.004 1 44 0.002 0.61 
508 SKP2 670 0.033 1 373 0.020 0.61 
509 MAP2K3 291 0.014 1 162 0.009 0.61 
510 NASP 812 0.040 1 452 0.025 0.61 
511 DNMT1 922 0.046 1 513 0.028 0.61 
512 PLCG1 283 0.014 1 157 0.009 0.61 
513 PAK1 193 0.010 1 107 0.006 0.61 
514 CENPN 74 0.004 1 41 0.002 0.61 
515 TSHR 65 0.003 1 36 0.002 0.61 
516 PSRC1 318 0.016 1 176 0.010 0.61 
517 NOX1 47 0.002 1 26 0.001 0.61 
518 NCL 17179 0.848 1 9503 0.517 0.61 
519 CCNB1 2627 0.130 1 1453 0.079 0.61 
520 PTTG2 2554 0.126 1 1412 0.077 0.61 
521 FBXW7 123 0.006 1 68 0.004 0.61 
522 MAPT 29 0.001 1 16 0.001 0.61 
523 MNAT1 167 0.008 1 92 0.005 0.61 
524 EFNB1 109 0.005 1 60 0.003 0.61 
525 COL11A2 40 0.002 1 22 0.001 0.61 
526 JPH3 82 0.004 1 45 0.002 0.60 
527 TIFA 359 0.018 1 197 0.011 0.60 
528 BCL10 966 0.048 1 530 0.029 0.60 
529 MAP3K2 301 0.015 1 165 0.009 0.60 
530 RAB27B 301 0.015 1 165 0.009 0.60 
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531 HSPA2 73 0.004 1 40 0.002 0.60 
532 MSH6 482 0.024 1 264 0.014 0.60 
533 CTNND2 42 0.002 1 23 0.001 0.60 
534 CHSY1 170 0.008 1 93 0.005 0.60 
535 DLGAP5 850 0.042 1 465 0.025 0.60 
536 RAG1 64 0.003 1 35 0.002 0.60 
537 XBP1 715 0.035 1 391 0.021 0.60 
538 KRT16 236 0.012 1 129 0.007 0.60 
539 CCT4 2101 0.104 1 1147 0.062 0.60 
540 HHIP 44 0.002 1 24 0.001 0.60 
541 BBC3 90 0.004 1 49 0.003 0.60 
542 TTK 421 0.021 1 229 0.012 0.60 
543 GBP2 114 0.006 1 62 0.003 0.60 
544 ADRA1A 92 0.005 1 50 0.003 0.60 
545 CCNO 116 0.006 1 63 0.003 0.60 
546 PRKCZ 70 0.003 1 38 0.002 0.60 
547 TAP2 144 0.007 1 78 0.004 0.60 
548 NAT8L 24 0.001 1 13 0.001 0.60 
549 RELA 48 0.002 1 26 0.001 0.60 
550 WNT16 48 0.002 1 26 0.001 0.60 
551 HMGA1 2257 0.111 1 1222 0.067 0.60 
552 FUT8 352 0.017 1 190 0.010 0.60 
553 WNT8A 63 0.003 1 34 0.002 0.59 
554 NOTCH1 126 0.006 1 68 0.004 0.59 
555 CACNA1G 39 0.002 1 21 0.001 0.59 
556 PTCHD1 39 0.002 1 21 0.001 0.59 
557 HNF1A 52 0.003 1 28 0.002 0.59 
558 TNFRSF9 52 0.003 1 28 0.002 0.59 
559 WNT9A 225 0.011 1 121 0.007 0.59 
560 CCL2 80 0.004 1 43 0.002 0.59 
561 MFNG 41 0.002 1 22 0.001 0.59 
562 TGFBR1 427 0.021 1 229 0.012 0.59 
563 MCM5 735 0.036 1 394 0.021 0.59 
564 AKR1B1 6825 0.337 1 3658 0.199 0.59 
565 MUC1 1394 0.069 1 747 0.041 0.59 
566 DNAJC5B 43 0.002 1 23 0.001 0.59 
567 RASGRF2 60 0.003 1 32 0.002 0.59 
568 PHGDH 818 0.040 1 436 0.024 0.59 
569 DPPA4 154 0.008 1 82 0.004 0.59 
570 TMEM57 216 0.011 1 115 0.006 0.59 
571 SIAH1 299 0.015 1 159 0.009 0.59 
572 IRF1 79 0.004 1 42 0.002 0.59 
573 TNFRSF17 49 0.002 1 26 0.001 0.58 
574 FOXC1 17 0.001 1 9 0.000 0.58 
575 HOXA10 17 0.001 1 9 0.000 0.58 
576 POLD4 51 0.003 1 27 0.001 0.58 
577 SPI1 68 0.003 1 36 0.002 0.58 
578 NLRP3 85 0.004 1 45 0.002 0.58 
579 TNFAIP2 85 0.004 1 45 0.002 0.58 
580 ACLY 2291 0.113 1 1212 0.066 0.58 
581 MCM2 465 0.023 1 245 0.013 0.58 
582 MMS19 380 0.019 1 200 0.011 0.58 
583 LIG1 333 0.016 1 175 0.010 0.58 
584 PMAIP1 198 0.010 1 104 0.006 0.58 
585 GPR160 40 0.002 1 21 0.001 0.58 
586 CNPY3 128 0.006 1 67 0.004 0.58 
587 CCT5 1811 0.089 1 947 0.052 0.58 
588 CYP1A2 44 0.002 1 23 0.001 0.58 
589 FOXD3 23 0.001 1 12 0.001 0.58 
590 PLA2G4E 69 0.003 1 36 0.002 0.58 
591 CDC20 2422 0.120 1 1262 0.069 0.57 
592 PRLR 48 0.002 1 25 0.001 0.57 
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593 RORC 73 0.004 1 38 0.002 0.57 
594 PTP4A1 892 0.044 1 464 0.025 0.57 
595 TMPRSS2 25 0.001 1 13 0.001 0.57 
596 MMP14 777 0.038 1 404 0.022 0.57 
597 ABCA4 77 0.004 1 40 0.002 0.57 
598 SLC45A3 231 0.011 1 120 0.007 0.57 
599 BTG2 617 0.030 1 320 0.017 0.57 
600 TIAM1 108 0.005 1 56 0.003 0.57 
601 IL7R 195 0.010 1 101 0.005 0.57 
602 MADCAM1 56 0.003 1 29 0.002 0.57 
603 TNFRSF25 114 0.006 1 59 0.003 0.57 
604 EPGN 892 0.044 1 461 0.025 0.57 
605 KLRG1 60 0.003 1 31 0.002 0.57 
606 CCNA2 1026 0.051 1 530 0.029 0.57 
607 MAD2L1 775 0.038 1 400 0.022 0.57 
608 SMO 64 0.003 1 33 0.002 0.57 
609 BIRC7 97 0.005 1 50 0.003 0.57 
610 DDIT3 33 0.002 1 17 0.001 0.57 
611 GNAZ 66 0.003 1 34 0.002 0.57 
612 RFC4 439 0.022 1 226 0.012 0.57 
613 BUB1B 212 0.010 1 109 0.006 0.57 
614 TYMP 395 0.020 1 203 0.011 0.57 
615 MRPL13 477 0.024 1 245 0.013 0.57 
616 IGF2 37 0.002 1 19 0.001 0.57 
617 FPR1 417 0.021 1 214 0.012 0.57 
618 LIG3 154 0.008 1 79 0.004 0.57 
619 DICER1 525 0.026 1 269 0.015 0.56 
620 PA2G4 3074 0.152 1 1575 0.086 0.56 
621 CHD7 256 0.013 1 131 0.007 0.56 
622 MAPK13 86 0.004 1 44 0.002 0.56 
623 RFC3 507 0.025 1 259 0.014 0.56 
624 FANCB 186 0.009 1 95 0.005 0.56 
625 PPARGC1B 237 0.012 1 121 0.007 0.56 
626 HNRNPA2B1 2706 0.134 1 1379 0.075 0.56 
627 GEMIN2 263 0.013 1 134 0.007 0.56 
628 AURKA 1727 0.085 1 879 0.048 0.56 
629 CD86 63 0.003 1 32 0.002 0.56 
630 PPP2R2C 203 0.010 1 103 0.006 0.56 
631 C3 2949 0.146 1 1494 0.081 0.56 
632 ITLN2 79 0.004 1 40 0.002 0.56 
633 MDM2 2824 0.139 1 1429 0.078 0.56 
634 SLK 832 0.041 1 421 0.023 0.56 
635 MAP2K4 319 0.016 1 161 0.009 0.56 
636 CMC2 465 0.023 1 234 0.013 0.55 
637 REL 211 0.010 1 106 0.006 0.55 
638 GTSE1 237 0.012 1 119 0.006 0.55 
639 SLC3A2 1103 0.054 1 553 0.030 0.55 
640 HIST1H3H 3524 0.174 1 1764 0.096 0.55 
641 HGF 8 0.000 1 4 0.000 0.55 
642 COMP 26 0.001 1 13 0.001 0.55 
643 TBX21 30 0.001 1 15 0.001 0.55 
644 MAGEB2 42 0.002 1 21 0.001 0.55 
645 PRKAG2 66 0.003 1 33 0.002 0.55 
646 PTCHD2 72 0.004 1 36 0.002 0.55 
647 NGFR 86 0.004 1 43 0.002 0.55 
648 BCL2 94 0.005 1 47 0.003 0.55 
649 BRCA2 202 0.010 1 101 0.005 0.55 
650 CAPN1 586 0.029 1 293 0.016 0.55 
651 XRCC6BP1 24 0.001 1 12 0.001 0.55 
652 ATG13 50 0.002 1 25 0.001 0.55 
653 BMP8A 74 0.004 1 37 0.002 0.55 
654 IGF1R 200 0.010 1 100 0.005 0.55 
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655 RPS6KA1 417 0.021 1 208 0.011 0.55 
656 CASP1 524 0.026 1 261 0.014 0.55 
657 CTSC 2319 0.114 1 1154 0.063 0.55 
658 ZAK 561 0.028 1 278 0.015 0.55 
659 DFFA 271 0.013 1 134 0.007 0.55 
660 DAB2IP 393 0.019 1 194 0.011 0.54 
661 LEF1 67 0.003 1 33 0.002 0.54 
662 LIPE 61 0.003 1 30 0.002 0.54 
663 GRIA3 57 0.003 1 28 0.002 0.54 
664 KCTD11 55 0.003 1 27 0.001 0.54 
665 MAPRE2 108 0.005 1 53 0.003 0.54 
666 LRG1 53 0.003 1 26 0.001 0.54 
667 CACNG1 51 0.003 1 25 0.001 0.54 
668 KDM5C 737 0.036 1 361 0.020 0.54 
669 SNAI3 45 0.002 1 22 0.001 0.54 
670 HSPE1 7143 0.353 1 3492 0.190 0.54 
671 SMPDL3B 119 0.006 1 58 0.003 0.54 
672 TCP1 3441 0.170 1 1675 0.091 0.54 
673 ADAM17 405 0.020 1 197 0.011 0.54 
674 MAP2K1 999 0.049 1 485 0.026 0.54 
675 CDX2 64 0.003 1 31 0.002 0.53 
676 DLL3 60 0.003 1 29 0.002 0.53 
677 LMO2 60 0.003 1 29 0.002 0.53 
678 DNAJB13 58 0.003 1 28 0.002 0.53 
679 NKX3_1 114 0.006 1 55 0.003 0.53 
680 NOS3 27 0.001 1 13 0.001 0.53 
681 PABPC1 81 0.004 1 39 0.002 0.53 
682 CDC7 192 0.009 1 92 0.005 0.53 
683 TNFRSF14 46 0.002 1 22 0.001 0.53 
684 PROM1 67 0.003 1 32 0.002 0.53 
685 NT5E 289 0.014 1 138 0.008 0.53 
686 TNFRSF21 267 0.013 1 127 0.007 0.52 
687 CCR3 61 0.003 1 29 0.002 0.52 
688 ANAPC2 179 0.009 1 85 0.005 0.52 
689 CEACAM7 59 0.003 1 28 0.002 0.52 
690 BLM 133 0.007 1 63 0.003 0.52 
691 ORC6 169 0.008 1 80 0.004 0.52 
692 BAG3 656 0.032 1 310 0.017 0.52 
693 TRIP4 91 0.004 1 43 0.002 0.52 
694 HSPA4L 377 0.019 1 178 0.010 0.52 
695 GM2A 303 0.015 1 143 0.008 0.52 
696 NKD1 34 0.002 1 16 0.001 0.52 
697 FAM162A 253 0.012 1 119 0.006 0.52 
698 FGFR2 47 0.002 1 22 0.001 0.52 
699 TDG 691 0.034 1 323 0.018 0.52 
700 FOS 2531 0.125 1 1181 0.064 0.51 
701 MCM3 533 0.026 1 248 0.013 0.51 
702 PPID 570 0.028 1 265 0.014 0.51 
703 EZR 994 0.049 1 462 0.025 0.51 
704 VAMP8 1070 0.053 1 494 0.027 0.51 
705 TIE1 52 0.003 1 24 0.001 0.51 
706 ORM1 91 0.004 1 42 0.002 0.51 
707 MCL1 4472 0.221 1 2064 0.112 0.51 
708 NRAS 404 0.020 1 186 0.010 0.51 
709 ANXA8 1838 0.091 1 846 0.046 0.51 
710 SREBF1 1489 0.074 1 685 0.037 0.51 
711 ACTR3B 50 0.002 1 23 0.001 0.51 
712 BOC 37 0.002 1 17 0.001 0.51 
713 THPO 85 0.004 1 39 0.002 0.51 
714 NODAL 83 0.004 1 38 0.002 0.50 
715 TSPAN14 996 0.049 1 456 0.025 0.50 
716 NR4A1 142 0.007 1 65 0.004 0.50 
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717 LYZ 59 0.003 1 27 0.001 0.50 
718 MLLT4 306 0.015 1 140 0.008 0.50 
719 RALA 460 0.023 1 210 0.011 0.50 
720 CASP14 57 0.003 1 26 0.001 0.50 
721 LAG3 112 0.006 1 51 0.003 0.50 
722 ITGB7 66 0.003 1 30 0.002 0.50 
723 ETV4 55 0.003 1 25 0.001 0.50 
724 PFKFB2 405 0.020 1 183 0.010 0.50 
725 CCL28 186 0.009 1 84 0.005 0.50 
726 CDC25A 182 0.009 1 82 0.004 0.50 
727 RAC3 188 0.009 1 84 0.005 0.49 
728 AQP1 18 0.001 1 8 0.000 0.49 
729 MUTYH 54 0.003 1 24 0.001 0.49 
730 PKMYT1 302 0.015 1 134 0.007 0.49 
731 MTFP1 230 0.011 1 102 0.006 0.49 
732 EGFR 954 0.047 1 423 0.023 0.49 
733 SLC2A1 1039 0.051 1 460 0.025 0.49 
734 SLC7A5 615 0.030 1 271 0.015 0.49 
735 PF4V1 84 0.004 1 37 0.002 0.49 
736 CEP55 50 0.002 1 22 0.001 0.49 
737 TAGLN 1082 0.053 1 476 0.026 0.48 
738 IL2RA 41 0.002 1 18 0.001 0.48 
739 ACACA 647 0.032 1 284 0.015 0.48 
740 STAT6 498 0.025 1 218 0.012 0.48 
741 VCAM1 64 0.003 1 28 0.002 0.48 
742 SLCO3A1 96 0.005 1 42 0.002 0.48 
743 AURKB 605 0.030 1 264 0.014 0.48 
744 TNFSF14 94 0.005 1 41 0.002 0.48 
745 RAD9A 101 0.005 1 44 0.002 0.48 
746 ESR1 74 0.004 1 32 0.002 0.48 
747 XRCC4 74 0.004 1 32 0.002 0.48 
748 HOXD1 58 0.003 1 25 0.001 0.48 
749 GABBR2 72 0.004 1 31 0.002 0.47 
750 TNC 144 0.007 1 62 0.003 0.47 
751 ANGPT2 7 0.000 1 3 0.000 0.47 
752 RIPK3 7 0.000 1 3 0.000 0.47 
753 TREX1 49 0.002 1 21 0.001 0.47 
754 MYOD1 42 0.002 1 18 0.001 0.47 
755 DSC2 173 0.009 1 74 0.004 0.47 
756 PELP1 131 0.006 1 56 0.003 0.47 
757 CSNK2A1 797 0.039 1 340 0.019 0.47 
758 RPS6KB2 455 0.022 1 194 0.011 0.47 
759 PFKFB3 176 0.009 1 75 0.004 0.47 
760 SPEF1 47 0.002 1 20 0.001 0.47 
761 XCR1 47 0.002 1 20 0.001 0.47 
762 TCF7L1 26 0.001 1 11 0.001 0.47 
763 DDX58 346 0.017 1 146 0.008 0.47 
764 NDRG1 524 0.026 1 221 0.012 0.46 
765 EPO 57 0.003 1 24 0.001 0.46 
766 PFDN2 3443 0.170 1 1449 0.079 0.46 
767 CCR6 50 0.002 1 21 0.001 0.46 
768 PRKX 360 0.018 1 151 0.008 0.46 
769 SLCO4A1 31 0.002 1 13 0.001 0.46 
770 HES1 117 0.006 1 49 0.003 0.46 
771 SLC7A8 79 0.004 1 33 0.002 0.46 
772 CCNB2 84 0.004 1 35 0.002 0.46 
773 RAD51C 192 0.009 1 80 0.004 0.46 
774 FST 118 0.006 1 49 0.003 0.46 
775 CCL5 94 0.005 1 39 0.002 0.46 
776 TLR2 82 0.004 1 34 0.002 0.46 
777 TRAF2 70 0.003 1 29 0.002 0.46 
778 CD70 298 0.015 1 123 0.007 0.46 
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779 STEAP4 80 0.004 1 33 0.002 0.45 
780 CCT6A 3304 0.163 1 1361 0.074 0.45 
781 ESM1 17 0.001 1 7 0.000 0.45 
782 HLA_B 1665 0.082 1 685 0.037 0.45 
783 ADORA2B 825 0.041 1 339 0.018 0.45 
784 GPD2 677 0.033 1 277 0.015 0.45 
785 KSR1 27 0.001 1 11 0.001 0.45 
786 CCL22 59 0.003 1 24 0.001 0.45 
787 HSPB7 32 0.002 1 13 0.001 0.45 
788 NR4A3 47 0.002 1 19 0.001 0.45 
789 SYK 124 0.006 1 50 0.003 0.44 
790 CDK8 362 0.018 1 145 0.008 0.44 
791 MAPK8IP2 5 0.000 1 2 0.000 0.44 
792 LECT1 40 0.002 1 16 0.001 0.44 
793 CHGA 60 0.003 1 24 0.001 0.44 
794 SOCS3 65 0.003 1 26 0.001 0.44 
795 XRCC2 501 0.025 1 200 0.011 0.44 
796 HMGCR 540 0.027 1 215 0.012 0.44 
797 CMTM2 73 0.004 1 29 0.002 0.44 
798 CAPN6 43 0.002 1 17 0.001 0.44 
799 PRKCB 43 0.002 1 17 0.001 0.44 
800 FANCA 86 0.004 1 34 0.002 0.44 
801 CCL3 81 0.004 1 32 0.002 0.44 
802 ABCA3 119 0.006 1 47 0.003 0.44 
803 SLC2A3 193 0.010 1 76 0.004 0.43 
804 EIF4EBP1 1104 0.055 1 434 0.024 0.43 
805 PTCHD3 56 0.003 1 22 0.001 0.43 
806 EIF4A1 13513 0.667 1 5285 0.288 0.43 
807 HSPA14 77 0.004 1 30 0.002 0.43 
808 CCNA1 95 0.005 1 37 0.002 0.43 
809 DKK2 67 0.003 1 26 0.001 0.43 
810 WASL 49 0.002 1 19 0.001 0.43 
811 CD8A 80 0.004 1 31 0.002 0.43 
812 NMU 411 0.020 1 159 0.009 0.43 
813 VCAN 539 0.027 1 208 0.011 0.43 
814 FHIT 127 0.006 1 49 0.003 0.43 
815 IL10RA 70 0.003 1 27 0.001 0.43 
816 ICAM1 172 0.008 1 66 0.004 0.42 
817 LTA 34 0.002 1 13 0.001 0.42 
818 PAX8 68 0.003 1 26 0.001 0.42 
819 DEFB1 97 0.005 1 37 0.002 0.42 
820 EBF4 21 0.001 1 8 0.000 0.42 
821 PTPN5 42 0.002 1 16 0.001 0.42 
822 ANGPTL4 651 0.032 1 248 0.013 0.42 
823 RBBP8 541 0.027 1 206 0.011 0.42 
824 PIDD1 305 0.015 1 116 0.006 0.42 
825 CDC6 500 0.025 1 190 0.010 0.42 
826 EDN1 129 0.006 1 49 0.003 0.42 
827 PCSK6 140 0.007 1 53 0.003 0.42 
828 SMUG1 107 0.005 1 40 0.002 0.41 
829 CXCR2 27 0.001 1 10 0.001 0.41 
830 TLR9 46 0.002 1 17 0.001 0.41 
831 SLC29A1 112 0.006 1 41 0.002 0.40 
832 SLC29A2 389 0.019 1 142 0.008 0.40 
833 CDC25B 1251 0.062 1 456 0.025 0.40 
834 MT2A 45572 2.250 1 16510 0.899 0.40 
835 FOXE1 58 0.003 1 21 0.001 0.40 
836 ATXN1 61 0.003 1 22 0.001 0.40 
837 TIMP3 272 0.013 1 98 0.005 0.40 
838 BBS4 25 0.001 1 9 0.000 0.40 
839 DUSP6 304 0.015 1 109 0.006 0.40 
840 UBE2C 112 0.006 1 40 0.002 0.39 
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841 EXO1 266 0.013 1 95 0.005 0.39 
842 ETV7 79 0.004 1 28 0.002 0.39 
843 NFKB2 173 0.009 1 61 0.003 0.39 
844 KIF2C 323 0.016 1 112 0.006 0.38 
845 SERPINB5 1068 0.053 1 370 0.020 0.38 
846 CD83 137 0.007 1 47 0.003 0.38 
847 VEGFC 248 0.012 1 85 0.005 0.38 
848 MTSS1 187 0.009 1 64 0.003 0.38 
849 PLAUR 702 0.035 1 235 0.013 0.37 
850 DLL4 9 0.000 1 3 0.000 0.37 
851 AQP2 18 0.001 1 6 0.000 0.37 
852 BCL2L11 66 0.003 1 22 0.001 0.37 
853 PTHLH 78 0.004 1 26 0.001 0.37 
854 IFI27 138 0.007 1 46 0.003 0.37 
855 PGC 3 0.000 1 1 0.000 0.37 
856 PTCRA 3 0.000 1 1 0.000 0.37 
857 IFNA2 24 0.001 1 8 0.000 0.37 
858 TWIST2 334 0.016 1 111 0.006 0.37 
859 KLF4 112 0.006 1 37 0.002 0.36 
860 HMGB3 185 0.009 1 61 0.003 0.36 
861 ANXA3 1693 0.084 1 558 0.030 0.36 
862 ODC1 405 0.020 1 132 0.007 0.36 
863 IL1RAP 384 0.019 1 125 0.007 0.36 
864 CCR1 40 0.002 1 13 0.001 0.36 
865 FOXA1 253 0.012 1 82 0.004 0.36 
866 RSPO1 71 0.004 1 23 0.001 0.36 
867 F11R 466 0.023 1 150 0.008 0.35 
868 CSF3 1298 0.064 1 417 0.023 0.35 
869 MST1R 131 0.006 1 42 0.002 0.35 
870 PTTG1 163 0.008 1 52 0.003 0.35 
871 IL4R 895 0.044 1 283 0.015 0.35 
872 CTNNBIP1 54 0.003 1 17 0.001 0.35 
873 TNF 54 0.003 1 17 0.001 0.35 
874 SOX9 732 0.036 1 229 0.012 0.34 
875 PPP1R15A 252 0.012 1 78 0.004 0.34 
876 SPATA2 88 0.004 1 27 0.001 0.34 
877 MACC1 170 0.008 1 52 0.003 0.34 
878 PRDM1 247 0.012 1 75 0.004 0.33 
879 EFNA1 449 0.022 1 136 0.007 0.33 
880 DSP 1596 0.079 1 482 0.026 0.33 
881 KRT5 9363 0.462 1 2827 0.154 0.33 
882 FASN 2096 0.103 1 632 0.034 0.33 
883 HEY1 10 0.000 1 3 0.000 0.33 
884 NFKBIA 433 0.021 1 129 0.007 0.33 
885 NFKBIE 195 0.010 1 58 0.003 0.33 
886 SOX7 350 0.017 1 104 0.006 0.33 
887 TSPAN13 288 0.014 1 85 0.005 0.33 
888 SGK2 17 0.001 1 5 0.000 0.32 
889 FAM213A 252 0.012 1 74 0.004 0.32 
890 FGF17 75 0.004 1 22 0.001 0.32 
891 VDR 550 0.027 1 161 0.009 0.32 
892 CCNC 225 0.011 1 65 0.004 0.32 
893 EPCAM 111 0.005 1 32 0.002 0.32 
894 IER3 1443 0.071 1 413 0.022 0.32 
895 CRTAC1 56 0.003 1 16 0.001 0.31 
896 BHLHE40 1330 0.066 1 380 0.021 0.31 
897 PLAU 704 0.035 1 200 0.011 0.31 
898 C1orf106 554 0.027 1 157 0.009 0.31 
899 GADD45G 50 0.002 1 14 0.001 0.31 
900 PIK3R5 43 0.002 1 12 0.001 0.31 
901 BMP6 18 0.001 1 5 0.000 0.31 
902 MMP3 36 0.002 1 10 0.001 0.31 
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903 HMGA2 500 0.025 1 138 0.008 0.30 
904 CTSV 240 0.012 1 66 0.004 0.30 
905 PLK3 603 0.030 1 165 0.009 0.30 
906 RAMP3 59 0.003 1 16 0.001 0.30 
907 CDK6 451 0.022 1 122 0.007 0.30 
908 NFKBIZ 832 0.041 1 224 0.012 0.30 
909 ASNS 399 0.020 1 106 0.006 0.29 
910 RAD54L 35 0.002 1 9 0.000 0.28 
911 PRR15L 176 0.009 1 45 0.002 0.28 
912 FGFR3 157 0.008 1 40 0.002 0.28 
913 GALNT3 838 0.041 1 213 0.012 0.28 
914 CKMT1A 489 0.024 1 124 0.007 0.28 
915 VSNL1 214 0.011 1 54 0.003 0.28 
916 KRT14 350 0.017 1 88 0.005 0.28 
917 KCND2 4 0.000 1 1 0.000 0.28 
918 PAX3 20 0.001 1 5 0.000 0.28 
919 CCR7 28 0.001 1 7 0.000 0.28 
920 GPR126 145 0.007 1 36 0.002 0.27 
921 TTC9 57 0.003 1 14 0.001 0.27 
922 TLR1 114 0.006 1 28 0.002 0.27 
923 DDR1 961 0.047 1 235 0.013 0.27 
924 CAMK2B 174 0.009 1 42 0.002 0.27 
925 FGF19 46 0.002 1 11 0.001 0.26 
926 GDF6 26 0.001 1 6 0.000 0.25 
927 FZD8 57 0.003 1 13 0.001 0.25 
928 EXOSC8 53 0.003 1 12 0.001 0.25 
929 TICAM1 55 0.003 1 12 0.001 0.24 
930 CXXC4 33 0.002 1 7 0.000 0.23 
931 IDO1 24 0.001 1 5 0.000 0.23 
932 ITGA2 882 0.044 1 181 0.010 0.23 
933 KIT 5 0.000 1 1 0.000 0.22 
934 ALB 20 0.001 1 4 0.000 0.22 
935 AREG 9999 0.494 1 1984 0.108 0.22 
936 BIRC3 1138 0.056 1 218 0.012 0.21 
937 IL20RA 63 0.003 1 12 0.001 0.21 
938 PTGS2 280 0.014 1 53 0.003 0.21 
939 RBL1 228 0.011 1 43 0.002 0.21 
940 CD24 869 0.043 1 162 0.009 0.21 
941 FCER2 11 0.001 1 2 0.000 0.20 
942 LIF 890 0.044 1 154 0.008 0.19 
943 SOD2 7007 0.346 1 1174 0.064 0.18 
944 GNGT2 12 0.001 1 2 0.000 0.18 
945 OAS1 12 0.001 1 2 0.000 0.18 
946 ABCC2 157 0.008 1 26 0.001 0.18 
947 TMEM132A 222 0.011 1 36 0.002 0.18 
948 KCNK5 32 0.002 1 5 0.000 0.17 
949 TNNI2 270 0.013 1 42 0.002 0.17 
950 KRT6A 262 0.013 1 40 0.002 0.17 
951 JAG1 606 0.030 1 92 0.005 0.17 
952 FAM83B 291 0.014 1 43 0.002 0.16 
953 CXCL3 901 0.044 1 133 0.007 0.16 
954 LAMB3 1577 0.078 1 229 0.012 0.16 
955 BECN1 69 0.003 1 10 0.001 0.16 
956 TGFA 410 0.020 1 58 0.003 0.16 
957 BIK 310 0.015 1 43 0.002 0.15 
958 CCND2 544 0.027 1 72 0.004 0.15 
959 ALDH1A3 4918 0.243 1 642 0.035 0.14 
960 INPP5J 23 0.001 1 3 0.000 0.14 
961 CLCA2 529 0.026 1 66 0.004 0.14 
962 ITGA6 1676 0.083 1 209 0.011 0.14 
963 TP63 303 0.015 1 37 0.002 0.13 
964 KRT17 2669 0.132 1 314 0.017 0.13 
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965 COL1A1 69 0.003 1 8 0.000 0.13 
966 CXCL2 1589 0.078 1 178 0.010 0.12 
967 CCL15 18 0.001 1 2 0.000 0.12 
968 ELMO1 27 0.001 1 3 0.000 0.12 
969 TNFAIP3 614 0.030 1 68 0.004 0.12 
970 INHBA 222 0.011 1 22 0.001 0.11 
971 SOX15 298 0.015 1 29 0.002 0.11 
972 IL1B 377 0.019 1 36 0.002 0.11 
973 SERPINB2 233 0.012 1 22 0.001 0.10 
974 CXCL1 640 0.032 1 59 0.003 0.10 
975 CXCL8 653 0.032 1 58 0.003 0.10 
976 DLL1 24 0.001 1 2 0.000 0.09 
977 SFRP1 648 0.032 1 51 0.003 0.09 
978 SFN 6460 0.319 1 507 0.028 0.09 
979 CBLC 188 0.009 1 13 0.001 0.08 
980 CDH1 1637 0.081 1 113 0.006 0.08 
981 HBEGF 75 0.004 1 5 0.000 0.07 
982 LAMA3 1951 0.096 1 126 0.007 0.07 
983 LAMC2 4464 0.220 1 277 0.015 0.07 
984 KLK5 311 0.015 1 19 0.001 0.07 
985 ACTA2 17 0.001 1 1 0.000 0.06 
986 ARHGEF16 55 0.003 1 3 0.000 0.06 
987 IL1A 1331 0.066 1 57 0.003 0.05 
988 FGFBP1 2307 0.114 1 81 0.004 0.04 
989 DSG3 978 0.048 1 28 0.002 0.03 
990 ITGB6 415 0.020 1 3 0.000 0.01 
991 COL17A1 517 0.026 1 3 0.000 0.01 								 	
	144	
Appendix 10: List of deregulated pathways in TRIM24-OE MCF10A cells by HTG 
Edgeseq analysis 
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